Nucleobase editing factor and use of the same
A dCas9-cytidine deaminase fusion addresses inefficiencies in current genome editing by providing precise nucleotide editing in the human genome, minimizing indels and enhancing editing efficiency.
Patent Information
- Application Number
- JP2024118365
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-10-14
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current genome editing technologies suffer from stochastic processes like NHEJ and HDR, leading to inefficient and unwanted genetic modifications, particularly in achieving precise single-nucleotide corrections in the human genome.
Development of a nucleobase editing system using a nuclease-inactive Cas9 (dCas9) fused with a cytidine deaminase domain, such as APOBEC1, to efficiently target and deaminate cytidine residues in specific DNA sequences, minimizing indels and enhancing precision.
The system achieves high-efficiency, precise editing of nucleotides without significant indels, enabling targeted nucleotide changes in the human genome, reducing unwanted genetic alterations.
Smart Images

Figure 2024164012000615 
Figure 2024164012000616 
Figure 2024164012000617
Abstract
Description
[Technical Field]
[0001] government assistance This invention was made with government support under Grant No. R01 EB022376 (formerly R01 GM065400) awarded by the National Institutes of Health, Training Grant Nos. F32 GM 112366-2 and F32 GM 106601-2 awarded by the National Institutes of Health, and Harvard Biophysics NIH Training Grant T32 GM008313 awarded by the National Institutes of Health. The government has certain rights in this invention.
[0002] Related Applications This application is a continuation of USSN 62 / 245,828 filed October 23, 2015, USSN 62 / 279,346 filed January 15, 2016, USSN 62 / 311,763 filed March 22, 2016, USSN 62 / 322,178 filed April 13, 2016, USSN 62 / 357,352 filed June 30, 2016, and USSN 62 / 357,352 filed August 3, 2016. This application claims priority under § 119(e) of U.S. provisional patent applications: USSN 62 / 370,700, filed September 22, 2016; USSN 62 / 398,490, filed October 14, 2016; and USSN 62 / 357,332, filed June 30, 2016; each of which is incorporated herein by reference. [Background technology]
[0003] Targeted editing of nucleic acid sequences, such as targeted cleavage or targeted introduction of specific modifications into genomic DNA, is a highly promising approach for studying gene function and also has the potential to provide new therapeutic approaches for human genetic diseases. 1An ideal nucleic acid editing technology would possess three properties: (1) high efficiency in implementing the desired modification; (2) minimal off-target activity; and (3) the ability to be programmed to precisely edit any site in a given nucleic acid, e.g., any site in the human genome. 2 Current genome engineering tools include engineered zinc finger nucleases (ZFNs). 3 , transcription activator-like effector nuclease (TALEN) 4 , and most recently the RNA-guided DNA endonuclease Cas9 5 These programs involve the generation of sequence-specific DNA breaks in the genome. This programmable break can result in mutation of the DNA at the break site by non-homologous end joining (NHEJ) or replacement of the DNA surrounding the break site by homology-directed repair (HDR). 6,7 .
[0004] One drawback of current technologies is that both NHEJ and HDR are stochastic processes that typically result in modest gene editing efficiency and unwanted gene changes that can compete with the desired changes. 8 In principle, many genetic diseases can be treated by making specific nucleotide changes at specific locations in the genome (e.g., a C to T change in a particular codon of a disease-associated gene). 9 The development of programmable methods to achieve such high-precision gene editing would represent a powerful new research tool and a potential new approach for gene-editing-based human therapy. Summary of the Invention
[0005] The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) system is a recently discovered prokaryotic adaptive immune system. 10 , which has been modified to enable robust and general genome engineering in a variety of organisms and cell lines. 11The CRISPR-Cas (CRISPR-associated) system is a protein-RNA complex that uses an RNA molecule (sgRNA) as a guide to localize the complex to a target DNA sequence by base pairing. 12 Then, in natural systems, Cas proteins act as endonucleases to cleave the target DNA sequence. 13 For the system to function, the target DNA sequence must be complementary to the sgRNA and must also contain a "protospacer adjacent motif" (PAM) at the 3' end of the complementary region. 14 .
[0006] Among the known Cas proteins, S. pyogenes Cas9 has been widely used primarily as a tool for genome manipulation. 15 The Cas9 protein is a large multidomain protein containing two separate nuclease domains. Point mutations can be introduced into Cas9 to abolish nuclease activity, resulting in an inactive Cas9 (dCas9) that still retains its ability to bind DNA in a manner programmed by the sgRNA. 16 In principle, when fused to another protein or domain, dCas9 can target that protein to virtually any DNA sequence simply by co-expression with the appropriate sgRNA.
[0007] The potential of the dCas9 complex for genome engineering purposes is enormous. Its unique ability to target proteins to specific sites in the genome programmed by sgRNA could theoretically be expanded into a variety of site-specific genome engineering tools beyond nucleases, including transcriptional activators, transcriptional repressors, histone-modifying proteins, integrases, and recombinases. 11 Some of their potential applications have recently been implemented by dCas9 fusions with transcriptional activators, allowing for the generation of RNA-guided transcriptional activators. 17,18 , transcriptional repressor 16,19,20 , and chromatin-modifying enzymes. 21Simple co-expression of these fusions with various sgRNAs results in specific expression of target genes. These pioneering studies paved the way for the design and construction of easily programmable sequence-specific effectors for precise manipulation of genomes.
[0008] Importantly, 80-90% of protein mutations responsible for human disease arise from single nucleotide substitutions, deletions, or insertions. 6 Most current strategies for single-base gene correction involve engineered nucleases, which rely on the creation of double-strand breaks (DSBs) followed by stochastic and inefficient homology-directed repair (HDR), and DNA-RNA chimeric oligonucleotides. 22 The latter strategy involves designing an RNA / DNA sequence to base-pair with a specific sequence in genomic DNA, excluding the nucleotide to be edited. The resulting mismatch is recognized and repaired by the cell's endogenous repair system, leading to either a chimera or a change in the genome sequence. Both of these strategies suffer from low gene editing efficiency and unwanted gene alterations because they suffer from both the stochasticity of HDR and the competition between HDR and non-homologous end joining (NHEJ). 23~25 HDR efficiency depends on the location of the target gene in the genome. 26 , cell cycle status 27 , and cell / tissue type 28 Thus, the development of a straightforward, programmable method to implement specific types of base modifications at precise locations in genomic DNA with non-stochastic, enzyme-like efficiency represents a powerful new approach for gene-editing-based research tools and human therapeutics.
[0009] Some aspects of the present disclosure are based on the recognition that certain configurations of a dCas9 domain and a cytidine deaminase domain fused by a linker are useful for efficiently deaminating target cytidine residues. Another aspect of the present disclosure relates to the recognition that a nucleobase editing fusion protein in which a cytidine deaminase domain is fused by a linker to the N-terminus of a nuclease-inactive Cas9 (dCas9) can efficiently deaminate a target nucleic acid in a double-stranded DNA target molecule. See, e.g., Examples 3 and 4 below. These demonstrate that the fusion proteins, also referred to herein as base editors, create fewer indels and efficiently deaminate target nucleic acids than other base editors, e.g., base editors without a UGI domain. In some embodiments, the fusion protein comprises a nuclease-inactivated Cas9 (dCas9) domain and an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the dCas9 domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7). In some embodiments, the nuclease-inactivated Cas9 (dCas9) domain comprises the amino acid sequence set forth in SEQ ID NO:263. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO:284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO:282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO:5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO:275). In some embodiments, the deaminase is any one of the human APOBEC3G variants set forth in SEQ ID NOs:5739-5741.
[0010] Some aspects of the present disclosure are based on the recognition that certain configurations of a dCas9 domain and a cytidine deaminase domain fused by a linker are useful for efficiently deaminating target cytidine residues. Another aspect of the present disclosure relates to the recognition that a nucleobase editing fusion protein in which an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain is fused to the N-terminus of a nuclease-inactivated Cas9 (dCas9) by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7) can efficiently deaminate a target nucleic acid in a double-stranded DNA target molecule. In some embodiments, the fusion protein comprises a nuclease-inactivated Cas9 (dCas9) domain and an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the dCas9 domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7).
[0011] In some embodiments, the fusion protein comprises amino acid residues 11 to 1629 of the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 5737, 5743, 5745, and 5746.
[0012] Some aspects of the present disclosure provide strategies, systems, reagents, methods, and kits that are useful for target-specific editing of nucleic acids, including editing a single site in a subject's genome, for example, a human genome. In some embodiments, a fusion protein of Cas9 (e.g., dCas9, nuclease-active Cas9, or Cas9 nickase) with a deaminase or deaminase domain is provided. In some embodiments, methods for target-specific nucleic acid editing are provided. In some embodiments, reagents and kits are provided for generating target-specific nucleic acid editing proteins, for example, fusion proteins of Cas9 with a deaminase or deaminase domain.
[0013] Some aspects of the present disclosure provide fusion proteins comprising a Cas9 protein provided herein, fused to a second protein (e.g., an enzymatic domain such as a cytidine deaminase domain), thereby forming a fusion protein. In some embodiments, the second protein comprises an enzymatic domain or a binding domain. In some embodiments, the enzymatic domain is a nuclease, nickase, recombinase, deaminase, methyltransferase, methylase, acetylase, acetyltransferase, transcriptional activator, or transcriptional repressor domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). It should be understood that the deaminase can be from any suitable organism (e.g., human or rat).In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.
[0014] Some aspects of the present disclosure provide fusion proteins comprising: (i) a nuclease-inactive Cas9 (dCas9) domain comprising the amino acid sequence of SEQ ID NO: 263; and (ii) an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the dCas9 domain by a linker comprising the amino acid sequence of SGSETPGTSESATPES (SEQ ID NO: 7). In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 591. In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 5737. In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of SEQ ID NOs: 5739-5741.
[0015] Some aspects of the present disclosure provide fusion proteins comprising (i) a Cas9 nickase domain and (ii) an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the Cas9 nickase domain. In some embodiments, the Cas9 nickase domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding amino acid position in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence set forth in SEQ ID NO: 267. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.
[0016] Some aspects of the present disclosure provide fusion proteins comprising (i) a Cas9 nickase domain and (ii) an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain, wherein the deaminase domain is fused to the N-terminus of the Cas9 nickase domain. In some embodiments, the Cas9 nickase domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding amino acid position in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence set forth in SEQ ID NO: 267. In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1.
[0017] Another aspect of the present disclosure relates to the recognition that a fusion protein comprising a deaminase domain, a dCas9 domain, and a uracil glycosylase inhibitor (UGI) domain demonstrates improved efficiency for deaminating target nucleotides in nucleic acid molecules. Without wishing to be bound by any particular theory, the cellular DNA repair response to the presence of U:G heteroduplex DNA may be responsible for the reduced nucleobase editing efficiency in cells. Uracil DNA glycosylase (UDG) catalyzes the removal of U from DNA in cells, which can initiate base excision repair, the most common outcome of which is reversion of a U:G pair to a C:G pair. As demonstrated herein, uracil DNA glycosylase inhibitor (UGI) can inhibit human UDG activity. Without wishing to be bound by any particular theory, base excision repair can be inhibited by molecules that bind to a single strand, block the edited base, inhibit UGI, inhibit base excision repair, protect the edited base, and / or promote "repair" of the unedited strand, etc. Therefore, the present disclosure contemplates a fusion protein comprising a dCas9-cytidine deaminase domain fused to a UGI domain.
[0018] In some embodiments, the fusion protein comprises a nuclease-inactivated Cas9 (dCas9) domain; a nucleic acid editing domain; and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the dCas9 domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than D. In some embodiments, the amino acid sequence of the dCas9 domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the dCas9 domain comprises a H840X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than H. In some embodiments, the amino acid sequence of the dCas9 domain comprises a H840A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the dCas9 domain comprises the amino acid sequence set forth in SEQ ID NO: 263.
[0019]
[0003] Further aspects of the present disclosure relate to the recognition that fusion proteins that utilize a Cas9 nickase as a Cas9 domain demonstrate improved efficiency for editing nucleic acids. For example, aspects of the present disclosure relate to the recognition that fusion proteins comprising a Cas9 nickase, a deaminase domain, and a UGI domain demonstrate improved efficiency for editing nucleic acids. For example, improved efficiency for editing nucleotides is described in the Examples section below.
[0020] Some aspects of the present disclosure are based on the recognition that any of the base editors provided herein can modify specific nucleotide bases without generating a significant proportion of indels. As used herein, "indel" refers to the insertion or deletion of a nucleotide base in a nucleic acid. Such insertions or deletions can lead to frameshift mutations within the coding region of a gene. In some embodiments, it is desirable to create base editors that efficiently modify (e.g., mutate or deaminate) specific nucleotides in nucleic acids without generating numerous insertions or deletions (i.e., indels) in the nucleic acid. In certain embodiments, any of the base editors provided herein can generate a higher proportion of intended modifications (e.g., point mutations or deaminations) compared to indels.
[0021] Some aspects of the present disclosure are based on the recognition that any of the base editors provided herein can efficiently generate intended mutations, such as point mutations, in a nucleic acid (e.g., a nucleic acid in a subject's genome) without generating a significant number of unintended mutations, such as unintended point mutations.
[0022] In some embodiments, the fusion protein comprises a Cas9 nickase domain, a nucleic acid editing domain, and a uracil glycosylase inhibitor (UGI) domain. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10X mutation in the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260, where X is any amino acid other than D. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation in the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided in SEQ ID NO: 10, or the corresponding amino acid position in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence set forth in SEQ ID NO: 267.
[0023] In some embodiments, the deaminase domain of the fusion protein is fused to the N-terminus of the dCas9 domain or Cas9 nickase. In some embodiments, the UGI domain is fused to the C-terminus of the dCas9 domain or Cas9 nickase. In some embodiments, the dCas9 domain or Cas9 nickase and the nucleic acid editing domain are fused via a linker. In some embodiments, the dCas9 domain or Cas9 nickase and the UGI domain are fused via a linker.
[0024] In certain embodiments, linkers can be used to link any of the peptides or peptide domains of the present invention. The linker can be as simple as a covalent bond, or it can be a polymeric linker many atoms in length. In certain embodiments, the linker is a polypeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, a disulfide bond, a carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide bond. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched, aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutyric acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises an amino acid. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may include a functional moiety (e.g., thiol, amino) to facilitate attachment of a nucleophile from the peptide to the linker. Any electrophile can be used as part of the linker. Exemplary electrophiles include, but are not limited to, active esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.
[0025] In some embodiments, the linker comprises the amino acid sequence (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , (SGGS) n (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), (XP) n or any combination thereof, wherein n is independently an integer between 1 and 30, and X is any amino acid. In some embodiments, the linker has the amino acid sequence (GGS) n wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7).
[0026] In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]. In some embodiments, the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker sequence]-[UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[dCas9 or Cas9 nickase]; [UGI]-[optional linker sequence]-[dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]; [dCas9 or Cas9 nickase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[nucleic acid editing domain]; or [dCas9 or Cas9 nickase]-[optional linker sequence]-[nucleic acid editing domain]-[optional linker sequence]-[UGI].
[0027] In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the nucleic acid editing domain comprises a deaminase. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, an APOBEC3H deaminase, or an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is lamprey CDA1 (pmCDA1) deaminase.
[0028] In some embodiments, the deaminase is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase is from a human. In some embodiments, the deaminase is from a rat. In some embodiments, the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 284). In some embodiments, the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 282). In some embodiments, the deaminase is pmCDA1 (SEQ ID NO: 5738). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a human APOBEC3G variant of any one of (SEQ ID NOs: 5739-5741). In some embodiments, the deaminase is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs:266-284 or 5725-5741.
[0029] In some embodiments, the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO: 600. In some embodiments, the UGI domain comprises the amino acid sequence set forth in SEQ ID NO: 600.
[0030] Some aspects of the present disclosure provide complexes comprising a Cas9 protein or a Cas9 fusion protein provided herein and a guide RNA bound to the Cas9 protein or the Cas9 fusion protein.
[0031] Some aspects of the present disclosure provide methods using the Cas9 protein, fusion protein, or complex provided herein. For example, some aspects of the present disclosure provide methods comprising contacting a DNA molecule with (a) a Cas9 protein or fusion protein and a guide RNA provided herein; or (b) a Cas9 protein, a Cas9 fusion protein, or a Cas9 protein or fusion protein complex with a gRNA provided herein, wherein the guide RNA is about 15 to 100 nucleotides in length and comprises a sequence of at least 10 consecutive nucleotides complementary to a target sequence.
[0032] Some aspects of the present disclosure provide kits comprising a nucleic acid construct comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein provided herein; and (b) a heterologous promoter driving expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
[0033] Some aspects of the present disclosure provide polynucleotides encoding the Cas9 protein of the fusion proteins provided herein. Some aspects of the present disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of the polynucleotide.
[0034] Some aspects of the present disclosure provide cells comprising the Cas9 proteins, fusion proteins, nucleic acid molecules, and / or vectors provided herein.
[0035] The above descriptions of exemplary embodiments of reporter systems are provided for illustrative purposes only and are not meant to be limiting. Additional reporter systems, such as variations of the exemplary systems described in detail above, are also encompassed by the present disclosure.
[0036] The above summary is meant to illustrate, in a non-limiting manner, some of the aspects, advantages, features, and uses of the technology disclosed herein. Other aspects, advantages, features, and uses of the technology disclosed herein will be apparent from the detailed description, drawings, examples, and claims. [Brief explanation of the drawings]
[0037] [Figure 1] Figure 1 shows the deaminase activity of the deaminases on single-stranded DNA substrates. A single-stranded DNA substrate with a randomized PAM sequence (NNN PAM) was used as a negative control. A canonical PAM sequence (NGG PAM) was used.
[0038] [Figure 2] Figure 2 shows the activity of the Cas9:deaminase fusion protein on single-stranded DNA substrates.
[0039] [Figure 3]Figure 3 illustrates double-stranded DNA substrate binding by the Cas9:deaminase:sgRNA complex.
[0040] [Figure 4] FIG. 4 illustrates the double-stranded DNA deamination assay.
[0041] [Figure 5] Figure 5 demonstrates that Cas9 fusions can target positions 3-11 of a double-stranded DNA target sequence (numbered according to the schematic in Figure 5). Top gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 equivalent of sgRNA. Middle gel: 1 μM rAPOBEC1-(GGS)3 (SEQ ID NO: 596)-dCas9, 125 nM dsDNA, 1 equivalent of sgRNA. Bottom gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 equivalent of sgRNA.
[0042] [Figure 6] Figure 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity.
[0043] [Figure 7] Figure 7 illustrates the mechanism of target DNA binding of in vivo target sequences by the deaminase-dCas9:sgRNA complex.
[0044] [Figure 8] FIG. 8 shows the successful deamination of an exemplary disease-associated target sequence.
[0045] [Figure 9] Figure 9 shows in vitro C to T editing efficiency using His6-rAPOBEC1-XTEN-dCas9.
[0046] [Figure 10]Figure 10 shows that C to T editing efficiency in HEK293T cells is greatly improved by fusion with UGI.
[0047] [Figure 11] Figures 11A to 11C show that NBE1 mediates C to U conversion programmed by a specific guide RNA in vitro. Figure 11A: Nucleobase editing strategy. DNA bearing a target C (red) at a locus specified by a guide RNA (green) is bound by dCas9 (blue), which mediates local denaturation of the DNA substrate. Cytidine deamination by a tethered APOBEC1 enzyme (orange) converts the target C to U. The resulting G:U heteroduplex can be permanently converted to an A:T base pair after DNA replication or repair. If a U is present in the template DNA strand, this will also result in an RNA transcript containing a G to A mutation after transcription. Figure 11B: Deamination assay showing an approximately 5-nucleotide activity window. After incubation of the NBE1-sgRNA complex with the dsDNA substrate for 2 h at 37 °C, the 5' fluorophore-labeled DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) at 37 °C for 1 h to induce DNA cleavage at either uracil site. The resulting DNA was separated on a denaturing polyacrylamide gel to visualize the strand linked to either fluorophore. Each lane is labeled according to the position of the target C within the protospacer, or by "-" if the target C is absent. The base distal to the PAM is counted as position 1. Figure 11C: Deaminase assay showing the sequence specificity and sgRNA dependency of NBE1. DNA substrates with a target C at position 7 were incubated with NBE1 as in Figure 11B, with either the correct sgRNA, a mismatched sgRNA, or no sgRNA. No C to U editing is observed with a mismatched sgRNA or no sgRNA. The positive control sample contains a DNA sequence in which a U has been synthetically incorporated at position 7.
[0048] [Figure 12] Figures 12A to 12B show the effects of sequence context and target C position on in vitro nucleobase editing efficiency. Figure 12A: Effect of varying the sequence surrounding the target C on in vitro editing efficiency. For C7 within the protospacer sequence 5'-TTATTTCGTGGATTTATTTA-3' (SEQ ID NO: 264), a deamination yield of 80% of the target strand (40% of the total sequencing reads from both strands) was defined as 1.0. The relative deamination efficiencies of substrates containing all possible single-base mutations at positions 1-6 and 8-13 are shown. Values and error bars reflect the mean and standard deviation of two or more independent biological replicates performed on different days. Figure 12B: Effect of position of each NC motif on in vitro editing efficiency. Each NC target motif was varied from positions 1 to 8 within the protospacer as shown in the sequence on the right (PAM is shown in red; the protospacer plus one base 5' of the protospacer is also shown). The graph shows the percentage of total sequence reads containing T at each of the numbered target C positions after incubation with NBE1. Note that the maximum possible in vitro deamination yield is 50% of the total sequencing reads (100% of the target strand). Values and error bars reflect the mean and standard deviation of two or three independent biological replicates performed on different days. Figure 12B illustrates SEQ ID NOs: 285 to 292 from top to bottom, respectively.
[0049] [Figure 13]Figures 13A to 13C show nucleobase editing in human cells. Figure 13A: Protospacer (black) and PAM (red) sequences of six mammalian cell genomic loci targeted by nucleobase editors. Target Cs are indicated by subscripted numbers corresponding to their position within the protospacer. Figure 13A illustrates SEQ ID NOs: 293 to 298 from top to bottom, respectively. Figure 13B: HEK293T cells were transfected with plasmids expressing NBE1, NBE2, or NBE3 and the appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed for the six loci by high-throughput DNA sequencing. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at the indicated target position, are shown for all six genomic loci for NBE1, NBE2, and NBE3, and for three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4) for wt Cas9 with the donor HDR template. Values and error bars reflect the mean and standard deviation of three independent biological replicates performed on different days. Figure 13C: The frequency of indel formation, calculated as described in the Methods, after treatment of HEK293T cells is shown for all six genomic loci for NBE2 and NBE3, or for three of the six sites (EMX1, HEK293 site 3, and HEK293 site 4) for wt Cas9 with the single-stranded DNA template for HDR. Values reflect the mean of at least three independent biological replicates performed on different days.
[0050] [Figure 14]Figures 14A to 14C show NBE2- and NBE3-mediated correction of three disease-associated mutations in mammalian cells. For each site, the sequence of the protospacer is shown to the right of the mutation name; the PAM is highlighted in green, and the base responsible for the mutation is bolded and indicated by a subscripted number corresponding to its position within the protospacer. The amino acid sequence above each disease-associated allele is shown along with the corrected amino acid sequence after nucleobase editing in red. Below each sequence is the percentage of total sequencing reads with the corresponding base. Cells were nucleofected with plasmids encoding NBE2 or NBE3 and the appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted and analyzed by HTS to assess correction of the pathogenic mutation. Figure 14A: In mouse astrocytes, the Alzheimer's disease-associated APOE4 allele is converted to APOE3' by NBE3 in 11% of total reads (44% of nucleofected astrocytes). Two nearby Cs were also converted to Ts, but the predicted sequence of the resulting protein was unchanged (SEQ ID NO: 299). Figure 14B shows that the cancer-associated p53 N239D mutation is corrected by NBE2 in 11% of treated human lymphoma cells (12% of nucleofected cells) that are heterozygous for the mutation (SEQ ID NO: 300). Figure 14C shows that the p53 Y163C mutation is corrected by NBE3 in 7.6% of nucleofected human breast cancer cells (SEQ ID NO: 301).
[0051] [Figure 15]Figures 15A to 15D show the effect of deaminase-dCas9 linker length and composition on nucleobase editing. Gel-based deaminase assays (Figure 15D) show the deamination window of nucleobase editors with deaminase-Cas9 linkers of GGS (Figure 15A), (GGS)3; (SEQ ID NO: 596) (Figure 15B), XTEN (Figure 15C), or (GGS)7 (SEQ ID NO: 597). After incubation of 1.85 μM editor-sgRNA complexes with 125 μM dsDNA substrate for 2 h at 37°C, the dye-conjugated DNA was isolated and incubated with USER enzyme (uracil DNA glycosylase and endonuclease VIII) for an additional hour at 37°C to cleave the DNA backbone at any uracil site. The resulting DNA was separated on a denaturing polyacrylamide gel, and the dye-conjugated strand was imaged. Each lane is numbered according to the position of the target C within the protospacer, or by "-" if the target C is absent. 8U is a positive control sequence in which a U was synthetically incorporated at position 8.
[0052] [Figure 16] Figures 16A to 16B demonstrate that NBE1 can correct disease-associated mutations in vitro. Figure 16A: Protospacer and PAM sequences (red) for seven disease-associated mutations. The disease-associated target C in each case is indicated by a subscripted number reflecting its position within the protospacer. For all mutations except for both APOE4 SNPs, the target C is on the template (non-coding) strand. Figure 16A illustrates SEQ ID NOS: 302 to 308 from top to bottom, respectively. Figure 16B: Deaminase assay showing each dsDNA oligonucleotide before (-) and after (+) incubation with NBE1, DNA isolation, and incubation with USER enzyme to cleave DNA at U-containing positions. Positive control lanes from incubation of synthetic oligonucleotides containing U at various positions within the protospacer with USER enzyme are indicated by the corresponding numbers indicating the position of the U.
[0053] [Figure 17] Figure 17 shows the processivity of NBE1. The protospacer and PAM (red) of a 60-mer DNA oligonucleotide containing eight consecutive Cs are shown at the top. The oligonucleotide (125 nM) was incubated with NBE1 (2 μM) for 2 h at 37°C. DNA was isolated and analyzed by high-throughput sequencing. The percent of total reads is shown for the nine most frequent sequences observed. The majority (>93%) of edited strands have more than one C converted to a T. This figure depicts SEQ ID NO: 309.
[0054] [Figure 18]Figures 18A to 18H show the effect of fusing UGI to NBEl to create NBE2. Figure 18A: Protospacer and PAM (red) sequences of six mammalian cell genomic loci targeted by nucleobase editors. Editable Cs are indicated by labels corresponding to their positions within the protospacer. Figure 18A illustrates SEQ ID NOs: 293 to 298 from top to bottom, respectively. Figures 18B to 18G: HEK293T cells were transfected with plasmids expressing NBEl, NBE2, or NBEl and UGI and the appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed for the six loci by high-throughput DNA sequencing. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with Ts at the indicated target positions, are shown for NBEl, NBEl and UGI, and NBE2 at all six genomic loci. Figure 18H: C to T mutation rates at 510 Cs surrounding the target protospacer are shown for NBE1, NBE1 plus UGI on separate plasmids, NBE2, and untreated cells. Data represent the results of 3,000,000 DNA sequencing reads from 1.5 x 10 cells. Values reflect the average of at least two biological experiments performed on different days.
[0055] [Figure 19]Figure 19 shows the nucleobase editing efficiency of NBE2 in U2OS and HEK293T cells. The cellular C to T conversion percentages by NBE2 are shown for each of the six target genomic loci in HEK293T and U2OS cells. HEK293T cells were transfected using lipofectamine 2000, and U2OS cells were nucleofected. The U2OS nucleofection efficiency was 74%. Three days after plasmid delivery, genomic DNA was extracted and analyzed for nucleobase editing at the six genomic loci by HTS. Values and error bars reflect the mean and standard deviation of at least two biological experiments performed on different days.
[0056] [Figure 20] Figure 20 shows that nucleobase editing persists after multiple cell divisions. The percentage of cellular C to T conversions by BE2 is displayed for two genomic loci in HEK293T cells before and after passaging the cells. HEK293T cells were transfected using Lipofectamine 2000. Three days after transfection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to grow for approximately five cell divisions, then harvested and subjected to HTS analysis.
[0057] [Figure 21] Figure 21 shows genetic variants from ClinVar that could, in principle, be corrected by nucleobase editing. The NCBI ClinVar database of human genetic variations and their corresponding phenotypes was searched for genetic diseases that could be corrected by current nucleobase editing technology. Results were filtered by imposing successive constraints, listed on the left. The x-axis shows the number of cases that meet that constraint and all the constraints above, on a logarithmic scale.
[0058] [Figure 22]Figure 22 shows the in vitro identification of editable Cs at six genomic loci. Synthetic 80-mers with sequences matching six different genomic sites were incubated with NBE1 and then analyzed by HTS for nucleobase editing. For each site, the sequence of the protospacer is shown to the right of the site name, and the PAM is highlighted in red. Beneath each sequence is the percentage of total DNA sequencing reads with the corresponding base. Targeted Cs were considered "editable" if their in vitro conversion efficiency was >10%. Note that because non-targeted strands are not substrates for nucleobase editing, the maximum yield is 50% of total DNA sequencing reads. This figure depicts SEQ ID NOs: 293 to 298 from top to bottom, respectively.
[0059] [Figure 23] Figure 23 shows the activity of NBE1, NBE2, and NBE3 at the EMX1 off-target. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing NBE1, NBE2, or NBE3 and an sgRNA matching the EMX1 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing for the on-target locus, plus the top 10 known Cas9 off-target loci for the EMX1 sgRNA, as previously determined using the GUTDE-seq method. The EMX1 off-target locus was not amplified and is not shown. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C-to-T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C within the protospacer, are shown for NBE1, NBE2, and NBE3. The total number of sequencing reads reported for each sequence is displayed on the far right. The figure depicts SEQ ID NOs: 293 and 310-318 from top to bottom, respectively.
[0060] [Figure 24] Figure 24 shows the activity of NBE1, NBE2, and NBE3 at FANCF off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing NBE1, NBE2, or NBE3 and an sgRNA matching the FANCF sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus all known Cas9 off-target loci of the FANCF sgRNA, as previously determined using the GUTDE-seq method. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. The cellular C-to-T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C within the protospacer, are shown for NBE1, NBE2, and NBE3. The total number of sequencing reads reported for each sequence is displayed on the far right. The figure depicts SEQ ID NOs: 294 and 319-326 from top to bottom, respectively.
[0061] [Figure 25]Figure 25 shows the activity of NBE1, NBE2, and NBE3 at HEK293 site 2 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing NBE1, NBE2, or NBE3 and an sgRNA matching the HEK293 site 2 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus all known Cas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined using the GUTDE-seq method. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. The cellular C-to-T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C within the protospacer, are shown for NBE1, NBE2, and NBE3. The total number of sequencing reads reported for each sequence is displayed on the far right. The figure depicts SEQ ID NOs: 295, 327, and 328 from top to bottom, respectively.
[0062] [Figure 26]Figure 26 shows the activity of NBE1, NBE2, and BE3 at HEK293 site 3 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing NBE1, NBE2, or NBE3 and an sgRNA matching the HEK293 site 3 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus all known Cas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined using the GUTDE-seq method. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. Cellular C-to-T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C within the protospacer, are shown for NBE1, NBE2, and NBE3. The total number of sequencing reads reported for each sequence is displayed on the far right. The figure depicts SEQ ID NOs: 296 and 659-663 from top to bottom, respectively.
[0063] [Figure 27]Figure 27 shows the activity of NBE1, NBE2, and NBE3 at HEK293 site 4 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing NBE1, NBE2, or NBE3 and an sgRNA matching the HEK293 site 4 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus the top 10 known Cas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using the GUIDE-seq method. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are displayed. Cellular C-to-T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C within the protospacer, are shown for NBE1, NBE2, and NBE3. The total number of sequencing reads reported for each sequence is displayed on the far right. The figure depicts SEQ ID NOs: 297 and 664-673 from top to bottom, respectively.
[0064] [Figure 28] Figure 28 shows the non-target C mutation rates, where C to T mutation rates at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested are shown, representing a total of 14,700,000 sequence reads derived from approximately 1.8 x 10 cells.
[0065] [Figure 29]Figures 29A to 29C show base editing in human cells. Figure 29A shows possible base editing outcomes in mammalian cells. The initial edit resulted in a U:G mismatch. Recognition and excision of the U by uracil DNA glycosylase (UDG) triggers base excision repair (BER), which leads to reversion to the C:G initial state. BER was blocked by BE2 and BE3, which inhibited UDG. The U:G mismatch was also processed by mismatch repair (MMR), which preferentially repaired the nicked strand of the mismatch. BE3 nicked the unedited strand containing the G, preferentially resolving the U:G mismatch to the desired U:A or T:A outcome. Figure 29B shows HEK293T cells treated as described in the Materials and Methods section of the example below. The percentage of total DNA sequencing reads with T at the indicated target positions indicates treatment with BE1, BE2, or BE3, or treatment with wt Cas9 with the donor HDR template. Figure 29C shows the frequency of indel formation after the treatments in Figure 29B. Values are listed in Figure 34. In Figures 29B and 29C, values and error bars reflect the mean and s.d. of three independent biological replicates performed on different days.
[0066] [Figure 30]Figures 30A–30B show BE3-mediated correction of two disease-associated mutations in mammalian cells. The sequence of the protospacer, with the PAM in blue and the target base in red, is shown to the right of the mutation, with a subscripted number indicating its position within the protospacer. Below each sequence is the percentage of total sequencing reads with the corresponding base. Cells were treated as described in Materials and Methods. Figure 30A shows that the Alzheimer's disease-associated APOE4 allele was converted to APOE3r by BE3 in 74.9% of total reads in mouse astrocytes. Two nearby Cs were also converted to Ts, but the predicted sequence of the resulting protein was unchanged. Identical treatment of these cells with wt Cas9 and donor ssDNA resulted in only 0.3% correction and 26.1% indel formation. Figure 30B shows that the cancer-associated p53 Y163C mutation was corrected by BE3 in 7.6% of nucleofected human breast cancer cells, resulting in 0.7% indel formation. Identical treatment of these cells with wt Cas9 and donor ssDNA did not result in mutation correction, resulting in 6.1% indel formation. This figure depicts SEQ ID NOs: 675 to 680 from top to bottom, respectively.
[0067] [Figure 31]Figure 31 shows the activity of BE1, BE2, and BE3 at HEK293 site 2 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing BE1, BE2, or BE3 and sgRNAs matching the HEK293 site 2 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus all known Cas9 and dCas9 off-target loci for the HEK293 site 2 sgRNA, as previously determined by Joung et al. (63) using the GutDe-seq method and Adli et al. (18) using chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. The cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C in the protospacer, are shown for BE1, BE2, and BE3. On the far right, the total number of reported sequencing reads and reported ChIP-seq signal intensities are displayed for each sequence. The figure depicts SEQ ID NOs: 681 to 688 from top to bottom, respectively.
[0068] [Figure 32]Figure 32 shows the activity of BE1, BE2, and BE3 at HEK293 site 3 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing BE1, BE2, or BE3 and an sgRNA matching the HEK293 site 3 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus all known Cas9 off-target loci and the top five known dCas9 off-target loci for the HEK293 site 3 sgRNA, as previously determined by Joung et al. using the GUIDE-seq method and chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. The cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C in the protospacer, are shown for BE1, BE2, and BE3. On the far right, the total number of reported sequencing reads and reported ChIP-seq signal intensities are displayed for each sequence. The figure depicts SEQ ID NOs: 689 to 699 from top to bottom, respectively.
[0069] [Figure 33]Figure 33 shows the activity of BE1, BE2, and BE3 at HEK293 site 4 off-targets. HEK293T cells were transfected using Lipofectamine 2000 with plasmids expressing BE1, BE2, or BE3 and an sgRNA matching the HEK293 site 4 sequence. Three days after transfection, genomic DNA was extracted, amplified by PCR, and analyzed by high-throughput DNA sequencing at the on-target locus, plus the top 10 known Cas9 off-target loci and the top 5 known dCas9 off-target loci for the HEK293 site 4 sgRNA, as previously determined using GUIDE-seq methods and chromatin immunoprecipitation high-throughput sequencing (ChIP-seq) experiments. The sequences of the on-target and off-target protospacers and protospacer adjacent motifs (PAMs) are shown. The cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with a T at each position of the original C in the protospacer, are shown for BE1, BE2, and BE3. On the far right, the total number of reported sequencing reads and reported ChIP-seq signal intensities are displayed for each sequence. The figure depicts SEQ ID NOs: 700 to 712 from top to bottom, respectively.
[0070] [Figure 34]Figure 34 shows the mutation rate of non-protospacer bases after BE3-mediated correction of the Alzheimer's disease-associated APOE4 allele to APOE3r in mouse astrocytes. The DNA sequences of 50 bases on either side of the protospacer from Figures 30A and 34B are shown with the position of each base relative to the protospacer. The side of the protospacer distal to the PAM is designated by a positive number, while the side encompassing the PAM is designated by a negative number, with the PAM shown in blue. Beneath each sequence is the percentage of total DNA sequencing reads bearing the corresponding base for untreated cells, cells treated with BE3 and an sgRNA targeting the APOE4 C158R mutation, or cells treated with BE3 and an sgRNA targeting the VEGFA locus. None of the BE3-treated samples resulted in a mutation rate above that of the untreated control. This figure illustrates SEQ ID NOs: 713 to 716 from top to bottom, respectively.
[0071] [Figure 35] Figure 35 shows the mutation rate of non-protospacer bases after BE3-mediated correction of the cancer-associated p53 Y163C mutation in HCC1954 human cells. The DNA sequence of 50 bases on either side of the protospacer from Figures 30B and 39B is shown with each base's position relative to the protospacer. The side of the protospacer distal to the PAM is designated by a positive number, while the side containing the PAM is designated by a negative number, with the PAM shown in blue. Beneath each sequence is the percentage of total sequencing reads containing the corresponding base for untreated cells, cells treated with BE3 and an sgRNA targeting the TP53 Y163C mutation, or cells treated with BE3 and an sgRNA targeting the VEGFA locus. None of the BE3-treated samples resulted in a mutation rate above that of the untreated control. This figure depicts SEQ ID NOs: 717 to 720, respectively, from top to bottom.
[0072] [Figure 36] Figures 36A to 36F show the effects of deaminase, linker length, and linker composition on base editing. Figure 36A shows a gel-based deaminase assay demonstrating the activity of rAPOBEC1, pmCDA1, hAID, hAPOBEC3G, rAPOBEC1-GGS-dCas9, rAPOBEC1-(GGS)3 (SEQ ID NO: 596)-dCas9, and dCas9-(GGS)3 (SEQ ID NO: 596)-rAPOBEC1 on ssDNA. The enzymes were expressed in an in vitro transcription-translation system from mammalian cell lysate and incubated with 1.8 μM dye-conjugated ssDNA and USER enzyme (uracil DNA glycosylase and endonuclease VIII) for 2 hours at 37°C. The resulting DNA was separated on a denaturing polyacrylamide gel and imaged. The positive control was a sequence in which U was synthetically incorporated at the same position as the target C. Figure 36B shows a Coomassie-stained denaturing PAGE gel of the expressed and purified proteins used in Figures 36C to 36F. Figures 36C to 36F show gel-based deaminase assays, demonstrating the deamination window of base editors with GGS (Figure 36C), (GGS)3 (SEQ ID NO: 596) (Figure 36D), XTEN (Figure 36E), or (GGS)7 (SEQ ID NO: 597) deaminase-Cas9 linkers (Figure 36F). After incubation of 1.85 μM deaminase-dCas9 fusion complexed with sgRNA with 125 nM dsDNA substrate at 37°C for 2 hours, the dye-conjugated DNA was isolated and incubated with USER enzyme at 37°C for 1 hour to cleave the DNA backbone at any uracil site. The resulting DNA was separated on a denaturing polyacrylamide gel, and the dye-conjugated strands were imaged. Each lane is numbered according to the position of the target C within the protospacer, or by "-" if the target C is absent. 8U is a positive control sequence in which a U was synthetically incorporated at position 8.
[0073] [Figure 37] Figures 37A to 37C show that BE1 base editing efficiency is dramatically reduced in mammalian cells. Figure 37A: Protospacer (black and red) and PAM (blue) sequences of six mammalian cell genomic loci targeted by base editors. Target Cs are indicated in red with subscripted numbers corresponding to their positions within the protospacer. Figure 37B shows that synthetic 80-mers with sequences matching six different genomic sites were incubated with BE1 and then analyzed for base editing by HTS. For each site, the sequence of the protospacer is shown to the right of the site name, and the PAM is highlighted in blue. Beneath each sequence is the percentage of total DNA sequencing reads with the corresponding base. We considered a target C "editable" if its in vitro conversion efficiency was >10%. Note that the maximum yield is 50% of total DNA sequencing reads, as the non-target strand is not affected by BE1. Values are shown from a single experiment. Figure 37C shows HEK293T cells were transfected with a plasmid expressing BE1 and the appropriate sgRNA. Three days after transfection, genomic DNA was extracted and analyzed at six loci by high-throughput DNA sequencing. The cellular C to T conversion percentage, defined as the percentage of total DNA sequencing reads with a T at the indicated target position, is shown for BE1 at all six genomic loci. Values and error bars for all data from HEK293T cells reflect the mean and standard deviation of three independent biological replicates performed on different days. Figure 37A depicts SEQ ID NOs: 721 to 726 from top to bottom, respectively. Figure 37B depicts SEQ ID NOs: 727 to 732 from top to bottom, respectively.
[0074] [Figure 38]Figure 38 shows that base editing persists after multiple cell divisions. The cellular C to T conversion percentages by BE2 and BE3 are shown for HEK293 sites 3 and 4 in HEK293T cells before and after passaging the cells. HEK293T cells were nucleofected with BE2 or BE3 and a plasmid expressing an sgRNA targeting HEK293 site 3 or 4. Three days after nucleofection, the cells were harvested and split in half. One half was subjected to HTS analysis, and the other half was allowed to grow for approximately five cell divisions, then harvested and subjected to HTS analysis. Values and error bars reflect the mean and standard deviation of at least two biological experiments.
[0075] [Figure 30] Figures 39A to 39C show non-target C / G mutation rates. Shown here are C to T and G to A mutation rates at 2,500 distinct cytosines and guanines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads derived from approximately 1.8 x 10 cells. Figures 39A and 39B show that the cellular non-target C to T and G to A conversion percentages by BE1, BE2, and BE3 are plotted individually for all 2,500 cytosines / guanines against their position relative to the protospacer. The side of the protospacer distal to the PAM is designated by a positive number, while the side encompassing the PAM is designated by a negative number. Figure 39C shows the average non-targeted C to T and G to A conversion percentages of cells by BE1, BE2, and BE3, along with the highest and lowest individual conversion percentages.
[0076] [Figure 40]Figures 40A–40B show additional datasets of BE3-mediated correction of two disease-associated mutations in mammalian cells. For each site, the sequence of the protospacer is shown to the right of the mutation name; the PAM is highlighted in blue; the base responsible for the mutation is shown in bold red with a subscripted number corresponding to its position in the protospacer. The amino acid sequence above each disease-associated allele is shown along with the corrected amino acid sequence after base editing in green. Below each sequence is the percentage of total sequencing reads with the corresponding base. Cells were nucleofected with a plasmid encoding BE3 and the appropriate sgRNA. Two days after nucleofection, genomic DNA was extracted from the nucleofected cells and analyzed by HTS to assess correction of the pathogenic mutation. Figure 40A shows that the Alzheimer's disease-associated APOE4 allele was converted to APOE3r by BE3 in 58.3% of total reads in mouse astrocytes only when treated with the correct sgRNA. Two nearby Cs are also converted to Ts, but the predicted sequence of the resulting protein is unchanged. Identical treatment of these cells with wt Cas9 and donor ssDNA resulted in 0.2% correction and 26.7% indel formation. Figure 40B shows that the cancer-associated p53 Y163C mutation is corrected by BE3 in 3.3% of nucleofected human breast cancer cells only when treated with the correct sgRNA. Identical treatment of these cells with wt Cas9 and donor ssDNA resulted in no detectable mutation correction and 8.0% indel formation. Figures 40A to 40B depict SEQ ID NOs: 733 to 740, respectively, from top to bottom.
[0077] [Figure 41] FIG. 41 shows a schematic of an exemplary USER (Uracil-Specific Excision Reagent) enzyme-based assay, which can be used to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates.
[0078] [Figure 42] Figure 42 is a schematic of the pmCDA-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and negative control (untreated).
[0079] [Figure 43] Figure 43 is a schematic of the pmCDA1-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-3 site relative to the base editor (rAPOBEC1) and negative control (untreated).
[0080] [Figure 44] Figure 44 shows the percent of total sequencing reads in which the target C was converted to a T using cytidine deaminase (CDA) or APOBEC.
[0081] [Figure 45] Figure 45 shows the percent of total sequencing reads in which the target C was converted to A using deaminase (CDA) or APOBEC.
[0082] [Figure 46] Figure 46 shows the percent of total sequencing reads in which the target C was converted to G using deaminase (CDA) or APOBEC.
[0083] [Figure 47] Figure 47 is a schematic of the huAPOBEC3G-XTEN-nCas9-UGI-NLS construct and its activity at the HeK-2 site relative to a mutated form (huAPOBEC3G*(D316R_D317R)-XTEN-nCas9-UGI-NLS), a base editor (rAPOBEC1), and a negative control (untreated).
[0084] [Figure 48]FIG. 48 shows a schematic of the LacZ construct used in the selection assay of Example 7.
[0085] [Figure 49] Figure 49 shows the reversion data from different plasmids and constructs.
[0086] [Figure 50] Figure 50 shows the verification of lacZ reversion and purification of revertant clones.
[0087] [Figure 51] Figure 51 is a schematic illustrating the deamination selection plasmid used in Example 7.
[0088] [Figure 52] FIG. 52 shows the results of a chloramphenicol reversion assay (pmCDA1 fusion).
[0089] [Figure 53] Figures 53A to 53B demonstrate the induction of DNA corrections for the two constructs.
[0090] [Figure 54] Figure 54 shows the results of a chloramphenicol reversion assay (huAPOBEC3G fusions).
[0091] [Figure 55] Figure 55 shows the activity of BE3 and HF-BE3 at the EMX1 off-target. Sequences correspond, from top to bottom, to SEQ ID NOs: 286-292, 299-301.
[0092] [Figure 56] Figure 56 shows the on-target base editing efficiency of BE3 and HF-BE3.
[0093] [Figure 57]Figure 57 is a graph demonstrating that mutations affect cytidine deamination to varying degrees. Combinations of mutations, each of which mildly impairs catalysis, allow selective deamination at one position over another. The FANCF site was GGAATC6C7C8TTTC11TGCAGCACCTGG (SEQ ID NO: 303).
[0094] [Figure 58] Figure 58 is a schematic illustrating next-generation base editors.
[0095] [Figure 59] Figure 59 is a schematic illustrating new base editors made from Cas9 variants.
[0096] [Figure 60] Figure 60 shows the base-edited percentage of different NGA PAM sites.
[0097] [Figure 61] Figure 61 shows the base-edited percentage of cytidines using the NGCG PAM EMX(VRER BE3) and C1TC3C4C5ATC8AC10ATCAACCGGT (SEQ ID NO: 304) spacer.
[0098] [Figure 62] Figure 62 shows the based-edited percentages resulting from different NNGRRT PAM sites.
[0099] [Figure 63] Figure 63 shows the based-edited percentage resulting from different NNHRRT PAM sites.
[0100] [Figure 64]Figures 64A to 64C show the base edit percentages produced using Cpfl BE2 from different TTTN PAM sites. The spacers used were: TTTCCTC3C4C5C6C7C8C9AC11AGGTAGAACAT (Figure 64A, SEQ ID NO: 305), TTTCC1C2TC4TGTC8C9AC11ACCCTCATCCTG (Figure 64B, SEQ ID NO: 306), and TTTCC1C2C3AGTC7C8TC10C11AC13AC15C16C17TGAAAC (Figure 64C, SEQ ID NO: 307).
[0101] [Figure 65] Figure 65 is a schematic illustrating selective deamination achieved by kinetic modulation of cytidine deaminase point mutagenesis.
[0102] [Figure 66] Figure 66 is a graph showing the effect of various mutations on the deamination window probed by multiple cytidines within the spacer in cell culture. The spacer used was: TGC3C4C5C6TC8C9C10TC12C13C14TGGCCC (SEQ ID NO: 308).
[0103] [Figure 67] Figure 67 is a graph showing the effect of various mutations on the deamination window probed by multiple cytidines within the spacer in cell culture. The spacer used was: AGAGC5C6C7C8C9C10C11TC13AAAGAGA (SEQ ID NO: 309).
[0104] [Figure 68] Figure 68 is a graph showing the effect of various mutations on a FANCF site with a limited number of cytidines. The spacer used was: GGAATC6C7C8TTTC11TGCAGCACCTGG (SEQ ID NO: 303). Note that the triple mutant (W90Y, R126E, R132E) preferentially edits the cytidine at position 6.
[0105] [Figure 69] Figure 69 is a graph showing the effect of various mutations on a HEK3 site with a limited number of cytidines. The spacer used was: GGCC4C5AGACTGAGCACGTGATGG (SEQ ID NO: 310). Note that the double and triple mutants preferentially edit the cytidine at the fifth position over the cytidine at the fourth position.
[0106] [Figure 70] Figure 70 is a graph showing the effect of various mutations on an EMX1 site with a limited number of cytidines. The spacer used was: GAGTC5C6GAGCAGAAGAAGAAGGG (SEQ ID NO: 311). Note that the triple mutant only edits the cytidine at the fifth position, not the sixth.
[0107] [Figure 71] Figure 71 is a graph showing the effect of various mutations on a HEK2 site with a limited number of cytidines. The spacer used was: GAAC4AC6AAAGCATAGACTGCGGG (SEQ ID NO: 312).
[0108] [Figure 72] Figure 72 shows the on-target base editing efficiency of BE3 and BE3 containing the mutation W90Y R132E in immortalized astrocytes.
[0109] [Figure 73] Figure 73 shows a schematic diagram of the three Cpf1 fusion constructs.
[0110] [Figure 74] Figure 74 shows a comparison of plasmid delivery of BE3 and HF-BE3 (EMX1, FANCF, and RNF2).
[0111] [Figure 75] Figure 75 shows a comparison of plasmid delivery in BE3 and HF-BE3 (HEK3 and HEK4).
[0112] [Figure 76] Figure 76 shows off-target editing of EMX-1 at all 10 sites.
[0113] [Figure 77] Figure 77 shows deaminase protein lipofection into HEK cells using a GAGTCCGAGCAGAAGAAGAAG (SEQ ID NO: 313) spacer. EMX-1 on-target and EMX-1 off-target site 2 were investigated.
[0114] [Figure 78] Figure 78 shows deaminase protein lipofection into HEK cells using a GGAATCCCTTCTGCAGCACCTGG (SEQ ID NO: 314) spacer. FANCF on-target and FANCF off-target sites 1 were investigated.
[0115] [Figure 79] Figure 79 shows deaminase protein lipofection into HEK cells using a GGCCCAGACTGAGCACGTGA (SEQ ID NO: 315) spacer. HEK-3 on-target sites were investigated.
[0116] [Figure 80] Figure 80 shows deaminase protein lipofection into HEK cells using the GGCACTGCGGCTGGAGGTGGGGG (SEQ ID NO: 316) spacer. HEK-4 on-target, off-target site 1, site 3, and site 4.
[0117] [Figure 81]Figure 81 shows the results of in vitro assays of sgRNA activity for sgHR_13 (GTCAGGTCGAGGGTTCTGTC (SEQ ID NO: 317) spacer; C8 target: G51 to stop), sgHR_14 (GGGCCGCAGTATCCTCACTC (SEQ ID NO: 318) spacer; C7 target; C7 target: Q68 to stop), and sgHR_15 (CCGCCAGTCCCAGTACGGGA (SEQ ID NO: 319) spacer; C10 and C11 are targets: W239 or W237 to stop).
[0118] [Figure 82] Figure 82 shows the results of an in vitro assay for sgHR_17 (CAACCACTGCTCAAAGATGC (SEQ ID NO: 320) spacer; C4 and C5 are targets: W410->Stop) and sgHR_16 (CTTCCAGGATGAGAACACAG (SEQ ID NO: 321) spacer; C4 and C5 are targets: W273->Stop).
[0119] [Figure 83] Figure 83 shows direct injection of BE3 protein complexed with sgHR_13 in zebrafish embryos.
[0120] [Figure 84] Figure 84 shows direct injection of BE3 protein complexed with sgHR_16 in zebrafish embryos.
[0121] [Figure 85] Figure 85 shows direct injection of BE3 protein complexed with sgHR_17 in zebrafish embryos.
[0122] [Figure 86] Figure 86 shows exemplary nucleic acid changes that can be made using base editors that can make cytosine to thymine changes.
[0123] [Figure 87] Figure 87 shows a diagram of apolipoprotein E (APOE) isoforms, demonstrating that a base editor (e.g., BE3) can be used to edit one APOE isoform (e.g., APOE4) into another APOE isoform (e.g., APOE3r) that is associated with a reduced risk of Alzheimer's disease.
[0124] [Figure 88] Figure 88 shows base editing of APOE4 to APOE3r in mouse astrocytes.
[0125] [Figure 89] Figure 89 shows base editing of PRNP to cause premature truncation of the protein at arginine residue 37.
[0126] [Figure 90] Figure 90 shows that knocking out UDG (which UGI inhibits) dramatically improves the cleanliness of C to T base editing efficiency.
[0127] [Figure 91] Figure 91 shows that the use of base editors with nickases but without UGIs leads to a mixture of outcomes, with very high indel rates.
[0128] [Figure 92]Figures 92A to 92G show that SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, and VRER-BE3 mediate efficient base editing at target sites containing non-NGG PAMs in human cells. Figure 92A shows the structures of base editors using S. pyogenes and S. aureus Cas9. Figure 92B shows recently characterized Cas9 variants with alternative or relaxed PAM requirements. Figures 92C and 92D show HEK293T cells treated with the indicated base editor variants as described in Example 12. The percentage of total DNA sequencing reads (without enrichment for transfected cells) in which C was converted to T at the indicated target positions is shown. The PAM sequence for each target tested is shown below the x-axis. The charts show results for SaBE3 and SaKKH-BE3 at genomic loci with NNGRRT PAMs (Figure 92C), SaBE3 and SaKKH-BE3 at genomic loci with NNNRRT PAMs (Figure 92D), VQR-BE3 and EQR-BE3 at genomic loci with NGAG PAMs (Figure 92E) and NGAH PAMs (Figure 92F), and VRER-BE3 at genomic loci with NGCG PAMs (Figure 92G). Values and error bars reflect the mean and standard deviation of at least two biological replicates.
[0129] [Figure 93]Figures 93A to 93C demonstrate that base editors with mutations in the cytidine deaminase domain exhibit narrower editing windows. Figures 93A to 93C show HEK293T cells transfected with plasmids expressing mutant base editors and appropriate sgRNAs. Three days after transfection, genomic DNA was extracted and analyzed by high-throughput DNA sequencing at the indicated loci. The percentage of total DNA sequencing reads with C to T changes at the indicated target positions (without enrichment for transfected cells) is shown for the EMX1 site, HEK293 site 3, FANCF site, HEK293 site 2, site A, and site B loci. Figure 93A illustrates certain cytidine deaminase mutations that narrow the base editing window. See Figure 98 for characterization of additional mutations. Figure 93B shows the effect of cytidine deaminase mutations affecting editing window width at genomic loci. Combining beneficial mutations has an additive effect on narrowing the editing window. Figure 93C shows that YE1-BE3, YE2-BE3, EE-BE3, and YEE-BE3 affect the product distribution of base edits, resulting in predominantly single-modified products, in contrast to BE3. Values and error bars reflect the mean and standard deviation of at least two biological replicates.
[0130] [Figure 94]Figures 94A and 94B show genetic variants from ClinVar that could, in principle, be corrected by the base editors developed in this study. The NCBI ClinVar database of human gene variations and their corresponding phenotypes was searched for genetic diseases that could theoretically be corrected by base editing. Figure 94A demonstrates the improved targeting scope of base editing by using base editors with altered PAM specificity for all pathogenic T to C mutations in the ClinVar database. The white fraction indicates the proportion of pathogenic T to C mutations accessible based on the PAM requirements of either BE3, or BE3 and the five altered PAM base editors developed in this study. Figure 94B shows the improved targeting scope of base editing by using base editors with narrowed activity windows for all pathogenic T to C mutations in the ClinVar database. BE3 appeared to edit Cs at positions 4–8 with comparable efficiency, as shown in Figures 93A–93C. YEE-BE3 appeared to edit with a preference for C5>C6>C7>others within its activity window. The white fraction indicates the proportion of pathogenic T->C mutations that can be edited by BE3 without equivalent editing of other Cs (left) or by BE3 or YEE-BE3 without equivalent editing of other Cs (right).
[0131] [Figure 95]Figures 95A to 95C show the effect of shortened guide RNAs on base editing window width. HEK293T cells were transfected with plasmids expressing BE3 and different 5'-truncated sgRNAs. Treated cells were analyzed as described in the Examples. Figure 95A shows the protospacer and PAM sequences (top, SEQ ID NO: 4270) and the cellular C to T conversion percentage, defined as the percentage of total DNA sequencing reads with a T at the indicated target position, for a site within the EMX1 genomic locus. At this site, the base editing window was altered by using a 17-nt shortened gRNA. Figure 95B shows the protospacer and PAM sequences (top, SEQ ID NO: 4270) and the cellular C to T conversion percentage, defined as the percentage of total DNA sequencing reads with a T at the indicated target position, for a site within the HEK site 3 and site 4 genomic loci. At these sites, no change in the base editing window was observed, but there was a linear decrease in editing efficiency for all substrate bases as the sgRNA was shortened.
[0132] [Figure 96] Figure 96 shows the effect of APOBEC1-Cas9 linker length on base editing window width. HEK293T cells were transfected with base editors bearing the XTEN, GGS, (GGS)3 (SEQ ID NO: 596), (GGS)5 (SEQ ID NO: 4271), or (GGS)7 (SEQ ID NO: 597) rAPOBEC1-Cas9 linkers and plasmids expressing sgRNAs. Treated cells were analyzed as described in the Examples. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at the indicated target positions, are shown for various base editors with different linkers.
[0133] [Figure 97]Figures 97A to 97C show the effect of rAPOBEC mutations on base editing window width. Figure 97C shows HEK293T cells transfected with sgRNAs targeting either site A or site B and plasmids expressing the indicated BE3 point mutants. Treated cells were analyzed as described in the Examples. All Cs within the protospacer and within 3 base pairs of the protospacer are labeled, and the cellular C to T conversion percentages are shown. The "editing window width," defined as the calculated number of nucleotides above which editing efficiency exceeds half-maximal, is displayed for all tested mutants.
[0134] [Figure 98] Figure 98 shows the effect of APOBEC1 mutations on base editing product distribution in mammalian cells. HEK293T cells were transfected with a plasmid expressing BE3 or its mutants and the appropriate sgRNA. Treated cells were analyzed as described in the Examples. The cellular C to T conversion percentage, defined as the percentage of total DNA sequencing reads with a T at the indicated target position, is shown (left). The percentage of total sequencing reads containing a C to T conversion is shown on the right. BE3 point mutations do not significantly affect base editing efficiency at HEK site 4, a site with only one target cytidine.
[0135] [Figure 99] Figure 99 shows a comparison of plasma delivery of on-target editing for BE3 and HF-BE3.
[0136] [Figure 100] Figure 100 shows a comparison of on-target editing for protein and plasma delivery of BE3.
[0137] [Figure 101]Figure 101 shows a comparison of on-target editing for protein plasma delivery of HF-BE3.
[0138] [Figure 102] Figure 102 shows that both lipofection and implementing the HF mutation reduce off-target deamination events. Diamonds indicate that no off-target events were detected and the specificity ratio was set to 100.
[0139] [Figure 103] Figure 103 shows in vitro C to T editing on a synthetic substrate with C placed at even positions within the protospacer (NNNNTC2TC4TC6TC8TC10TC12TC14TC16TC18TC20NGG, SEQ ID NO: 4272).
[0140] [Figure 104] Figure 104 shows in vitro C to T editing on a synthetic substrate with C placed at odd positions within the protospacer (NNNNTC2TC4TC6TC8TC10TC12TC14TC16TC18TC20NGG, SEQ ID NO: 4272).
[0141] [Figure 105] Figure 105 includes two graphs illustrating the specificity ratio of base editing by plasmid vs. protein delivery.
[0142] [Figure 106]Figures 106A to 106B show BE3 activity at non-NGG PAM sites. HEK293T cells were transfected with a plasmid expressing BE3 and the appropriate sgRNA. Treated cells were analyzed as described in the Examples. Figure 106A shows BE3 activity at sites that can be efficiently targeted by SaBE3 or SaKKH-BE3. BE3 shows low but significant activity at NAG PAMs. Figure 106B shows that BE3 has significantly reduced editing at sites with NGA or NGCG PAMs, in contrast to VQR-BE3 or VRER-BE3.
[0143] [Figure 107] Figures 107A to 107B show the effects of APOBEC1 mutations on VQR-BE3 and SaKKH-BE3. HEK293T cells were transfected with plasmids expressing VQR-BE3, SaKKH-BE3, or their mutants and the appropriate sgRNA. Treated cells were analyzed as described in the Methods. Cellular C to T conversion percentages, defined as the percentage of total DNA sequencing reads with T at the indicated target positions, are shown. Figure 107A shows that window-modulating mutations can be applied to VQR-BE3 to enable selective base editing at sites targetable by NGA PAM. Figure 107B shows that when applied to SaKKH-BE3, the mutations cause an overall decrease in base editing efficiency without conferring base selectivity within the target window.
[0144] [Figure 108] Figure 108 shows a schematic diagram of nucleotide editing. The following abbreviations are used: (MMR) - mismatch repair, (BE3 nickase) - refers to base editor 3 containing the Cas9 nickase domain, (UGI) - uracil glycosylase inhibitor, (UDG) - uracil DNA glycosylase, (APOBEC) - refers to APOBEC cytidine deaminase. Definitions
[0145] As used in this specification and claims, the singular forms "a," "an," and "the" include singular and plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a substance" includes a single substance as well as a plurality of such substances.
[0146] The term "Cas9" or "Cas9 nuclease" refers to an RNA-guided nuclease comprising the Cas9 protein or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active Cas9 DNA cleavage domain and / or a Cas9 gRNA-binding domain). Cas9 nuclease is sometimes also referred to as casn1 nuclease or CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)-associated nuclease. CRISPR is an adaptive immune system that provides defense against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). CRISPR clusters contain an ancestral mobile element and a sequence complementary to the target invading nucleic acid, a spacer. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, proper processing of the pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and the Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-assisted processing of the pre-crRNA. The Cas9 / crRNA / tracrRNA then endolytically cleaves linear or circular dsDNA targets complementary to the spacer. The target strand not complementary to the crRNA is first endolytically cleaved and then 3'-5' exolytically trimmed. In nature, DNA binding and cleavage typically require both proteins and both RNAs. However, single-guide RNAs ("sgRNAs" or simply "gRNAs") can be engineered to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I, Hauer M., Doudna JA, Charpentier E. Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference.Cas9 recognizes a short motif (PAM or protospacer adjacent motif) in the CRISPR repeat sequence, helping it distinguish self from non-self. Cas9 nuclease sequences and structures are well known to those skilled in the art (e.g., "Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti et al., JJ, McShan WM, Ajdic DJ, Savic DJ, Savic G., Lyon K., Primeaux C, Sezate S., Suvorov AN, Kenton S., Lai HS, Lin SP, Qian Y., Jia HG, Najar FZ, Ren Q., Zhu H., Song L., White J., Yuan X., Clifton SW, Roe BA, McLaughlin RE, Proc. Natl. Acad. Sci. USA 98:4658-4663(2001);"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma CM., Gonzales K., Chao Y., Pirzada ZA, Eckert MR, Vogel J., Charpentier E., Nature 471:602-607(2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I, Hauer M., Doudna JA, Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference. Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus.Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure. Such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) RNA Biology 10:5, 726-737, the entire contents of which are incorporated herein by reference. In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain, i.e., the Cas9 is a nickase.
[0147] Nuclease-inactivated Cas9 proteins can be interchangeably referred to as "dCas9" proteins (nuclease-inactive Cas9). Methods for generating Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains are known (see, e.g., Jinek et al., Science. 337:816-821(2012); Qi et al., "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) Cell. 28; 152(5): 1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to contain two subdomains: an HNH nuclease subdomain and a RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, while the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can suppress the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28; 152(5): 1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided. For example, in some embodiments, the protein comprises one of two Cas9 domains: (1) the gRNA-binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or fragments thereof are referred to as "Cas9 variants." Cas9 variants share homology with Cas9 or fragments thereof. For example, a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild-type Cas9.In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more amino acid changes compared to wild-type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA cleavage domain), wherein the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild-type Cas9. In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of the corresponding wild-type Cas9.
[0148] In some embodiments, the fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length. In some embodiments, the wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, SEQ ID NO: 1 (nucleotide), SEQ ID NO: 2 (amino acid)).
number
number
number
number
[0149] In some embodiments, the wild-type Cas9 corresponds to or comprises SEQ ID NO:3 (nucleotide) and / or SEQ ID NO:4 (amino acid):
number
number
number
number
[0150] In some embodiments, the wild-type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2, SEQ ID NO: 8 (nucleotide); and Uniport Reference Sequence: Q99ZW2, SEQ ID NO: 10 (amino acid)).
number
number
number
number
number
[0151] In some embodiments, Cas9 is: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1);Prevotella intermedia(NCBI Ref: NC_017861.1);Spiroplasma taiwanense(NCBI Ref: NC_021846.1);Streptococcus iniae(NCBI Ref: NC_021314.1);Belliella baltica(NCBI Ref: NC_018010.1) torquisl(NCBI Ref: NC_018721.1); Cas9 from Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Campylobacter jejuni (NCBI Ref: YP_002344900.1), or Neisseria meningitidis (NCBI Ref: YP_002342100.1), or any of the organisms listed in Example 5.
[0152] In some embodiments, the dCas9 corresponds to or comprises part or all of a Cas9 amino acid sequence with one or more mutations that inactivate Cas9 nuclease activity. For example, in some embodiments, the dCas9 domain comprises a D10A and / or H840A mutation. dCas9 (D10A and H840A):
number
number
[0153] In some embodiments, the Cas9 domain contains a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, while the residue at position 840, or the corresponding position in any of the amino acid sequences provided by SEQ ID NOs: 11-260, remains a histidine. Without wishing to be bound by any particular theory, the presence of the catalytic residue H840 restores Cas9's activity to cleave the non-edited (e.g., non-deaminated) strand containing a G opposite the target C. Restoration of H840 (e.g., from A840) does not result in cleavage of the target strand containing a C. Such Cas9 variants are capable of creating a single-strand DNA break (nick) at a specific location based on the target sequence defined by the gRNA, leading to repair of the non-edited strand and ultimately to a G-to-A change in the non-edited strand. A schematic of this process is shown in Figure 108. Briefly, the C in a CG base pair can be deaminated to U by a deaminase, e.g., an APOBEC deaminase. Nicking the unedited strand with a G prompts the mismatch repair mechanism to remove the G. UGI inhibits UDG, which prevents the removal of the U.
[0154] In other embodiments, dCas9 variants are provided that have mutations other than D10A and H840A, resulting in, for example, nuclease-inactivated Cas9 (dCas9). Such mutations include, for example, other amino acid substitutions at D10 and H820, or other substitutions within the nuclease domain of Cas9 (e.g., substitutions in the HNH nuclease subdomain and / or the RuvC1 subdomain). In some embodiments, dCas9 variants or homologs (e.g., variants of SEQ ID NO: 10) are provided that are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to SEQ ID NO: 10. In some embodiments, variants of dCas9 (e.g., variants of SEQ ID NO: 10) are provided and have amino acid sequences that are shorter or longer than SEQ ID NO: 10 by about 5 amino acids, about 10 amino acids, about 15 amino acids, about 20 amino acids, about 25 amino acids, about 30 amino acids, about 40 amino acids, about 50 amino acids, about 75 amino acids, about 100 amino acids, or more.
[0155] In some embodiments, the Cas9 fusion proteins provided herein comprise the full-length amino acid sequence of a Cas9 protein, such as one of the Cas9 sequences provided herein. However, in other embodiments, the fusion proteins provided herein comprise only a fragment thereof, rather than the full-length Cas9 sequence. For example, in some embodiments, the Cas9 fusion proteins provided herein comprise a Cas9 fragment, which binds to crRNA and tracrRNA or sgRNA but does not comprise a functional nuclease domain, e.g., it comprises only a truncated version of the nuclease domain or no nuclease domain at all. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and fragments will be apparent to those skilled in the art.
[0156] These include Case9: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); NC_016786.1);Spiroplasma syrphidicola(NCBI Ref: NC_021284.1);Prevotella intermedia(NCBI Ref: NC_017861.1);Spiroplasma taiwan(NCBI Ref: NC_021846.1); NC_021314.1);Belliella baltica(NCBI Ref: NC_018010.1);Psychroflexus torquisI(NCBI Ref: NC_018721.1);Streptococcus thermophilus(NCBI Ref: YP_820832.1); NP_472073.1);Campylobacter jejuni (NCBI Ref: YP_002344900.1);
[0157] As used herein, the term "deaminase" or "deaminase domain" refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. In some embodiments, the deaminase or deaminase domain is a cytidine deaminase domain, catalyzing the hydrolytic deamination of cytosine to uracil. In some embodiments, the deaminase or deaminase domain is a naturally occurring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain is a non-naturally occurring variant of a naturally occurring deaminase from an organism. For example, in some embodiments, the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally occurring deaminase from an organism.
[0158] As used herein, the term "effective amount" refers to the amount of a biologically active substance that is sufficient to induce a desired biological response. For example, in some embodiments, an effective amount of a nuclease can refer to the amount of nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. In some embodiments, an effective amount of a fusion protein provided herein, such as a fusion protein comprising a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain), can refer to the amount of fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein. As will be understood by those skilled in the art, the effective amount of a substance, such as a fusion protein, nuclease, deaminase, recombinase, hybrid protein, protein dimer, protein (or protein dimer) and polynucleotide complex, or polynucleotide, can vary depending on various factors, such as the desired biological response, e.g., the specific allele, genome, or target site to be edited, the cell or tissue to be targeted, and the substance to be used.
[0159] As used herein, the term "linker" refers to a chemical group or molecule that links two molecules or moieties, for example, two domains of a fusion protein, such as a nuclease-inactive Cas9 domain and a nucleic acid editing domain (e.g., a deaminase domain). In some embodiments, the linker connects the gRNA binding domain of an RNA-programmable nuclease, including a Cas9 nuclease domain, to the catalytic domain of a nucleic acid editing protein. In some embodiments, the linker connects dCas9 to a nucleic acid editing protein. Typically, the linker is located between or flanked by two groups, molecules, or other moieties, covalently connecting each one and thus connecting the two. In some embodiments, the linker is an amino acid or multiple amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5 to 100 amino acids in length, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.
[0160] As used herein, the term "mutation" refers to the substitution of a residue in a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or the deletion or insertion of one or more residues in a sequence. Typically, mutations are described herein by identifying the original residue, then the position of the residue in the sequence, and the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art and are described, for example, in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4 thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012).
[0161] As used herein, the terms "nucleic acid" and "nucleic acid molecule" refer to a compound comprising a nucleobase and an acid moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides, are linear molecules in which adjacent nucleotides are linked by phosphodiester bonds. In some embodiments, "nucleic acid" refers to an individual nucleic acid residue (e.g., a nucleotide and / or a nucleoside). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms "oligonucleotide" and "polynucleotide" can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, "nucleic acid" encompasses RNA and single- and / or double-stranded DNA. Nucleic acids can exist naturally, for example, in the context of a genome, transcript, mRNA, tRNA, rRNA, siRNA, snRNA, plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule can be a non-naturally occurring molecule, e.g., recombinant DNA or RNA, an artificial chromosome, an engineered genome, or a fragment thereof, or synthetic DNA, RNA, or DNA / RNA hybrid, or can include non-naturally occurring nucleotides or nucleosides. Furthermore, the terms "nucleic acid," "DNA," "RNA," and / or similar terms encompass nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced and optionally purified using recombinant expression systems, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can include nucleoside analogs, e.g., analogs with chemically modified bases or sugars, and backbone modifications. Nucleic acid sequences are presented in the 5' to 3' direction unless otherwise indicated.In some embodiments, nucleic acids are selected from natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine; chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5'-N-phosphoramidite linkages).
[0162] As used herein, the term "nucleic acid editing domain" refers to a protein or enzyme that can make one or more modifications (e.g., deamination of a cytidine residue) in a nucleic acid (e.g., DNA or RNA). Exemplary nucleic acid editing domains include, but are not limited to, deaminase, nuclease, nickase, recombinase, methyltransferase, methylase, acetylase, acetyltransferase, transcriptional activator, or transcriptional repressor domains. In some embodiments, the nucleic acid editing domain is a deaminase (e.g., a cytidine deaminase, such as APOBEC or AID deaminase).
[0163] As used herein, the term "proliferative disorder" refers to any disorder in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated rate of proliferation. Proliferative disorders include hyperproliferative disorders, such as preneoplastic hyperplasia and neoplastic disorders. Neoplastic disorders are characterized by abnormal cell proliferation and include both benign and malignant neoplasms. Malignant neoplasms are also referred to as cancer.
[0164] The terms "protein," "peptide," and "polypeptide" are used interchangeably herein and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to proteins, peptides, or polypeptides of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids in length. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity, such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, or a linker for conjugation, functionalization, or other modification. A protein, peptide, or polypeptide may also be a single molecule or a multimolecular complex. A protein, peptide, or polypeptide may be simply a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, synthetic, or any combination thereof. As used herein, the term "fusion protein" refers to a hybrid polypeptide containing protein domains from at least two different proteins. One protein can be located at the amino-terminal (N-terminal) or carboxy-terminal (C-terminal) portion of the fusion protein, thus forming an "amino-terminal fusion protein" or a "carboxy-terminal fusion protein," respectively. The protein can include different domains, such as a nucleic acid-binding domain of a nucleic acid-editing protein (e.g., the gRNA-binding domain of Cas9, which guides the protein to bind to a target site) and a nucleic acid cleavage domain or catalytic domain. In some embodiments, the protein includes a proteinaceous portion, such as an amino acid sequence constituting a nucleic acid-binding domain, and an organic compound, such as a compound that can act as a nucleic acid cleavage agent. In some embodiments, the protein is complexed with or associated with a nucleic acid, such as RNA. Any of the proteins provided herein can be produced by any method known in the art.For example, the proteins provided herein can be produced by recombinant protein expression and purification, which is particularly suitable for fusion proteins containing peptide linkers. Methods for recombinant protein expression and purification are well known and are described in Green and Sambrook, Molecular Cloning: A Laboratory Manual (4). th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), the entire contents of which are incorporated herein by reference.
[0165] The terms "RNA-programmable nuclease" and "RNA-guided nuclease" are used interchangeably herein to refer to a nuclease that forms a complex with (e.g., binds to or associates with) one or more RNAs that are not targets for cleavage. In some embodiments, when an RNA-programmable nuclease is complexed with an RNA, it can be referred to as a nuclease:RNA complex. Typically, the bound RNA(s) is referred to as a guide RNA (gRNA). A gRNA can exist as a complex of two or more RNAs or as a single RNA molecule. A gRNA that exists as a single RNA molecule can be referred to as a single guide RNA (sgRNA), although "gRNA" is used interchangeably to refer to a guide RNA that exists either as a single molecule or as a complex of two or more molecules. Typically, a gRNA that exists as a single RNA species contains two domains: (1) a domain that shares homology with the target nucleic acid (e.g., and directs binding of the Cas9 complex to the target); and (2) a domain that binds to the Cas9 protein. In some embodiments, domain (2) corresponds to a sequence known as tracrRNA and includes a stem-loop structure. For example, in some embodiments, domain (2) is identical to or homologous to the tracrRNA provided by Jinek et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Other examples of gRNAs (e.g., those including domain 2) can be found in US Provisional Patent Application USSN 61 / 874,682, entitled "Switchable Cas9 Nucleases And Uses Thereof," filed September 6, 2013, and US Provisional Patent Application USSN 61 / 874,746, entitled "Delivery System For Functional Nucleases," filed September 6, 2013, the entire contents of each of which are incorporated herein by reference. In some embodiments, a gRNA includes two or more of domains (1) and (2) and may be referred to as an "extended gRNA."For example, an extended gRNA will bind, e.g., two or more Cas9 proteins and bind to a target nucleic acid at two or more separate regions as described herein. The gRNA comprises a target-complementary nucleotide sequence that mediates binding of the nuclease / RNA complex to the target site and provides sequence specificity for the nuclease:RNA complex.Additionally, RNA-induced RNA-induced polymerization (CRIS PR vaccine) Cas9 strain strain Streptococcus pyogenes and Cas9(Csn1) "Complete genome sequence of an M1 strain of Streptococcus pyogenes ." Ferretti JJ , McShan WM , Ajdic DJ , Savic DJ , Savic G , Lyon K , Primeaux C , Sezate S , Suvorov AN . Kenton S, Lai HS, Lin SP, Qian Y, Jia HG, Ren Q, Zhu H, Song L, White J, Roe BA, McLaughlin RE, Proc RNA and host factor RNase III." Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E, Nature 471 :602–607(2011);および"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. Science 337:816-821(2012) of which the chemical components of this material are prepared in a light-weight manner.
[0166] Because RNA-programmable nucleases (e.g., Cas9) use RNA:DNA hybridization to target DNA cleavage sites, in principle, these proteins are capable of being targeted to any sequence specified by a guide RNA. Methods for using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (e.g., to modify genomes) are known in the art (e.g., Cong, L. et al., Multiplex genome engineering using CRISPR / Cas systems. Science 339, 819-823 (2013); Mali, P. et al., RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, WY et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013); Jinek, M. et al., RNA-programmed genome editing in human cells. eLife 2, e00471 (2013); Dicarlo, JE et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic acids research (2013); Jiang, W. et al., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nature biotechnology 31, 233-239 (2013); the entire contents of each of which are incorporated herein by reference).
[0167] As used herein, the term "subject" refers to an individual organism, e.g., an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, goat, cattle, cat, or dog. In some embodiments, the subject is a vertebrate, amphibian, reptile, fish, insect, fly, or nematode. In some embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject can be of either sex and at any stage of development.
[0168] The term "target site" refers to a sequence in a nucleic acid molecule that is deaminated by a deaminase or a fusion protein that includes a deaminase (e.g., a dCas9-deaminase fusion protein provided herein).
[0169] The terms "treatment," "treat," and "treating" refer to a clinical intervention aimed at reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder described herein, or one or more symptoms thereof. As used herein, the terms "treatment," "treat," and "treating" refer to a clinical intervention aimed at reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder described herein, or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have occurred and / or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay the onset of symptoms, or to inhibit the onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, e.g., to prevent or delay their recurrence.
[0170] The term "recombinant," as used herein in the context of a protein or nucleic acid, refers to a protein or nucleic acid that is not naturally occurring and is the product of human manipulation. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that contains at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations compared to any naturally occurring sequence.
[0171] As used herein, the term "nucleobase editor (NBE)" or "base editor (BE)" refers to a Cas9 fusion protein described herein. In some embodiments, the fusion protein comprises a nuclease-inactivated Cas9 (dCas9) fused to a deaminase. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase. In some embodiments, the fusion protein comprises a nuclease-inactivated Cas9 fused to a deaminase and further fused to a UGI domain. In some embodiments, the fusion protein comprises a Cas9 nickase fused to a deaminase and further fused to a UGI domain. In some embodiments, the dCas9 of the fusion protein comprises the D10A and H840A mutations of SEQ ID NO: 10, or the corresponding mutations in any of SEQ ID NOs: 11-260, which inactivate the nuclease activity of the Cas9 protein. In some embodiments, the fusion protein contains a D10A mutation, a histidine at residue 840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260, which enables Cas9 to cleave only one strand of a nucleic acid duplex. An example of a Cas9 nickase is shown below in SEQ ID NO: 674. The terms "nucleobase editor (NBE)" and "base editor (BE)" may be used interchangeably.
[0172] As used herein, the term "uracil glycosylase inhibitor" or "UGI" refers to a protein that is capable of inhibiting the uracil DNA glycosylase base excision repair enzyme.
[0173] As used herein, the term "Cas9 nickase" refers to a Cas9 protein that can cleave only one strand of a double-stranded nucleic acid molecule (e.g., a double-stranded DNA molecule). In some embodiments, the Cas9 nickase comprises a D10A mutation and a histidine at position H840 of SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. For example, the Cas9 nickase may comprise the amino acid sequence set forth in SEQ ID NO: 674. Such a Cas9 nickase has an active HNH nuclease domain and is capable of cleaving the non-target strand of DNA, i.e., the strand bound by the gRNA. Additionally, such a Cas9 nickase has an inactive RuvC nuclease domain and is incapable of cleaving the target strand of DNA, i.e., the strand where base editing is desired.
[0174] An exemplary Cas9 nickase (cloning vector pPlatTET-gRNA2; Accession No. BAV54124).
number
number
[0175] Some aspects of the present disclosure provide fusion proteins comprising a domain capable of binding to a nucleotide sequence (e.g., a Cas9 or Cpf1 protein) and an enzymatic domain, e.g., a DNA editing domain, such as a deaminase domain. Deamination of nucleic acid bases by a deaminase can lead to point mutations at the respective residues, a process referred to herein as nucleic acid editing. Therefore, fusion proteins comprising a Cas9 variant or domain and a DNA editing domain can be used for targeted editing of nucleic acid sequences. Such fusion proteins are useful for targeted editing of DNA in vitro, e.g., for generating mutant cells or animals; for introducing targeted mutations, e.g., for correcting genetic defects in ex vivo cells, e.g., cells obtained from a subject that are then reintroduced into the same or another subject; and for introducing targeted mutations, e.g., for correcting genetic defects or introducing inactivating mutations in disease-associated genes in a subject. Typically, the Cas9 domain of the fusion proteins described herein does not have any nuclease activity and is instead a Cas9 fragment or dCas9 protein or domain. Methods for using the Cas9 fusion proteins described herein are also provided.
[0176] Nucleobase editor Cas9 domain Non-limiting exemplary Cas9 domains are provided herein. The Cas9 domain can be a nuclease-active Cas9 domain, a nuclease-inactive Cas9 domain, or a Cas9 nickase. In some embodiments, the Cas9 domain is a nuclease-active domain. For example, the Cas9 domain can be a Cas9 domain that cleaves both strands of a double-stranded nucleic acid (e.g., both strands of a double-stranded DNA molecule). In some embodiments, the Cas9 domain comprises any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263. In some embodiments, the Cas9 domain comprises an amino acid sequence having at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical stretches of amino acid residues compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263.
[0177] In some embodiments, the Cas9 domain is a nuclease-inactivated Cas9 domain (dCas9). For example, the dCas9 domain can bind to a double-stranded nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the double-stranded nucleic acid molecule. In some embodiments, the nuclease-inactivated dCas9 domain comprises a D10X mutation and a H840X mutation in the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid change. In some embodiments, the nuclease-inactivated dCas9 domain comprises a D10A mutation and a H840A mutation in the amino acid sequence set forth in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In one example, the nuclease-inactivated Cas9 domain comprises the amino acid sequence set forth in SEQ ID NO: 263 (cloning vector pPlatTET-gRNA2, Accession No. BAV54124).
number
number
[0178] Additional suitable nuclease-inactive dCas9 domains are within the scope of this disclosure and will be apparent to those of skill in the art based on this disclosure and knowledge in the art. Exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, the D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference). In some embodiments, the dCas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the dCas9 domains provided herein. In some embodiments, the Cas9 domain comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263.In some embodiments, the Cas9 domain comprises an amino acid sequence having at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 consecutive amino acid residues compared to any one of the amino acid sequences set forth in SEQ ID NOs: 10-263.
[0179] In some embodiments, the Cas9 domain is a Cas9 nickase. The Cas9 nickase can be a Cas9 protein that can cleave only one strand of a double-stranded nucleic acid molecule (e.g., a double-stranded DNA molecule). In some embodiments, the Cas9 nickase cleaves the target strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base-paired with (complementary to) the gRNA (e.g., sgRNA) bound to the Cas9. In some embodiments, the Cas9 nickase comprises a D10A mutation of SEQ ID NO: 10, a histidine at position 840, or a mutation in any of SEQ ID NOs: 11-260. For example, the Cas9 nickase can comprise the amino acid sequence set forth in SEQ ID NO: 674. In some embodiments, the Cas9 nickase cleaves the non-target, non-base-edited strand of a double-stranded nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base-paired with the gRNA (e.g., sgRNA) bound to the Cas9. In some embodiments, the Cas9 nickase comprises an H840A mutation in SEQ ID NO: 10, with an aspartic acid residue at position 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments, the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases are within the scope of this disclosure and will be apparent to those of skill in the art based on this disclosure and knowledge in the art.
[0180] Cas9 domains with reduced PAM exclusivity Some aspects of the present disclosure provide Cas9 domains with different PAM specificities. Typically, Cas9 proteins, such as Cas9 from S. pyogenes (spCas9), require a canonical NGG PAM sequence to bind to specific nucleic acid regions. This can limit their ability to edit desired bases in a genome. In some embodiments, the base-editing fusion proteins provided herein may require precise placement, for example, placing the target base within a four-base region (e.g., a "deamination window") approximately 15 bases upstream of the PAM. See Komor, AC, et al., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage," Nature 533, 420-424 (2016), the entire contents of which are incorporated herein by reference. Thus, in some embodiments, any of the fusion proteins provided herein may contain a Cas9 domain capable of binding to nucleotide sequences that do not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-classical PAM sequences have been described in the art and will be apparent to those skilled in the art. For example, Cas9 domains that bind to non-classical PAM sequences are described in Kleinstiver, BP, et al., "Engineered CRISPR-Cas9 nucleases with altered PAM specificities" Nature 523, 481-485 (2015); and Kleinstiver, BP, et al., "Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition" Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each are incorporated herein by reference.
[0181] In some embodiments, the Cas9 domain is a Cas9 domain from Staphylococcus aureus (SaCas9). In some embodiments, the SaCas9 domain is nuclease-active SaCas9, nuclease-inactive SaCas9 (SaCas9d), or SaCas9 nickase (SaCas9n). In some embodiments, the SaCas9 comprises the amino acid sequence SEQ ID NO: 4273. In some embodiments, the SaCas9 comprises an N579X mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than N. In some embodiments, the SaCas9 comprises an N579A mutation of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence having an NNGRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of the E781X, N967X, and R1014X mutations of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid. In some embodiments, the SaCas9 domain comprises one or more of the E781K, N967K, and R1014H mutations of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SaCas9 domain comprises the E781K, N967K, or R1014H mutations of SEQ ID NO: 4273, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
[0182] In some embodiments, the Cas9 domain of any of the fusion proteins provided herein is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4273-4275. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4273-4275. Exemplary SaCas9 Sequences
number
number
number
number
[0183] In some embodiments, the Cas9 domain is a Cas9 domain from Streptococcus pyogenes (SpCas9). In some embodiments, the SpCas9 domain is nuclease-active SpCas9, nuclease-inactive SpCas9 (SpCas9d), or SpCas9 nickase (SpCas9n). In some embodiments, the SpCas9 comprises the amino acid sequence SEQ ID NO: 4276. In some embodiments, the SpCas9 comprises a D9X mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than D. In some embodiments, the SpCas9 comprises a D9A mutation of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain, SpCas9d domain, or SpCas9n domain can bind to a nucleic acid sequence with a non-canonical PAM. In some embodiments, the SpCas9 domain, SpCas9d domain, or SpCas9n domain can bind to a nucleic acid sequence having an NGG, NGA, or NGCG PAM sequence. In some embodiments, the SpCas9 domain comprises one or more of the D1134X, R1334X, and T1336X mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of the D1134E, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises the D1134E, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.In some embodiments, the SpCas9 domain comprises one or more of the D1134X, R1334X, and T1336X mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of the D1134V, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises the D1134V, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of the D1134X, G1217X, R1334X, and T1336X mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid. In some embodiments, the SpCas9 domain comprises one or more of the D1134V, G1217R, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, the SpCas9 domain comprises one or more of the D1134V, G1217R, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
[0184] In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein comprises the amino acid sequence of any one of SEQ ID NOs: 4276-4280. In some embodiments, the Cas9 domain of any of the fusion proteins provided herein consists of the amino acid sequence of any one of SEQ ID NOs: 4276-4280. Exemplary SpCas9
number
number
number
number
number
number
number
number
number
[0185] The following are exemplary fusion proteins (e.g., base editing proteins) that can bind to nucleic acid sequences with non-classical (e.g., non-NGG) PAM sequences:
number
number
number
number
number
number
number
number
[0186] High-Fidelity Base Editors Some aspects of the present disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain with high fidelity. Additional aspects of the present disclosure provide Cas9 fusion proteins (e.g., any of the fusion proteins provided herein) comprising a Cas9 domain with reduced electrostatic interactions between the Cas9 domain and the sugar-phosphate backbone of DNA compared to a wild-type Cas9 domain. In some embodiments, the Cas9 domain (e.g., a wild-type Cas9 domain) comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of DNA. In some embodiments, any of the Cas9 fusion proteins provided herein comprise one or more N497X, R661X, Q695X, and / or Q926X mutations in the amino acid sequence provided by SEQ ID NO: 10, or corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid. In some embodiments, any of the Cas9 fusion proteins provided herein comprises one or more of the N497A, R661A, Q695A, and / or Q926A mutations of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain comprises the D10A mutation of the amino acid sequence provided in SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided in SEQ ID NOs: 11-260. In some embodiments, the Cas9 domain (e.g., of any of the fusion proteins provided herein) comprises the amino acid sequence set forth in SEQ ID NO: 325. In some embodiments, the fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 285. Cas9 domains with high fidelity are known in the art and will be apparent to those of skill in the art.For example, high-fidelity Cas9 domains are described in Kleinstiver, BP, et al., "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects." Nature 529, 490-495 (2016); and Slaymaker, IM, et al., "Rationally engineered Cas9 nucleases with improved specificity." Science 351, 84-88 (2015), the entire contents of each of which are incorporated herein by reference.
[0187] It should be understood that base editors provided herein, such as base editor 2 (BE2) or base editor 3 (BE3), can be converted to high fidelity base editors by modifying the Cas9 domain described herein to create high fidelity base editors, such as high fidelity base editor 2 (HF-BE2) or high fidelity base editor 3 (HF-BE3). In some embodiments, base editor 2 (BE2) comprises a deaminase domain, dCas9, and a UGI domain. In some embodiments, base editor 3 (BE3) comprises a deaminase domain, an nCas9 domain, and a UGI domain. Cas9 domain with mutations shown in bold and underlined relative to Cas9 of SEQ ID NO: 10
number
number
number
[0188] Cas9 fusion protein Any of the Cas9 domains disclosed herein (e.g., a nuclease-active Cas9 protein, a nuclease-inactive dCas9 protein, or a Cas9 nickase protein) can be fused to a second protein; thus, the fusion proteins provided herein comprise a Cas9 domain provided herein and a second protein or "fusion partner." In some embodiments, the second protein is fused to the N-terminus of the Cas9 domain. However, in other embodiments, the second protein is fused to the C-terminus of the Cas9 domain. In some embodiments, the second protein fused to the Cas9 domain is a nucleic acid editing domain. In some embodiments, the Cas9 domain and the nucleic acid editing domain are fused via a linker, while in other embodiments, the Cas9 domain and the nucleic acid editing domain are fused directly to each other. In some embodiments, the linker is (GGGS) n (SEQ ID NO: 265), (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , (SGGS) n , (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), or (XP) n In some embodiments, the linker comprises a (GGS) motif, ... n In some embodiments, the linker comprises the (GGS) motif, where n is 1, 3, or 7. nThe linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7) (also referred to in the examples as an XTEN linker). The length of the linker can affect the bases to be edited, as illustrated in the examples. For example, a 3 amino acid long linker (e.g., (GGS)1) can provide an editing window of 2-5, 2-4, 2-3, or 3-4 bases relative to the PAM sequence, while a 9 amino acid linker (e.g., (GGS)3 (SEQ ID NO: 596)) can provide an editing window of 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, or 5-6 bases relative to the PAM sequence. A 16-amino acid linker (e.g., an XTEN linker) can confer an exceptionally potent activity window of 2-7, 2-6, 2-5, 2-4, 2-3, 3-7, 3-6, 3-5, 3-4, 4-7, 4-6, 4-5, 5-7, 5-6, or 6-7 bases relative to the PAM sequence, while a 21-amino acid linker (e.g., (GGS)7 (SEQ ID NO: 597)) can confer an editing window of 3-8, 3-7, 3-6, 3-5, 3-4, 4-8, 4-7, 4-6, 4-5, 5-8, 5-7, 5-6, 6-8, 6-7, or 7-8 bases relative to the PAM sequence. The novel finding that varying linker lengths can allow the disclosed dCas9 fusion proteins to edit nucleobases at different distances from the PAM sequence provides significant clinical importance. Because the PAM sequence can be at various distances from the disease-causing mutation in the gene to be corrected, it will be understood that the linker lengths given as examples herein are not meant to be limiting.
[0189] In some embodiments, the second protein comprises an enzymatic domain. In some embodiments, the enzymatic domain is a nucleic acid editing domain. Such a nucleic acid editing domain can be, without limitation, a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, or an acetyltransferase. Non-limiting exemplary binding domains that can be used in accordance with the present disclosure include transcriptional activator domains and transcriptional repressor domains. Deaminase domain
[0190] In some embodiments, the second protein comprises a nucleic acid editing domain. In some embodiments, the nucleic acid editing domain can catalyze a C to U base change. In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytidine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is an activation-induced deaminase (AID). In some embodiments, the deaminase is a vertebrate deaminase. In some embodiments, the deaminase is an invertebrate deaminase. In some embodiments, the deaminase is a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse deaminase. In some embodiments, the deaminase is a human deaminase. In some embodiments, the deaminase is a rat deaminase, e.g., rAPOBEC1. In some embodiments, the deaminase is Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deminase is human APOBEC3G (SEQ ID NO: 275).In some embodiments, the deaminase is a fragment of human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R D317R mutation (SEQ ID NO: 5739). In some embodiments, the deaminase is a fragment of human APOBEC3G and comprises mutations corresponding to the D316R D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).
[0191] In some embodiments, the nucleic acid editing domain is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the deaminase domain of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741. In some embodiments, the nucleic acid editing domain comprises the amino acid sequence of any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741.
[0192] Deaminase domains that regulate the editing window of base editors Some aspects of the present disclosure are based on the recognition that modulating the catalytic activity of the deaminase domain of any of the fusion proteins provided herein, for example, by making point mutations in the deaminase domain, affects the processivity of the fusion protein (e.g., a base editor). For example, mutations that reduce, but do not eliminate, the catalytic activity of the deaminase domain in a base editing fusion protein can make the deaminase domain less likely to catalyze the deamination of residues adjacent to a target residue, thereby narrowing the deamination window. The ability to narrow the deamination window can prevent unwanted deamination of residues adjacent to a particular target residue, which can reduce or prevent off-target effects.
[0193] In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) with reduced deaminase catalytic activity. In some embodiments, any of the fusion proteins provided herein comprise a deaminase domain (e.g., a cytidine deaminase domain) with reduced deaminase catalytic activity compared to a suitable control. For example, a suitable control can be the deaminase activity of a deaminase prior to the introduction of one or more mutations into the deaminase. In other embodiments, a suitable control can be a wild-type deaminase. In some embodiments, a suitable control is a wild-type apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the suitable control is APOBEC1 deaminase, APOBEC2 deaminase, APOBEC3A deaminase, APOBEC3B deaminase, APOBEC3C deaminase, APOBEC3D deaminase, APOBEC3F deaminase, APOBEC3G deaminase, or APOBEC3H deaminase. In some embodiments, the suitable control is activation-induced deaminase (AID). In some embodiments, the suitable control is cytidine deaminase 1 (pmCDA1) from Petromyzon marinus. In some embodiments, the deaminase domain can be a deaminase domain that has at least 1%, at least 5%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% less deaminase catalytic activity compared to a suitable control.
[0194] In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBECl (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase, where X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBECl (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.
[0195] In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase, where X is any amino acid. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.
[0196] In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the H121R and H122R mutations of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R126A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R126E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R118A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W90A mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W90Y mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R132E mutation of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W90Y and R126E mutations of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R126E and R132E mutations of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W90Y and R132E mutations of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W90Y, R126E, and R132E mutations of rAPOBEC1 (SEQ ID NO: 284), or one or more corresponding mutations in another APOBEC deaminase.
[0197] In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the D316R and D317R mutations of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R320A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R320E mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R313A mutation of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising a W285A mutation in hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising a W285Y mutation in hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising a R326E mutation in hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising a W285Y and R320E mutations in hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the R320E and R326E mutations of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W285Y and R326E mutations of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any of the fusion proteins provided herein comprises an APOBEC deaminase comprising the W285Y, R320E, and R326E mutations of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.
[0198] Some aspects of the present disclosure provide fusion proteins comprising (i) a nuclease-inactivated Cas9 domain; and (ii) a nucleic acid editing domain. In some embodiments, the nuclease-inactivated Cas9 domain (dCas9) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 provided by any one of SEQ ID NOS: 10-263, and includes a mutation that inactivates the nuclease activity of Cas9. Mutations that inactivate the nuclease domain of Cas9 are well known in the art. For example, the DNA cleavage domain of Cas9 is known to contain two subdomains: an HNH nuclease subdomain and a RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, while the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can suppress the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi et al., Cell. 28; 152(5):1173-83 (2013)). In some embodiments, a dCas9 of the present disclosure comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, a dCas9 of the present disclosure comprises a H840A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. In some embodiments, a dCas9 of the present disclosure comprises both the D10A and H840A mutations in the amino acid sequence provided by SEQ ID NO: 10, or the corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.In some embodiments, the Cas9 further comprises a histidine residue at position 840 of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. The presence of catalytic residue H840 restores the activity of Cas9 to cleave the unedited strand containing a G opposite the target C. Restoration of H840 does not result in cleavage of the target strand containing a C. In some embodiments, the dCas9 comprises the amino acid sequence of SEQ ID NO: 263. It should be understood that other mutations that inactivate the nuclease domain of Cas9 can also be encompassed by the dCas9 of the present disclosure.
[0199] The Cas9 or dCas9 domain containing the mutations disclosed herein can be a full-length Cas9 or a fragment thereof. In some embodiments, a protein containing Cas9 or a fragment thereof is referred to as a "Cas9 variant." A Cas9 variant shares homology with Cas9 or a fragment thereof. For example, a Cas9 variant can be at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild-type Cas9. In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA cleavage domain) that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild-type Cas9, e.g., a Cas9 comprising the amino acid sequence of SEQ ID NO: 10.
[0200] Any of the Cas9 fusion proteins of the present disclosure can further comprise a nucleic acid editing domain (e.g., an enzyme capable of modifying a nucleic acid, such as a deaminase). In some embodiments, the nucleic acid editing domain is a DNA editing domain. In some embodiments, the nucleic acid editing domain has deaminase activity. In some embodiments, the nucleic acid editing domain comprises or consists of a deaminase or deaminase domain. In some embodiments, the deaminase is a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 family deaminase. In some embodiments, the deaminase is activation-induced cytidine deaminase (AID). Several nucleic acid editing domains and Cas9 fusion proteins comprising such domains are described in detail herein. Additional suitable nucleic acid editing domains will be apparent to those of skill in the art based on this disclosure and knowledge in the art.
[0201] Some aspects of the present disclosure provide fusion proteins comprising a Cas9 domain fused to a nucleic acid editing domain, wherein the nucleic acid editing domain is fused to the N-terminus of the Cas9 domain. In some embodiments, the Cas9 domain and the nucleic acid editing-editing domain are fused via a linker. In some embodiments, the linker is (GGGS) n (SEQ ID NO: 265), (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , (SGGS) n(SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7) motif (see, e.g., Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fok1 nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents of which are incorporated herein by reference), or (XP) n In some embodiments, n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, or any combination thereof when more than one linker or more than one linker motif is present. In some embodiments, the linker is (GGS) n In some embodiments, the linker comprises the motif (GGS) n motif, where n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7). Additional suitable linker motifs and linker configurations will be apparent to those of skill in the art. In some embodiments, suitable linker motifs and configurations include those described in Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. 2013; 65(10): 1357-69, the entire contents of which are incorporated herein by reference. Additional suitable linker sequences will be apparent to those of skill in the art based on this disclosure. In some embodiments, the general structure of exemplary Cas9 fusion proteins provided herein has the structure: [NH2]-[nucleic acid editing domain]-[Cas9]-[COOH] or [NH2]-[nucleic acid editing domain]-[linker]-[Cas9]-[COOH] Including, NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein.
[0202] The fusion proteins of the present disclosure may include one or more additional features. For example, in some embodiments, the fusion protein includes a nuclear localization sequence (NLS). In some embodiments, the NLS of the fusion protein is located between the nucleic acid editing domain and the Cas9 domain. In some embodiments, the NLS of the fusion protein is located at the C-terminus of the Cas9 domain.
[0203] Other exemplary features that may be present are localization sequences, e.g., cytoplasmic localization sequences, export sequences, e.g., nuclear export sequences, or other localization sequences, and sequence tags useful for solubilizing, purifying, or detecting the fusion protein. Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc tags, calmodulin tags, FLAG tags, hemagglutinin (HA) tags, polyhistidine tags, also referred to as histidine tags or His tags, maltose-binding protein (MBP) tags, nus tags, glutathione-S-transferase (GST) tags, green fluorescent protein (GFP) tags, thioredoxin tags, S tags, Softag (e.g., Softag 1, Softag 3), strep tags, biotin ligase tags, FlAsH tags, V5 tags, and SBP tags. Additional suitable sequences will be apparent to those skilled in the art. In some embodiments, the fusion protein comprises one or more His tags.
[0204] In some embodiments, the nucleic acid editing domain is a deaminase. For example, in some embodiments, the general structure of an exemplary Cas9 fusion protein having a deaminase domain is the structure: [NH2]-[NLS]-[deaminase]-[Cas9]-[COOH], [NH2]-[Cas9]-[deaminase]-[COOH], [NH2]-[deaminase]-[Cas9]-[COOH], or [NH2]-[deaminase]-[Cas9]-[NLS]-[COOH], Including, The NLS is a nuclear localization sequence, NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. Nuclear localization sequences are known in the art and would be apparent to one skilled in the art. For example, NLS sequences are described in Plank et al., PCT / EP2000 / 011690, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, the NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 741) or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 742). In some embodiments, a linker is inserted between Cas9 and the deaminase. In some embodiments, the NLS is located at the C-terminus of the Cas9 domain. In some embodiments, the NLS is located at the N-terminus of the Cas9 domain. In some embodiments, the NLS is located between the deaminase and the Cas9 domain. In some embodiments, the NLS is located at the N-terminus of the deaminase domain. In some embodiments, the NLS is located at the C-terminus of the deaminase domain.
[0205] One exemplary suitable type of nucleic acid editing domain is a cytidine deaminase, e.g., of the APOBEC family. The apolipoprotein B mRNA editing complex (APOBEC) family of cytidine deaminase enzymes encompasses 11 proteins that serve to initiate mutagenesis in a controlled, beneficial manner. 29 One family member, activation-induced cytidine deaminase (AID), is responsible for antibody maturation by converting cytosine to uracil in ssDNA in a strand-biased, transcription-dependent manner. 30Apolipoprotein B editing complex 3 (APOBEC3) enzymes provide human cells with protection against certain HIV-1 strains by deaminating cytosines in reverse-transcribed viral ssDNA. 31 All of these proteins require Zn for catalytic activity. 2+ Coordination motif (His-X-Glu-X 23-26 -Pro-Cys-X 2-4 The deamination reaction requires a water molecule bound to the Glu residue (-Cys; SEQ ID NO: 598). The Glu residue serves to activate the water molecule to zinc hydroxide for nucleophilic attack. Each family member preferentially deaminates at its own specific "hot spot," ranging from WRC (W is A or T, R is A or G) in hAID to TTC in hAPOBEC3F. 32 The recent crystal structure of the catalytic domain of APOBEC3G revealed a secondary structure comprising a five-stranded β-sheet core flanked by six α-helices, which is believed to be conserved throughout the family. 33 The active center loop has been shown to be responsible for both ssDNA binding and determining "hot spot" identity. 34 Overexpression of these enzymes has been linked to genomic instability and cancer, therefore highlighting the importance of sequence-specific targeting. 35 .
[0206] Some aspects of the present disclosure relate to the recognition that the activity of cytidine deaminase enzymes, such as APOBEC enzymes, can be directed to specific sites in genomic DNA. Without wishing to be bound by any particular theory, advantages of using Cas9 as a recognition agent include: (1) the sequence specificity of Cas9 can be easily altered by simply changing the sgRNA sequence; and (2) Cas9 binds to its target sequence by denaturing dsDNA, resulting in a stretch of DNA that is single-stranded and thus a suitable substrate for the deaminase. It should be understood that other catalytic domains, or catalytic domains from other deaminases, can also be used to create fusion proteins with Cas9, and the present disclosure is not limited in this respect.
[0207] Some aspects of the present disclosure are based on the recognition that Cas9:deaminase fusion proteins can efficiently deaminate nucleotides at positions 3-11 according to the numbering scheme of Figure 3. In light of the results provided herein regarding the nucleotides that can be targeted by Cas9:deaminase fusion proteins, one of skill in the art will be able to design a suitable guide RNA for targeting the fusion protein to a target sequence containing the nucleotide to be deaminated.
[0208] In some embodiments, the deaminase domain and the Cas9 domain are fused to each other by a linker. Various linker lengths and flexibilities between the deaminase domain (e.g., AID) and the Cas9 domain can be used to achieve the optimal length for deaminase activity for a particular application (e.g., in the form (GGGGS) n (SEQ ID NO: 5), (GGS) n , and (G) n From the highly flexible linker, the form (EAAAK) n (SEQ ID NO: 6), (SGGS) n(SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7) (see, e.g., Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fok1 nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82; the entire contents of which are incorporated herein by reference), and (XP) n (ranges from 1 to 2) 36 In some embodiments, the linker is (GGS) n motif, and n is 1, 3, or 7. In some embodiments, the linker comprises a SGSETPGTSESATPES (SEQ ID NO: 7) motif.
[0209] Some exemplary suitable nucleic acid editing domains, such as deaminases and deaminase domains, that can be fused to a Cas9 domain in accordance with aspects of the present disclosure are provided below. It should be understood that in some embodiments, the active domain of each sequence can be used, for example, a domain without a localization signal (nuclear localization sequence, no nuclear export signal, cytoplasmic localization signal).
[0210] Human AID:
number
[0211] Mouse AID:
number
[0212] Dog AID:
number
[0213] Bovine AID:
number
[0214] Rat AID:
number
[0215] Mouse APOBEC-3:
number
number
[0216] Rat APOBEC-3:
number
[0217] Rhesus APOBEC-3G:
number
[0218] Chimpanzee APOBEC-3G:
number
[0219] Green monkey APOBEC-3G:
number
[0220] Human APOBEC-3G:
number
[0221] Human APOBEC-3F:
number
[0222] Human APOBEC-3B:
number
number
[0223] Rat APOBEC-3B:
number
[0224] Bovine APOBEC-3B:
number
[0225] Chimpanzee APOBEC-3B:
number
[0226] Human APOBEC-3C:
number
[0227] Gorilla APOBEC-3C:
number
[0228] Human APOBEC-3A:
number
[0229] Rhesus APOBEC-3A:
number
[0230] Bovine APOBEC-3A:
number
[0231] Human APOBEC-3H:
number
[0232] Rhesus APOBEC-3H:
number
number
[0233] Human APOBEC-3D:
number
[0234] Human APOBEC-1:
number
[0235] Mouse APOBEC-1:
number
[0236] Rat APOBEC-1:
number
[0237] Human APOBEC-2:
number
number
[0238] Mouse APOBEC-2:
number
[0239] Rat APOBEC-2:
number
[0240] Bovine APOBEC-2:
number
[0241] Petromyzon marinus CDA1 (pmCDA1):
number
[0242] Human APOBEC3G D316R_D317R:
number
number
[0243] Human APOBEC3G A chain:
number
[0244] Human APOBEC3G A chain D120R_D121R:
number
[0245] In some embodiments, the fusion proteins provided herein comprise the full-length amino acid sequence of a nucleic acid editing enzyme, such as one of the sequences provided above. However, in other embodiments, the fusion proteins provided herein comprise only a fragment of a nucleic acid editing enzyme, rather than the full-length sequence. For example, in some embodiments, the fusion proteins provided herein comprise a Cas9 domain and a fragment of a nucleic acid editing enzyme, e.g., the fragment comprises a nucleic acid editing domain. Exemplary amino acid sequences of nucleic acid editing domains are shown in italics in the sequences above, and additional suitable sequences of such domains will be apparent to those skilled in the art.
[0246] Additional suitable nucleic acid editing enzyme sequences, e.g., deaminase enzyme and domain sequences, that can be used in accordance with aspects of the present invention, e.g., fused to a nuclease-inactive Cas9 domain, will be apparent to those of skill in the art based on this disclosure. In some embodiments, such additional enzyme sequences include deaminase enzyme or deaminase domain sequences that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% similar to the sequences provided herein. Additional suitable Cas9 domains, variants, and sequences will be apparent to those of skill in the art. Examples of such additional suitable Cas9 domains include, but are not limited to, D10A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference). In some embodiments, Cas9 comprises a histidine residue at position 840 of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260. The presence of catalytic residue H840 restores the activity of Cas9 to cleave the unedited strand containing a G opposite the target C. Restoration of H840 does not result in cleavage of the target strand containing a C.
[0247] Additional suitable strategies for generating fusion proteins comprising a Cas9 domain and a deaminase domain will be apparent to those skilled in the art based on the present disclosure in combination with general knowledge in the art. Suitable strategies for generating fusion proteins according to aspects of the present disclosure, with or without the use of a linker, will also be apparent to those skilled in the art in light of the present disclosure and knowledge in the art. For example, Gilbert et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154(2):442-51, showed that a C-terminal fusion of Cas9 with VP64 using two NLSs as a linker (SPKKKRKVEAS, SEQ ID NO: 599) can be used for transcriptional activation. Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8, report that C-terminal fusions to VP64 without a linker can be used for transcriptional activation, and Maeder et al., CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10: 977-979, report that C-terminal fusions to VP64 using a Gly4Ser (SEQ ID NO: 5) linker can be used as transcriptional activators.Recently, dCas9-Fok1 nuclease fusions have been successfully generated, showing improved enzymatic specificity compared to the parental Cas9 enzyme (Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to Fok1 nuclease improves the specificity of genome modification. Nat. Biotechnol. 2014; 32(6): 577-82 and Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, Goodwin MJ, Aryee MJ, Joung JK. Dimeric CRISPR RNA-guided Fok1 nucleases for highly specific genome editing. Nat Biotechnol. 2014; 32(6): 569-76. PMID: In 24770325, SGSETPGTSESATPES (SEQ ID NO: 7) or GGGGS (SEQ ID NO: 5) linkers are used in the Fok1-dCas9 fusion proteins, respectively.
[0248] Some aspects of the present disclosure provide fusion proteins comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein). In some aspects, the fusion proteins provided herein further include (iii) a programmable DNA-binding protein, such as a zinc finger domain, a TALE, or a second Cas9 protein (e.g., a third protein). Without wishing to be bound by any particular theory, fusing a programmable DNA-binding protein (e.g., a second Cas9 protein) to a fusion protein comprising (i) a Cas9 enzyme or domain (e.g., a first protein); and (ii) a nucleic acid-editing enzyme or domain (e.g., a second protein) may be useful for improving the specificity of the fusion protein for a target nucleic acid sequence, or for improving the specificity or binding affinity of the fusion protein for binding to a target nucleic acid sequence that does not contain a canonical PAM (NGG) sequence. In some embodiments, the third protein is a Cas9 protein (e.g., a second Cas9 protein). In some embodiments, the third protein is any of the Cas9 proteins provided herein. In some embodiments, the third protein is fused to the fusion protein at the N-terminus of the Cas9 protein (e.g., the first protein). In some embodiments, the third protein is fused to the fusion protein at the C-terminus of the Cas9 protein (e.g., the first protein). In some embodiments, the Cas9 domain (e.g., the first protein) and the third protein (e.g., the second Cas9 protein) are fused by a linker (e.g., a second linker). In some embodiments, the linker is (GGGGS) n (SEQ ID NO: 5), (G)n, (EAAAK) n (SEQ ID NO: 6), (GGS) n , (SGGS) n (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), or (XP) n motif, or any combination thereof, wherein n is independently an integer between 1 and 30. In some embodiments, the general structure of exemplary Cas9 fusion proteins provided herein comprises the structure: [NH2]-[nucleic acid editing enzyme or domain]-[Cas9]-[third protein]-[COOH]; [NH2]-[third protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[COOH]; [NH2]-[Cas9]-[nucleic acid editing enzyme or domain]-[third protein]-[COOH]; [NH2]-[third protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[COOH]; [NH2]-[UGI]-[nucleic acid editing enzyme or domain]-[Cas9]-[third protein]-[COOH]; [NH2]-[UGI]-[third protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[COOH]; [NH2]-[UGI]-[Cas9]-[nucleic acid editing enzyme or domain]-[third protein]-[COOH]; [NH2]-[UGI]-[third protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[COOH]; [NH2]-[nucleic acid editing enzyme or domain]-[Cas9]-[third protein]-[UGI]-[COOH]; [NH2]-[third protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[UGI]-[COOH]; [NH2]-[Cas9]-[nucleic acid editing enzyme or domain]-[third protein]-[UGI]-[COOH]; or [NH2]-[third protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[UGI]-[COOH]; Including, NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the "]-[" used in the above general structure indicates the presence of an optional linker sequence. In other examples, the general structure of exemplary Cas9 fusion proteins provided herein has the structure: [NH2]-[nucleic acid editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[COOH]; [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[COOH]; [NH2]-[Cas9]-[nucleic acid editing enzyme or domain]-[second Cas9 protein]-[COOH]; [NH2]-[second Cas9 protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[COOH]; [NH2]-[UGI]-[nucleic acid editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[COOH]; [NH2]-[UGI]-[second Cas9 protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[COOH]; [NH2]-[UGI]-[Cas9]-[nucleic acid editing enzyme or domain]-[second Cas9 protein]-[COOH]; [NH2]-[UGI]-[second Cas9 protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[COOH]; [NH2]-[nucleic acid editing enzyme or domain]-[Cas9]-[second Cas9 protein]-[UGI]-[COOH]; [NH2]-[second Cas9 protein]-[Cas9]-[nucleic acid editing enzyme or domain]-[UGI]-[COOH]; [NH2]-[Cas9]-[nucleic acid editing enzyme or domain]-[second Cas9 protein]-[UGI]-[COOH]; or [NH2]-[second Cas9 protein]-[nucleic acid editing enzyme or domain]-[Cas9]-[UGI]-[COOH], Including, NH2 is the N-terminus of the fusion protein, and COOH is the C-terminus of the fusion protein. In some embodiments, the "]-[" used in the above general structure indicates the presence of an optional linker sequence. In some embodiments, the second Cas9 is a dCas9 protein. In some examples, the general structures of exemplary Cas9 fusion proteins provided herein include the structures shown in Figure 3. It should be understood that any of the proteins provided in any of the general structures of exemplary Cas9 fusion proteins can be connected by one or more of the linkers provided herein. In some embodiments, the linkers are the same. In some embodiments, the linkers are different. In some embodiments, one or more of the proteins provided in any of the general structures of exemplary Cas9 fusion proteins are not fused by a linker. In some embodiments, the fusion protein further comprises a nuclear targeting sequence, e.g., a nuclear localization sequence. In some embodiments, the fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of a third protein. In some embodiments, the NLS is fused to the C-terminus of a third protein. In some embodiments, the NLS is fused to the N-terminus of a Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of a Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of a nucleic acid editing enzyme or domain. In some embodiments, the NLS is fused to the C-terminus of a nucleic acid editing enzyme or domain. In some embodiments, the NLS is fused to the N-terminus of a UGI protein. In some embodiments, the NLS is fused to the C-terminus of a UGI protein. In some embodiments, the NLS is fused to the fusion protein by one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker.
[0249] Uracil glycosylase inhibitor fusion protein Some aspects of the present disclosure relate to fusion proteins comprising a uracil glycosylase inhibitor (UGI) domain. In some embodiments, any of the fusion proteins provided herein comprising a Cas9 domain (e.g., a nuclease-active Cas9 domain, a nuclease-inactive dCas9 domain, or a Cas9 nickase) can be further fused to a UGI domain, either directly or via a linker. Some aspects of the present disclosure provide deaminase-dCas9 fusion proteins, deaminase-nuclease-active Cas9 fusion proteins, and deaminase-Cas9 nickase fusion proteins with increased nucleobase editing efficiency. Without wishing to be bound by any particular theory, the cellular DNA repair response to the presence of U:G heteroduplex DNA may be responsible for the decreased nucleobase editing efficiency of cells. For example, uracil DNA glycosylase (UDG) catalyzes the removal of U from intracellular DNA, which may initiate base excision repair, the most common outcome of which is reversion of a U:G pair to a C:G pair. As demonstrated in the examples below, uracil DNA glycosylase inhibitor (UGI) can inhibit human UDG activity. Therefore, the present disclosure further contemplates a fusion protein comprising a dCas9-nucleic acid editing domain fused to a UGI domain. The present disclosure also contemplates a fusion protein comprising a Cas9 nickase-nucleic acid editing domain fused to a UGI domain. It should be understood that the use of a UGI domain can increase the editing efficiency of a nucleic acid editing domain capable of catalyzing a C to U change. For example, a fusion protein comprising a UGI domain may be more efficient at deaminating C residues. In some embodiments, the fusion protein has the structure: [deaminase]-[any linker sequence]-[dCas9]-[any linker sequence]-[UGI]; [deaminase]-[any linker sequence]-[UGI]-[any linker sequence]-[dCas9]; [UGI]-[any linker sequence]-[deaminase]-[any linker sequence]-[dCas9]; [UGI]-[any linker sequence]-[dCas9]-[any linker sequence]-[deaminase]; [dCas9]-[any linker sequence]-[deaminase]-[any linker sequence]-[UGI]; or [dCas9]-[any linker sequence]-[UGI]-[any linker sequence]-[deaminase], Includes: In other embodiments, the fusion protein has the structure: [deaminase]-[optional linker sequence]-[Cas9 nickase]-[optional linker sequence]-[UGI]; [deaminase]-[optional linker sequence]-[UGI]-[optional linker sequence]-[Cas9 nickase]; [UGI]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[Cas9 nickase]; [UGI]-[optional linker sequence]-[Cas9 nickase]-[optional linker sequence]-[deaminase]; [Cas9 nickase]-[optional linker sequence]-[deaminase]-[optional linker sequence]-[UGI]; or [Cas9 nickase]-[any linker sequence]-[UGI]-[any linker sequence]-[deaminase], Includes:
[0250] In some embodiments, the fusion proteins provided herein do not include a linker sequence. In some embodiments, one or both of the optional linker sequences are present.
[0251] In some embodiments, the "-" used in the general structure above indicates the presence of an optional linker sequence. In some embodiments, the fusion protein comprising a UGI further comprises a nuclear targeting sequence, e.g., a nuclear localization sequence. In some embodiments, the fusion proteins provided herein further comprise a nuclear localization sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In some embodiments, the NLS is fused to the N-terminus of the UGI protein. In some embodiments, the NLS is fused to the C-terminus of the UGI protein. In some embodiments, the NLS is fused to the N-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the C-terminus of the Cas9 protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the N-terminus of a second Cas9. In some embodiments, the NLS is fused to the C-terminus of a second Cas9. In some embodiments, the NLS can be fused to the fusion protein via one or more linkers. In some embodiments, the NLS can be fused to the fusion protein without a linker. In some embodiments, the NLS comprises the amino acid sequence of any one of the NLS sequences provided or referenced herein. In some embodiments, the NLS comprises the amino acid sequence set forth in SEQ ID NO: 741 or SEQ ID NO: 742.
[0252] In some embodiments, the UGI domain comprises wild-type UGI or the UGI set forth in SEQ ID NO: 600. In some embodiments, UGI proteins provided herein include fragments of UGI and proteins homologous to UGI or UGI fragments. For example, in some embodiments, the UGI domain comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, the UGI fragment comprises an amino acid sequence comprising at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 600, or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO: 600. In some embodiments, proteins comprising UGI or a fragment of UGI or a homolog of UGI or a UGI fragment are referred to as "UGI variants." UGI variants share homology with UGI or a fragment thereof. For example, UGI variants are at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% identical to wild-type UGI or the UGI set forth in SEQ ID NO: 600. In some embodiments, UGI variants comprise fragments of UGI, wherein the fragments are at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% identical to wild-type UGI or the corresponding fragment of UGI set forth in SEQ ID NO: 600. In some embodiments, UGI comprises the following amino acid sequence: >sp|P14739|UNGI_BPPB2 Uracil DNA glycosylase inhibitor
number
[0253] Suitable UGI protein and nucleotide sequences are provided herein; additional suitable UGI sequences are known to those of skill in the art, see, e.g., Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264: 1163-1171 (1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419 (1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887 (1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346 (1999), the entire contents of each of which are incorporated herein by reference.
[0254] It should be understood that additional proteins can be uracil glycosylase inhibitors. For example, other proteins that can inhibit (e.g., sterically block) uracil-DNA glycosylase base excision repair enzymes are within the scope of this disclosure. In addition, any protein that blocks or inhibits base excision repair is also within the scope of this disclosure. In some embodiments, a protein that binds to DNA is used. In other embodiments, a surrogate for UGI is used. In some embodiments, the uracil glycosylase inhibitor is a protein that binds to single-stranded DNA. For example, the uracil glycosylase inhibitor can be Erwinia tasmaniensis single-stranded binding protein. In some embodiments, the single-stranded binding protein comprises the amino acid sequence (SEQ ID NO: 322). In some embodiments, the uracil glycosylase inhibitor is a protein that binds to uracil. In some embodiments, the uracil glycosylase inhibitor is a protein that binds to uracil in DNA. In some embodiments, the uracil glycosylase inhibitor is a catalytically inactive uracil-DNA glycosylase protein. In some embodiments, the uracil glycosylase inhibitor is a catalytically inactive uracil DNA glycosylase protein that does not excise uracil from DNA. For example, the uracil glycosylase inhibitor is UdgX. In some embodiments, UdgX comprises the amino acid sequence (SEQ ID NO: 323). As another example, the uracil glycosylase inhibitor is catalytically inactive UDG. In some embodiments, the catalytically inactive UDG comprises the amino acid sequence (SEQ ID NO: 324). It should be understood that other uracil glycosylase inhibitors are within the scope of the present disclosure and will be apparent to those of skill in the art. In some embodiments, the uracil glycosylase inhibitor is a protein homologous to any one of SEQ ID NOs: 322-324.In some embodiments, the uracil glycosylase inhibitor is a protein that is at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to any one of SEQ ID NOs: 322-324. Erwinia tasmaniensis SSB (themostable single-stranded DNA binding protein)
number
number
number
number
[0255] In some embodiments, the nucleic acid editing domain is a deaminase domain. In some embodiments, the deaminase is a cytosine deaminase or a cytidine deaminase. In some embodiments, the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. In some embodiments, the deaminase is an APOBEC1 deaminase. In some embodiments, the deaminase is an APOBEC2 deaminase. In some embodiments, the deaminase is an APOBEC3 deaminase. In some embodiments, the deaminase is an APOBEC3A deaminase. In some embodiments, the deaminase is an APOBEC3B deaminase. In some embodiments, the deaminase is an APOBEC3C deaminase. In some embodiments, the deaminase is an APOBEC3D deaminase. In some embodiments, the deaminase is an APOBEC3E deaminase. In some embodiments, the deaminase is an APOBEC3F deaminase. In some embodiments, the deaminase is an APOBEC3G deaminase. In some embodiments, the deaminase is an APOBEC3H deaminase. In some embodiments, the deaminase is an APOBEC4 deaminase. In some embodiments, the deaminase is activation-induced deaminase (AID). In some embodiments, the deaminase is rat APOBEC1 (SEQ ID NO: 282). In some embodiments, the deaminase is human APOBEC1 (SEQ ID NO: 284). In some embodiments, the deaminase is Petromyzon marinus cytidine deaminase 1 (pmCDA1). In some embodiments, the deaminase is human APOBEC3G (SEQ ID NO: 275). In some embodiments, the deaminase is a fragment of human APOBEC3G (SEQ ID NO: 5740). In some embodiments, the deaminase is a human APOBEC3G variant comprising a D316R D317R mutation (SEQ ID NO: 5739).In some embodiments, the deaminase is a fragment of human APOBEC3G and contains mutations corresponding to the D316R D317R mutations in SEQ ID NO: 275 (SEQ ID NO: 5741).
[0256] In some embodiments, the linker is (GGGS) n (SEQ ID NO: 265), (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , SGSETPGTSESATPES (SEQ ID NO: 7), or (XP) n motif, or any combination thereof, wherein n is independently an integer between 1 and 30.
[0257] Suitable UGI protein and nucleotide sequences are provided herein; additional suitable UGI sequences are known to those of skill in the art, see, e.g., Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J. Biol. Chem. 264: 1163-1171 (1989); Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J. Biol. Chem. 272:21408-21419 (1997); Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nucleic Acids Res. 26:4880-4887 (1998); and Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J. Mol. Biol. 287:331-346 (1999), the entire contents of which are incorporated herein by reference. In some embodiments, the optional linker is (GGS) nIn some embodiments, the optional linker comprises a (GGS) motif, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, the optional linker comprises a (GGS) n motif, and n is 1, 3, or 7. In some embodiments, the optional linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 7), which is also referred to in the examples as an XTEN linker.
[0258] In some embodiments, the Cas9 nickase can further facilitate removal of bases on the non-edited strand in organisms whose genomes are edited in vivo. The Cas9 nickase described herein can include a D10A mutation in SEQ ID NO: 10, or a corresponding mutation in any of SEQ ID NOs: 11-260. In some embodiments, the Cas9 nickase of the present disclosure can include a histidine at mutation 840 in SEQ ID NO: 10, or a corresponding residue in any of SEQ ID NOs: 11-260. Such fusion proteins containing the Cas9 nickase can cleave a single strand of a target DNA sequence, e.g., the strand not being edited. Without wishing to be bound by any particular theory, this cleavage can inhibit mismatch repair mechanisms that reverse the C to U edit made by the deaminase.
[0259] Cas9 complex with guide RNA Some aspects of the present disclosure provide complexes comprising any of the fusion proteins provided herein and a guide RNA linked to a Cas9 domain (e.g., dCas9, nuclease-active Cas9, or Cas9 nickase) of the fusion protein.
[0260] In some embodiments, the guide RNA is 15-100 nucleotides in length and comprises a sequence of at least 10 consecutive nucleotides that are complementary to the target sequence. In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 consecutive nucleotides that are complementary to the target sequence. In some embodiments, the target sequence is a DNA sequence. In some embodiments, the target sequence is a sequence in a mammalian genome. In some embodiments, the target sequence is a sequence in a human genome. In some embodiments, the 3' end of the target sequence is immediately adjacent to a classic PAM sequence (NGG). In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder. In some embodiments, the guide RNA is complementary to a sequence associated with a disease or disorder having a mutation in a gene selected from the genes disclosed in any one of Tables 1-3. In some embodiments, the guide RNA comprises the nucleotide sequence of any one of the guide sequences provided in Table 2 or Table 3. Exemplary sequences in the human genome that can be targeted by the conjugates of the present disclosure are provided herein in Tables 1-3.
[0261] Method using Cas9 fusion protein Some aspects of the present disclosure provide methods using the Cas9 protein, fusion protein, or complex provided herein. For example, some aspects of the present disclosure provide methods comprising contacting a DNA molecule with (a) any of the Cas9 proteins or fusion proteins provided herein and at least one guide RNA; or (b) a Cas9 protein, Cas9 fusion protein, or Cas9 protein or fusion protein complex with at least one gRNA provided herein, wherein the guide RNA is about 15-100 nucleotides in length and comprises a sequence of at least 10 consecutive nucleotides complementary to the target sequence. In some embodiments, the 3' end of the target sequence is not immediately adjacent to a canonical PAM sequence (NGG). In some embodiments, the 3' end of the target sequence is immediately adjacent to an AGC, GAG, TTT, GTG, or CAA sequence.
[0262] In some embodiments, the target DNA sequence comprises a sequence associated with a disease or disorder. In some embodiments, the target DNA sequence comprises a point mutation associated with a disease or disorder. In some embodiments, activity of the Cas9 protein, Cas9 fusion protein, or complex results in correction of the point mutation. In some embodiments, the target DNA sequence comprises a T to C point mutation associated with a disease or disorder, and deamination of the mutant C base results in a sequence not associated with the disease or disorder. In some embodiments, the target DNA sequence encodes a protein, and the point mutation is in a codon, resulting in a change in the amino acid encoded by the mutant codon compared to the wild-type codon. In some embodiments, deamination of the mutant C results in a change in the amino acid encoded by the mutant codon. In some embodiments, deamination of the mutant C results in a codon encoding the wild-type amino acid. In some embodiments, the contacting is in vivo in a subject. In some embodiments, the subject has or has been diagnosed with a disease or disorder. In some embodiments, the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot-Marie-Tooth disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), congenital myotonia, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, prion disease, chronic infantile neurological cutaneous and articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with a mutant PI3KCA protein, a mutant CTNNB1 protein, a mutant HRAS protein, or a mutant p53 protein.
[0263] Some embodiments provide methods for using the Cas9 DNA editing fusion proteins provided herein. In some embodiments, the fusion proteins are used to introduce point mutations into nucleic acids by deaminating a targeted nucleobase, e.g., a C residue. In some embodiments, deamination of the targeted nucleobase results in the correction of a genetic defect, e.g., a point mutation that leads to loss of function of the gene product. In some embodiments, the genetic defect is associated with a disease or disorder, e.g., a lysosomal storage disorder or a metabolic disorder, e.g., type I diabetes. In some embodiments, the methods provided herein are used to introduce inactivating point mutations into genes or alleles encoding gene products associated with the disease or disorder. For example, in some embodiments, methods are provided herein that use a Cas9 DNA editing fusion protein to introduce inactivating point mutations into cancer genes (e.g., for the treatment of proliferative diseases). In some embodiments, the inactivating mutation can create a premature stop codon in the coding sequence, resulting in the expression of a truncated gene product, e.g., a truncated protein that lacks the function of the full-length protein.
[0264] In some embodiments, the purpose of the methods provided herein is to restore the function of a dysfunctional gene by genome editing. The Cas9 deaminase fusion proteins provided herein can be validated in vitro for human therapy based on gene editing, for example, by correcting disease-associated mutations in human cell cultures. It will be understood by those skilled in the art that the fusion proteins provided herein, such as fusion proteins comprising a Cas9 domain and a nucleic acid deaminase domain, can be used to correct any single T->C or A->G point mutation. In the first case, deamination of the mutant C back to U corrects the mutation, and in the latter case, deamination of the C base-paired with the mutant G, followed by one round of replication, corrects the mutation.
[0265] An exemplary disease-associated mutation that can be corrected in vitro or in vivo by the provided fusion proteins is the H1047R (A3140G) polymorphism of the PI3KCA protein. The phosphoinositide-3-kinase catalytic alpha subunit (PI3KCA) protein functions to phosphorylate the 3-OH group of the inositol ring of phosphatidylinositol. The PI3KCA gene has been found to be mutated in many different carcinomas and is therefore considered a potent oncogene. 37 In fact, the A3140G mutation is present in several NCI-60 cancer cell lines, such as HCT116, SKOV3, and T47D cell lines, which are readily available from the American Type Culture Collection (ATCC). 38 .
[0266] In some embodiments, cells carrying a mutation to be corrected, such as a point mutation, for example, an A3140G point mutation in exon 20 of the PI3KCA gene, which causes a H1047R substitution in the PI3KCA protein, are contacted with an expression construct encoding a Cas9 deaminase fusion protein and an appropriately designed sgRNA that targets the fusion protein to the respective mutation site in the PI3KCA gene. Control experiments can be performed, in which the sgRNA is designed to target the fusion enzyme to a non-C residue in the PI3KCA gene. The genomic DNA of the treated cells is extracted, and the relevant sequence of the PI3KCA gene is PCR amplified and sequenced, and the activity of the fusion protein can be evaluated in human cell culture.
[0267] It will be understood that the example of correcting a point mutation in PI3KCA is provided for illustrative purposes and is not meant to limit the disclosure. Those skilled in the art will understand that the DNA editing fusion proteins of the present disclosure can be used to correct other point mutations and mutations associated with other cancers and diseases other than cancer, including other proliferative disorders.
[0268] Successful correction of point mutations in disease-associated genes and alleles opens new strategies for gene correction with applications in therapy and basic research. Site-specific single-base modification systems, such as the disclosed fusions of Cas9 with deaminase enzymes or domains, also have applications in "reverse" gene therapy, where certain gene functions are intentionally suppressed or abolished. In these cases, site-specific mutation of Trp (TGG), Gln (CAA and CAG), or Arg (CGA) residues to premature stop codons (TAA, TAG, TGA) can be used to abolish protein function in vitro, ex vivo, or in vivo.
[0269] The present disclosure provides methods for treating a subject diagnosed with a disease associated with or caused by a point mutation that can be corrected by the Cas9 DNA editing fusion protein provided herein. For example, in some embodiments, a method is provided comprising administering to a subject with such a disease, such as a cancer associated with a PI3KCA point mutation described above, an effective amount of a Cas9 deaminase fusion protein that corrects the point mutation or introduces an inactivating mutation into a disease-associated gene. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments, the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing an inactivating mutation into a disease-associated gene will be known to those skilled in the art. The disclosure is not limited in this respect.
[0270] The present disclosure provides methods for treating additional diseases or disorders, such as those associated with or caused by point mutations that can be corrected by deaminase-mediated gene editing. Some such diseases are described herein, and additional suitable diseases that can be treated using the strategies and fusion proteins provided herein will be apparent to those skilled in the art based on this disclosure. Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of specific positions or residues in each sequence depends on the specific protein and the numbering scheme used. Numbering may differ, for example, between the precursor and the mature protein itself, and sequence differences between species may affect numbering. Those skilled in the art will be able to identify any homologous proteins and their respective residues in their encoding nucleic acids by methods well known in the art, such as sequence alignment and determining homologous residues. Exemplary suitable diseases and disorders include, without limitation, cystic fibrosis (see, e.g., Schwank et al., Functional repair of CFTR by CRISPR / Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell. 2013; 13: 653-658; and Wu et al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell stem cell. 2013; 13: 659-662, neither of which uses a deaminase fusion protein to correct the genetic defect); phenylketonuria—e.g., a phenylalanine to serine mutation (T>C mutation) at position 835 (mouse) or 240 (human) of the phenylalanine hydroxylase gene or a homologous residue—e.g., McDonald et al., Genomics.1997; 39:402-405; Bernard-Soulier syndrome (BSS)—e.g., a phenylalanine to serine mutation at position 55 or a homologous residue of platelet glycoprotein IX, or a cysteine to arginine at residue 24 or a homologous residue (T>C mutation)—see, e.g., Noris et al., British Journal of Haematology. 1997; 97: 312-320 and Ali et al., Hematol. 2014; 93: 381-384; epidermolytic hyperkeratosis (EHK)—e.g., a leucine to proline mutation at position 160 or 161 (counting the initiator methionine) or a homologous residue of keratin 1 (T>C mutation)—see, e.g., Chipev et al., Cell. 1992; 70: 821-828, see also UNIPROT database accession number P04264 at www.uniprot.org; chronic obstructive pulmonary disease (COPD) - e.g., a leucine to proline mutation (T>C mutation) at position 54 or 55 (counting the initiator methionine) or a homologous residue in the processed form of α1-antitrypsin, or at residue 78 or a homologous residue in the unprocessed form - see e.g., Poller et al., Genomics. 1993; 17: 740-743, see also UNIPROT database accession number P01011; Charcot-Marie-Tooth disease type 4J - e.g., an isoleucine to threonine mutation (T>C mutation) at position 41 or a homologous residue in FIG4 - see e.g., Lenk et al., PLoS Genetics. 2011; 7: See e1002104; neuroblastoma (NB) - e.g., leucine to proline mutation (T>C mutation) at position 197 or a homologous residue in caspase 9 - e.g., Kundu et al., 3 Biotech.2013, 3:225-234; von Willebrand disease (vWD)—e.g., a cysteine to arginine mutation (T>C mutation) at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor—see, e.g., Lavergne et al., Br. J. Haematol. 1992, see also UNIPROT database accession number P04275; 82: 66-72; myotonia congenita—e.g., a cysteine to arginine mutation (T>C mutation) at position 277 or a homologous residue in the muscle-type chloride channel gene CLCN1—see, e.g., Weinberger et al., The J. of Physiology. 2012; 590: 3449-3464; hereditary renal amyloidosis—e.g., a stop codon to arginine mutation (T>C mutation) at position 78 or a homologous residue in the processed form of apolipoprotein AII, or at position 101 or a homologous residue in the unprocessed form—see, e.g., Yazaki et al., Kidney Int. 2003; 64: 11-16; dilated cardiomyopathy (DCM)—e.g., a tryptophan to arginine mutation (T>C mutation) at position 148 or a homologous residue in the FOXD4 gene, see, e.g., Minoretti et al., Int. J. of Mol. Med. 2007; 19: 369-372; hereditary lymphedema—e.g., a histidine to arginine mutation (A>G mutation) at position 1035 or a homologous residue in VEGFR3 tyrosine kinase, see, e.g., Irrthum et al., Am. See J. Hum. Genet. 2000; 67: 295-301; familial Alzheimer's disease—e.g., an isoleucine to valine mutation (A>G mutation) at position 143 or a homologous residue in presenilin 1, see e.g., Gallo et al., J. Alzheimer's disease. 2011; 25: 425-431; prion disease—e.g., a methionine to valine mutation (A>G mutation) at position 129 or a homologous residue in prion protein—see e.g., Lewis et al., J. of General Virology. 2006; 87: 2443-2449; chronic infantile neurological, cutaneous, and articular syndrome (CINCA)—e.g., a tyrosine to cysteine mutation (A>G mutation) at position 570 or a homologous residue in cryopyrin—see, e.g., Fujisawa et al. Blood. 2007; 109: 2903-2911; and desmin-related myopathy (DRM)—e.g., an arginine to glycine mutation (A>G mutation) at position 120 or a homologous residue in αβ-crystallin—see, e.g., Kumar et al., J. Biol. Chem. 1999; 274: 24137-24141. The entire contents of all references and database entries are incorporated herein by reference.
[0271] The present disclosure provides a list of genes containing pathogenic T>C or A>G mutations. The names of these genes, their respective sequence numbers, their gene IDs, and sequences flanking the mutation sites are provided herein (Tables 2 and 3). In some cases, gRNA sequences that can be used to correct the mutations in these genes are disclosed (Tables 2 and 3).
[0272] In some embodiments, the Cas9-deaminase fusion protein recognizes a canonical PAM and can therefore correct a pathogenic T>C or A>G mutation with a canonical PAM, e.g., NGG, in the flanking sequence (listed in Tables 2 and 3, SEQ ID NOS:2540-2702 and 5084-5260, respectively). For example, a Cas9 protein that recognizes a canonical PAM comprises an amino acid sequence at least 90% identical to the amino acid sequence of Streptococcus pyogenes Cas9 provided by SEQ ID NO:10, or a fragment thereof comprising the RuvC and HNH domains of SEQ ID NO:10.
[0273] It will be apparent to those skilled in the art that targeting the Cas9:nucleic acid editing enzyme / domain fusion proteins disclosed herein to a target site, e.g., a site containing a point mutation to be edited, typically requires co-expression of the Cas9:nucleic acid editing enzyme / domain fusion protein with a guide RNA, e.g., an sgRNA. As described in more detail elsewhere herein, the guide RNA typically comprises a tracrRNA framework that permits Cas9 binding and a guide sequence that confers sequence specificity to the Cas9:nucleic acid editing enzyme / domain fusion protein. In some embodiments, the guide RNA comprises the structure 5'-[guide sequence]-guuuuagagcuagaaauagcaaguuaaaauaaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuuu-3' (SEQ ID NO: 601), where the guide sequence comprises a sequence that is complementary to the target sequence. Typically, the guide sequence is 20 nucleotides in length. Suitable guide RNA sequences for targeting a Cas9:nucleic acid editing enzyme / domain fusion protein to a specific genomic target site will be apparent to one of skill in the art based on this disclosure. Typically, such suitable guide RNA sequences include a guide sequence that is complementary to a nucleic acid sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited. Some exemplary guide RNA sequences suitable for targeting a Cas9:nucleic acid editing enzyme / domain fusion protein to a specific target sequence are provided below.
[0274] Base editor efficiency Some aspects of the present disclosure are based on the recognition that any of the base editors provided herein can modify specific nucleotide bases without generating a significant proportion of indels. As used herein, "indel" refers to the insertion or deletion of a nucleotide base into a nucleic acid. Such insertions or deletions can lead to frameshift mutations within the coding region of a gene. In some embodiments, it is desirable to create base editors that efficiently modify (e.g., mutate or deaminate) specific nucleotides in nucleic acids without generating numerous insertions or deletions (i.e., indels) in the nucleic acid. In certain embodiments, any of the base editors provided herein can generate a higher proportion of intended modifications (e.g., point mutations or deaminations) compared to indels. In some embodiments, the base editors provided herein can generate a ratio of intended point mutations to indels that is greater than 1:1. In some embodiments, base editors provided herein are capable of generating a ratio of intended point mutations to indels that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 200:1, at least 300:1, at least 400:1, at least 500:1, at least 600:1, at least 700:1, at least 800:1, at least 900:1, or at least 1000:1, or more. The number of intended mutations and indels can be determined using any suitable method, such as the method used in the examples below.
[0275] In some embodiments, the base editors provided herein can limit the formation of indels in a region of a nucleic acid. In some embodiments, the region is the nucleotide targeted by the base editor, or a region within 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the nucleotide targeted by the base editor. In some embodiments, any of the base editors provided herein can limit the formation of indels in a region of a nucleic acid to less than 1%, less than 1.5%, less than 2%, less than 2.5%, less than 3%, less than 3.5%, less than 4%, less than 4.5%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9%, less than 10%, less than 12%, less than 15%, or less than 20%. The number of indels formed in a region of a nucleic acid depends on the amount of time that the nucleic acid (e.g., the nucleic acid in the genome of a cell) is exposed to the base editor. In some embodiments, the number or percentage of indels is determined after at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 3 days, at least 4 days, at least 5 days, at least 7 days, at least 10 days, or at least 14 days of exposure of the nucleic acid (e.g., the nucleic acid in the genome of the cell) to the base editor.
[0276] Some aspects of the present disclosure are based on the recognition that any of the base editors provided herein can efficiently generate intended mutations, such as point mutations, in nucleic acids (e.g., nucleic acids in a subject's genome) without generating a significant number of unintended mutations, such as unintended point mutations. In some embodiments, the intended mutation is a mutation generated by a specific base editor bound to a gRNA specifically designed to create the intended mutation. In some embodiments, the intended mutation is a mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation associated with a disease or disorder. In some embodiments, the intended mutation is a cytosine (C) to thymine (T) point mutation within a coding region of a gene. In some embodiments, the intended mutation is a guanine (G) to adenine (A) point mutation within a coding region of a gene. In some embodiments, the intended mutation is a point mutation that creates a stop codon, e.g., a premature stop codon, within the coding region of a gene. In some embodiments, the intended mutation is a mutation that eliminates a stop codon. In some embodiments, the intended mutation is a mutation that alters the splicing of a gene. In some embodiments, the intended mutation is a mutation that alters a regulatory sequence of a gene (e.g., a gene promoter or a gene repressor). In some embodiments, any of the base editors provided herein are capable of generating a ratio of intended mutations to unintended mutations (e.g., intended point mutations:unintended point mutations) that is greater than 1:1.In some embodiments, any of the base editors provided herein can generate a ratio of intended to unintended mutations (e.g., intended point mutations:unintended point mutations) that is at least 1.5:1, at least 2:1, at least 2.5:1, at least 3:1, at least 3.5:1, at least 4:1, at least 4.5:1, at least 5:1, at least 5.5:1, at least 6:1, at least 6.5:1, at least 7:1, at least 7.5:1, at least 8:1, at least 10:1, at least 12:1, at least 15:1, at least 20:1, at least 25:1, at least 30:1, at least 40:1, at least 50:1, at least 100:1, at least 150:1, at least 200:1, at least 250:1, at least 500:1, or at least 1000:1, or more. It should be understood that the properties of base editors described herein in the "Base Editor Efficiency" section can be applied to any of the fusion proteins or methods using the fusion proteins provided herein.
[0277] Methods for editing nucleic acids Some aspects of the present disclosure provide a method for editing nucleic acids. In some embodiments, the method is a method for editing nucleobases of nucleic acids (e.g., base pairs of double-stranded DNA sequences). In some embodiments, the method comprises: a) contacting a target region of a nucleic acid (e.g., a double-stranded DNA sequence) with a complex comprising a base editor (e.g., a Cas9 domain fused to a cytidine deaminase domain) and a guide nucleic acid (e.g., gRNA), wherein the target region comprises a target nucleobase pair; b) inducing strand separation in the target region; c) converting a first nucleobase of the target nucleobase pair on a single strand of the target region to a second nucleobase; and d) cutting only one strand of the target region, wherein a third nucleobase complementary to the first nucleobase is replaced by a fourth nucleobase complementary to the second nucleobase; the method results in less than 20% indel formation in the nucleic acid. It should be understood that in some embodiments, step b is omitted. In some embodiments, the first nucleobase is cytosine. In some embodiments, the second nucleobase is deaminated cytosine or uracil. In some embodiments, the third nucleobase is guanine. In some embodiments, the fourth nucleobase is adenine. In some embodiments, the first nucleobase is cytosine, the second nucleobase is deaminated cytosine or uracil, the third nucleobase is guanine, and the fourth nucleobase is adenine. In some embodiments, the method results in less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the method further comprises replacing the second nucleobase with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating the intended edited base pair (e.g., C:G->T:A). In some embodiments, the fifth nucleobase is thymine. In some embodiments, at least 5% of the intended base pairs are edited, hi some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended base pairs are edited.
[0278] In some embodiments, the ratio of intended product to unintended product in the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1, or more. In some embodiments, the ratio of intended point mutation to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:1, or more. In some embodiments, the single strand to be cleaved (the strand to be nicked) hybridizes to the guide nucleic acid. In some embodiments, the single strand to be cleaved is opposite the strand comprising the first nucleobase. In some embodiments, the base editor comprises a Cas9 domain. In some embodiments, the first base is cytosine and the second base is not G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the first base is cytosine. In some embodiments, the second base is not G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base excision repair of the edited strand. In some embodiments, the base editor protects or binds to the non-edited strand. In some embodiments, the base editor comprises UGI activity. In some embodiments, the base editor comprises nickase activity. In some embodiments, the intended edited base pair is upstream of the PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited base pair is downstream of the PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream of the PAM site. In some embodiments, the method does not require a classical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker.In some embodiments, the linker is 1-25 amino acids in length. In some embodiments, the linker is 5-20 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, and the target window comprises the target nucleic acid base pair. In some embodiments, the target window comprises 1-10 nucleotides. In some embodiments, the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotide in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair is within the target window. In some embodiments, the target window comprises the intended edited base pair. In some embodiments, the method is performed using any of the base editors provided herein. In some embodiments, the target window is a deamination window.
[0279] In some embodiments, the present disclosure provides a method for editing nucleotides. In some embodiments, the present disclosure provides a method for editing nucleobase pairs of a double-stranded DNA sequence. In some embodiments, the method includes: a) contacting a target region of a double-stranded DNA sequence with a complex comprising a base editor and a guide nucleic acid (e.g., gRNA), wherein the target region comprises a target nucleobase pair; b) inducing strand separation in the target region; c) converting a first nucleobase of the target nucleobase pair on a single strand of the target region to a second nucleobase; d) cleaving only one strand of the target region, wherein a third nucleobase complementary to the first nucleobase is replaced with a fourth nucleobase complementary to the second nucleobase, and the second nucleobase is replaced with a fifth nucleobase complementary to the fourth nucleobase, thereby generating an intended edited base pair, and the efficiency of generating the intended edited base pair is at least 5%. It should be understood that in some embodiments, step b is omitted. In some embodiments, at least 5% of the intended base pairs are edited. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of the intended base pairs are edited. In some embodiments, the method causes less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, 1%, 0.5%, 0.2%, or less than 0.1% indel formation. In some embodiments, the ratio of intended product to unintended product at the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:1 or more. In some embodiments, the ratio of intended point mutation to indel formation is 1:1, 10:1, 50:1, 100:1, 500:1, or greater than 1000:1, or more. In some embodiments, the single strand to be cleaved hybridizes to the guide nucleic acid. In some embodiments, the single strand to be cleaved is opposite the strand containing the first nucleobase. In some embodiments, the first base is cytosine.In some embodiments, the second nucleobase is not G, C, A, or T. In some embodiments, the second base is uracil. In some embodiments, the base editor inhibits base excision repair of the edited strand. In some embodiments, the base editor protects or binds to the non-edited strand. In some embodiments, the nucleobase editor comprises UGI activity. In some embodiments, the nucleobase editor comprises nickase activity. In some embodiments, the intended edited base pair is upstream of the PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site. In some embodiments, the intended edited base pair is downstream of the PAM site. In some embodiments, the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream of the PAM site. In some embodiments, the methods do not require a classical (e.g., NGG) PAM site. In some embodiments, the nucleobase editor comprises a linker. In some embodiments, the linker is 1 to 25 amino acids in length. In some embodiments, the linker is 5 to 20 amino acids in length. In some embodiments, the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In some embodiments, the target region comprises a target window, and the target window comprises the target nucleobase pair. In some embodiments, the target window comprises 1 to 10 nucleotides. In some embodiments, the target window is 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 nucleotide in length. In some embodiments, the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the intended edited base pair is present within the target window. In some embodiments, the target window includes the intended edited base pair.In some embodiments, the nucleobase editor is any one of the base editors provided herein.
[0280] Kits, vectors, and cells
[0281] Some aspects of the present disclosure provide kits comprising a nucleic acid construct comprising (a) a nucleotide sequence encoding a Cas9 protein or a Cas9 fusion protein provided herein; and (b) a heterologous promoter driving expression of the sequence of (a). In some embodiments, the kit further comprises an expression construct encoding a guide RNA backbone, wherein the construct comprises a cloning site positioned to allow cloning of a nucleic acid sequence identical or complementary to a target sequence into the guide RNA backbone.
[0282] Some aspects of the present disclosure provide polynucleotides encoding the Cas9 protein of the fusion proteins provided herein. Some aspects of the present disclosure provide vectors comprising such polynucleotides. In some embodiments, the vector comprises a heterologous promoter driving expression of the polynucleotide.
[0283] Some aspects of the present disclosure provide cells comprising the Cas9 proteins, fusion proteins, nucleic acid molecules encoding the fusion proteins, complexes comprising a Cas9 protein and a gRNA, and / or vectors provided herein.
[0284] The above descriptions of exemplary embodiments of reporter systems are provided for illustrative purposes only and are not meant to be limiting. Additional reporter systems, such as variations of the exemplary systems described in detail above, are also encompassed by the present disclosure. [Example]
[0285] Example 1: Cas9 deaminase fusion protein A number of Cas9:deaminase fusion proteins were generated and the deaminase activity of the generated fusions was characterized. The following deaminases were tested:
number
number
number
[0286] Deaminase activity on ssDNA. Assays based on the USER (Uracil-Specific Excision Reagent) enzyme for deamination were used to test the activity of various deaminases on single-stranded DNA (ssDNA) substrates. The USER enzyme was obtained from New England Biolabs. The ssDNA substrates were provided with target cytosine residues at different positions. Deamination of the cytosine target residue in ssDNA results in the conversion of the target cytosine to uracil. The USER enzyme excises the uracil base, cleaving the ssDNA backbone at that position and splitting the ssDNA substrate into two shorter pieces of DNA. In some assays, the ssDNA substrate is labeled at one end with a dye, e.g., a 5' Cy3 label (see the scheme below). * After deamination, excision, and cleavage of the strands, the substrate can be subjected to electrophoresis, and the substrate and any fragments released from it can be visualized by detecting the label. Where Cy5 images, only fragments bearing the label will be visible upon imaging.
[0287] In one USER Enzyme assay, ssDNA substrates matching the target sequences of the various deaminases tested were used. Expression cassettes encoding the tested deaminases were inserted into a CMV backbone plasmid (Addgene Plasmid 52970) previously used in our laboratory. Deaminase proteins were expressed using the TNT Quick Coupled Transcription / Translation System (Promega) according to the manufacturer's recommendations. After 90 min of incubation, 5 mL of lysate was incubated with 5' Cy3-labeled ssDNA substrate and 1 unit of USER Enzyme (NEB) for 3 h. DNA was separated on a 10% TBE-PAGE gel, and the DNA was imaged using Cy dye imaging. A schematic representation of the USER Enzyme assay is shown in Figure 41.
[0288] Figure 1 shows the deaminase activity of deaminases tested against ssDNA substrates, including Doench 1, Doench 2, G7', and VEGF Target 2. The rAPOBEC1 enzyme exhibited substantial deamination of single-stranded DNA substrates using the canonical NGG PAM, but not the negative control non-canonical NNN PAM. Cas9 fusion proteins with deaminases from the APOBEC family have been generated. The following fusions were constructed and tested on ssDNA:
number
number
number
number
number
number
number
[0289] Figure 2 shows that the N-terminal deaminase fusions exhibited significant activity against single-stranded DNA substrates. For this reason, only the N-terminal constructs were chosen for further experiments.
[0290] Figure 3 shows double-stranded DNA substrate binding by the deaminase dCas9:sgRNA complex. Numerous double-stranded deaminase substrate sequences were generated. The sequences are as follows: The structures according to Figure 3 are identified in these sequences (36 bp: underlined, sgRNA target sequence: bold; PAM: box; 21 bp: italic). All substrates were labeled with a 5'-Cy3 label:
number
number
[0291] Figure 4 shows the results of a double-stranded DNA deamination assay. Fusions were expressed and purified via the N-terminal His6 tag by both Ni-NTA and Sepharose chromatography. To assess deamination with dsDNA substrates, various dsDNA substrates, as shown in the previous slide, were incubated at a 1:8 dsDNA:fusion protein ratio and incubated at 37°C for 2 hours. Once the dCas9 portion of the fusion binds to the DNA, it blocks access of the USER enzyme to the DNA. Therefore, after incubation, the fusion protein was denatured, and the dsDNA was purified by spin column chromatography, followed by a 45-minute incubation with the USER enzyme and separation of the resulting DNA substrate and substrate fragments on a 10% TBE-urea gel.
[0292] Figure 5 demonstrates that Cas9 fusions can target positions 3-11 of double-stranded DNA target sequences (numbered according to the schematic in Figure 3). Top gel: 1 μM rAPOBEC1-GGS-dCas9, 125 nM dsDNA, 1 eq sgRNA. Middle gel: 1 μM rAPOBEC1-(GGS)3-dCas9, 125 nM dsDNA, 1 eq sgRNA. Bottom gel: 1.85 μM rAPOBEC1-XTEN-dCas9, 125 nM dsDNA, 1 eq sgRNA. Based on the data from these gels, positions 3-11 (according to the numbering in Figure 3) are sufficiently exposed to deaminase activity and are targeted by the fusion proteins tested. Most likely, deaminase access to other positions is blocked by the dCas9 protein.
[0293] Furthermore, the data indicate that a linker of only 3 amino acids (GGS) is not optimal for allowing the deaminase to access the single-stranded portion of DNA. A 9 amino acid linker [(GGS)3] (SEQ ID NO: 596) and a more structured 16 amino acid linker (XTEN) allow more efficient deamination.
[0294] Figure 6 demonstrates that the correct guide RNA, e.g., the correct sgRNA, is required for deaminase activity. The gel shows that fusing the deaminase to dCas9 renders the deaminase enzyme sequence-specific (e.g., using a fusion with eGFP sgRNA results in no deamination) and also confers the deaminase with the ability to deaminate dsDNA. The natural substrate for the deaminase enzyme is ssDNA, and deamination did not occur without the addition of an sgRNA. This is consistent with reported knowledge that APOBEC deaminases by themselves do not deaminate dsDNA. The data indicate that Cas9 opens the double-stranded DNA helix within a short window, exposing single-stranded DNA that is then accessible to APOBEC deaminases for cytidine deamination. The sgRNA sequence used is provided below. Sequence (36 bp: underlined; sgRNA target sequence: bold; PAM: boxed; 21 bp: italic) DNA sequence 8:
number
[0295] Example 2: Deamination of a DNA target sequence Exemplary Deamination Targets. The dCas9:deaminase fusion proteins described herein can be delivered to cells in vitro or ex vivo, or to subjects in vivo, and used to generate C to T or G to A transitions when the target nucleotide is at positions 3-11 relative to the PAM. Exemplary deamination targets include, without limitation: CCR5 truncations: Any of the codons encoding Q93, Q102, Q186, R225, W86, or Q261 of CCR5 can be deaminated to create a stop codon, resulting in a non-functional truncation of CCR5, which has applications in HIV treatment. APOE4 mutations: Mutant codons encoding C11R and C57R mutant APOE4 proteins can be deaminated to revert to the wild-type amino acid, which has applications in Alzheimer's treatment. eGFP truncation: Any of the codons encoding Q158, Q184, or Q185 can be deaminated to create a stop codon, or the codon encoding M1 can be deaminated to encode I, all of which result in loss of eGFP fluorescence, which has applications in reporter systems. eGFP restoration: Mutant codons encoding T65A or Y66C mutant GFP, which do not exhibit substantial fluorescence, can be deaminated to restore the wild-type amino acid and confer fluorescence. PIK3CA mutation: Mutant codons encoding K111E mutant PIK3CA can be deaminated to restore the wild-type amino acid residue, which has applications in cancer. CTNNB1 mutation: Mutant codons encoding T41A mutant CTNNB1 can be deaminated to restore the wild-type amino acid residue, which has applications in cancer. HRAS mutation: Mutant codons encoding Q61R mutant HRAS can be deaminated to restore the wild-type amino acid residue, which has applications in cancer. P53 mutations: Any of the mutant codons encoding Y163C, Y236C, or N239D mutant p53 can be deaminated to encode wild-type amino acid sequences with cancer applications. The feasibility of deaminating these target sequences in double-stranded DNA is demonstrated in Figures 7 and 8. Figure 7 illustrates the mechanism of target DNA binding of the target sequence in vivo by the deaminase-dCas9:sgRNA complex.
[0296] FIG. 8 shows the successful deamination of an exemplary disease-associated target sequence. Upper gel: CCR5 Q93: coding strand target at position 10 (potential off-target at positions 2, 5, 6, 8, and 9); CCR5 Q102: coding strand target at position 9 (potential off-target at positions 1, 12, and 14); CCR5 Q186: coding strand target at position 9 (potential off-target at positions 1, 5, and 15); CCR5 R225: coding strand target at position 6 (no potential off-target); eGFP Q158: coding strand target at position 5 (potential off-target at positions 1, 13, and 16); eGFP Q184 / 185: coding strand target at positions 4 and 7 (potential off-target at positions 3, 12, 14, 15, 16, 17, and 18); eGFP M1: template strand target at position 12 (potential off-target at positions 2, 3, 7, 9, and 11) (targets positions 7 and 9 to a lesser extent); eGFP T65A: template strand target at position 7 (potential off-targets at positions 1, 8, 17); PIK3CA K111E: template strand target at position 2 (potential off-targets at positions 5, 8, 10, 16, 17); PIK3CA K111E: template strand target at position 13 (potential off-targets at positions 11, 16, 19) X.Lower gel: CCR5 W86: template strand target at positions 2 and 3 (potential off-target at positions 1 and 13); APOE4 C11R: coding strand target at position 11 (potential off-target at positions 7, 13, 16, and 17); APOE4 C57R: coding strand target at position 5 (potential off-target at positions 7, 8, and 12); eGFP Y66C: template strand target at position 11 (potential off-target at positions 1, 4, 6, 8, 9, and 16); eGFP Y66C: template strand target at position 3 (potential off-target at positions 1, 8, and 17); CCR5 Q261: coding strand target at position 10 (potential off-target at positions 3, 5, 6, 9, and 18); CTNNB1 T41A: template strand target at position 7 (potential off-target at positions 1, 13, 15, and 16); HRAS Q61R: template strand target at position 6 (potential off-targets at positions 1, 2, 4, 5, 9, 10, 13); p53 Y163C: template strand target at position 6 (potential off-targets at positions 2, 13, 14); p53 Y236C: template strand target at position 8 (potential off-targets at positions 2, 4); p53 N239D: template strand target at position 4 (potential off-targets at positions 6, 8). Exemplary DNA sequences of disease targets are provided below (PAM(5'-NGG-3') and target positions are boxed):
number
number
[0297] Example 3: Uracil glycosylase inhibitor fusion improves deamination efficiency The efficiency of direct, programmable nucleobase editing in mammalian cells by dCas9:deaminase fusion proteins can be significantly improved by fusing a uracil glycosylase inhibitor (UGI) to the dCas9:deaminase fusion protein.
[0298] Figure 9 shows in vitro C→T editing efficiency in human HEK293 cells using rAPOBEC1-XTEN-dCas9:
number
number
number
number
[0299] Figure 10 shows that when a UGI domain is fused to a rAPOBEC1:dCas9 fusion protein, the C→T editing efficiency of the same proteospacer sequence in HEK293T cells is significantly enhanced.
number
number
number
[0300] The percentages in Figures 9 and 10 are based on sequencing both strands of the target sequence. Because only one strand is a substrate for deamination, the maximum possible deamination value in this assay is 50%. Therefore, the deamination efficiency is double the percentage shown in the table. For example, a value of 50% relates to 100% deamination of the double-stranded target sequence. When a uracil glycosylase inhibitor (UGI) was fused to a dCas9:deaminase fusion protein (e.g., rAPOBEC1-XTEN-dCas9-[UGI]-NLS), a significant increase in editing efficiency was observed in cells. This result indicates that in mammalian cells, the DNA repair mechanism that excises uracil bases from U:G base pairs is the rate-limiting process for DNA editing. Tethering UGI to a dCas9:deaminase fusion protein greatly increases editing yields.
[0301] Without UGI, typical editing efficiencies in human cells ranged from 2% to 14% yield (Figures 9 and 10, "XTEN" entry). With UGI (Figure 10, "UGI" entry), editing was observed in the range of 6% to 40%. Therefore, using UGI fusions is more efficient than current alternative methods of correcting point mutations via HDR, which, in addition to correcting the point mutation, also creates excess indels. No indels were observed to result from treatment with cas9:deaminase:UGI fusions.
[0302] Example 4: Direct and programmable conversion of target nucleotides in genomic DNA without double-strand DNA breaks Current genome editing technologies introduce double-stranded DNA breaks at the desired target locus as the first step toward gene correction. 39,40 Although most genetic diseases arise from mutations of a single nucleobase to a different nucleobase, current approaches to revert such changes are highly inefficient and typically induce large numbers of random insertions and deletions (indels) at the target locus as a consequence of the cellular response to double-stranded DNA breaks. 39,40Herein, we report the development of nucleobase editing, a novel strategy for genome editing that enables the direct conversion of one targeted nucleobase to another in a programmable manner without requiring double-stranded DNA backbone cleavage. CRISPR / Cas9 fusions were engineered. The cytidine deaminase enzyme APOBEC1, which retains the ability to be programmed by guide RNA, does not induce double-stranded DNA breaks but mediates the direct conversion of cytidine to uracil, thereby generating a C to T (or G to A) substitution during DNA replication, DNA repair, or post-transcription when the template strand is targeted. The resulting "nucleobase editor" converts cytidines within a window of approximately five nucleotides and can efficiently correct various point mutations associated with human disease in vitro. In four transformed human and mouse cell lines, second- and third-generation nucleobase editors, each incorporating a uracil glycosylase inhibitor (UGI) and targeting the unedited strand, respectively, were able to overcome the cellular DNA repair response to nucleobase editing, resulting in permanent correction of up to 37% or (~15-75%) of total cellular DNA in human cells, with minimal (typically ≤1%) indel formation. In contrast, classical Cas9-mediated HDR on the same targets produced an average of 0.7% correction and 4% indel formation. Nucleobase editors were used to revert two oncogenic p53 mutations to wild-type alleles in human breast cancer and lymphoma cells and to convert an Alzheimer's disease-associated Arg codon in ApoE4 to a non-disease-associated Cys codon in mouse astrocytes. Base editing expands the scope and efficiency of genome editing for point mutations.
[0303] The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) system is a prokaryotic adaptive immune system that has been adapted to mediate genome manipulation in a variety of organisms and cell lines. 41The CRISPR / Cas9 protein-RNA complex localizes to the target DNA sequence through base pairing with the guide RNA and essentially creates a DNA double-strand break (DSB) at the locus specified by the guide RNA. In response to the DSB, endogenous DNA repair processes result in primarily random insertions or deletions (indels) at the site of the DNA break by non-homologous end joining (NHEJ). In the presence of a homologous DNA template, the DNA surrounding the break site can be replaced by homology-directed repair (HDR). When simple disruption of a disease-related gene is sufficient (e.g., to treat some gain-of-function diseases), targeted DNA cleavage followed by indel formation can be effective. However, for most known genetic diseases, correction of point mutations at the target locus, rather than stochastic disruption of the gene, is required to address or study the underlying cause of the disease. 68 .
[0304] Motivated by this need, researchers have invested intensive efforts to increase the efficiency of HDR and suppress NHEJ. For example, small molecule inhibitors of ligase IV, an essential enzyme in the NHEJ pathway, have been shown to increase HDR efficiency. 42,43 However, this strategy is challenging in postmitotic cells, which typically downregulate HDR, and its therapeutic relevance is limited by the potential risk of inhibiting ligase IV in non-target cells. Improved HDR efficiency can be achieved by timed delivery of Cas9-guide RNA complexes to chemically synchronized cells, because HDR efficiency is highly cell cycle dependent. 44 However, synchronizing cells is highly disruptive, limiting such approaches to research applications in cell culture. Despite these developments, current strategies for replacing point mutations using HDR are highly inefficient in most contexts (typically ~0.1 to 5%), especially in unmodified, non-dividing cells. 42,43,45,46,75Additionally, HDR competes with NHEJ during double-strand break resolution, generally resulting in indels rather than gene replacement. These observations highlight the need to develop alternative approaches to implement specific modifications of genomic DNA that do not rely on creating double-strand DNA breaks. Small-molecule inhibitors of ligase IV, an essential enzyme in the NHEJ pathway, have been shown to increase HDR efficiency. 42,43 However, this strategy is challenging in postmitotic cells, which typically downregulate HDR, and its therapeutic relevance is limited by the potential risk of inhibiting ligase IV in non-target cells. Improved HDR efficiency can also be achieved by timed delivery of Cas9-guide RNA complexes to chemically synchronized cells, because HDR efficiency is highly cell cycle dependent. 44 However, because synchronizing cells is highly disruptive, such approaches are limited to cell culture research applications. In some cases, it is possible to design HDR templates such that successful HDR products contain mutations in the PAM sequence and are therefore no longer substrates for subsequent Cas9 modification, increasing the overall yield of HDR products. 75 However, such an approach imposes constraints on the product sequence. Recently, this strategy has been coupled with ssDNA donors complementary to the non-target strand and highly efficient ribonucleoprotein (RNP) delivery to substantially increase the efficiency of HDR, but even in those cases, the ratio of HDR to NHEJ outcomes is relatively low (<2). 83 .
[0305] It was anticipated that direct catalysis of the conversion of one nucleobase to another at a programmable target locus, without requiring DNA backbone cleavage, could increase the efficiency of gene correction relative to HDR without introducing unwanted random indels into the target locus. Catalytically inactive Cas9 (dCas9), which contains AsplOOAla and His840Ala mutations that inactivate its nuclease activity, retains its ability to bind to DNA in a guide RNA-programmed manner but does not cleave the DNA backbone. 16,47 In principle, conjugation of dCas9 with enzymes or chemical catalysts that mediate the direct conversion of one nucleobase to another could enable RNA-programmed nucleobase editing. Deamination of cytosine (C) is catalyzed by cytidine deaminase. 29 , yielding uracil (U), which has the base-pairing properties of thymine (T). dCas9 was fused to a cytidine deaminase enzyme to test their ability to convert C to U at DNA loci specified by guide RNAs. Most known cytidine deaminases act on RNA, and the few known to accept DNA require single-stranded DNA. 48 Recent studies of dCas9-target DNA complexes reveal that at least nine nucleotides of the displaced DNA strand are unpaired by the formation of a Cas9:guide RNA:DNA "R-loop" complex. 12 Indeed, in the structure of the Cas9 R-loop complex, the first 11 nucleotides of the protospacer on the displaced DNA strand are disordered, suggesting that their movement is not highly restricted. 76 It has also been speculated that Cas9 nickase-induced mutations at cytosines on the non-template strand may arise from their accessibility by cellular cytidine deaminase enzymes. 77Recent studies of dCas9-target DNA complexes have revealed that at least 26 bases on the non-template strand are unpaired when Cas9 binds to its target DNA sequence. 49 It was reasoned that a subset of this stretch of single-stranded DNA in the R-loop could serve as a substrate for dCas9-tethered cytidine deaminase, resulting in the direct, programmable conversion of C to U in DNA (Figure 11A).
[0306] Four different cytidine deaminase enzymes (hAID, hAPOBEC3G, rAPOBEC1, and pmCDA1) were expressed using an in vitro transcription-translation system derived from mammalian cell lysates and evaluated for ssDNA deamination. Of the four enzymes, rAPOBEC1 exhibited the highest deaminase activity under the conditions tested and was chosen for dCas9 fusion experiments (Figure 36A). Adding rAPOBEC1 to the C-terminus of dCas9 abolished deaminase activity, whereas fusing rAPOBEC1 to the N-terminus of dCas9 maintained deaminase activity against ssDNA at a level comparable to that of the unfused enzyme. Four rAPOBEC1-dCas9 fusions were expressed and purified with linkers of different lengths and compositions (Figure 36B), and each fusion was evaluated for single-guide RNA (sgRNA)-programmed dsDNA deamination in vitro (Figures 11A-11C and Figures 15A-15D). Efficient, sequence-specific, sgRNA-dependent C to U conversion was observed in vitro (Figures 11A to 11C). Conversion efficiency was highest using rAPOBEC1-dCas9 linkers greater than 9 amino acids in length. The number of positions susceptible to deamination (the deamination "activity window") increased as the linker length was extended from 3 to 21 amino acids (Figures 36C to 36F, 15A to 15D). 16-residue XTEN linker 50was found to offer a promising balance between these two properties, with an efficient deamination window of approximately 5 nucleotides from positions 4 to 8 within the protospacer, counting the end distal to the protospacer adjacent motif (PAM) as position 1. The rAPOBEC1-XTEN-dCas9 protein served as a first-generation nucleobase editor (NBE1).
[0307] We selected seven mutations associated with human diseases that could theoretically be corrected by C to T nucleobase editing, synthesized 80-mer double-stranded DNA fragments of the corresponding sequences, and assessed the ability of NBE1 to correct these mutations in vitro (Figures 16A-16B). NBE1 generated products consistent with efficient editing of the target C, or at least one C within the activity window when multiple Cs were present, for six of these seven targets in vitro, with an average apparent editing efficiency of 44% (Figures 16A-16B). In three cases where multiple Cs were present within the deamination window, evidence of deamination of some or all of those cytosines was observed. In only one of the seven cases tested was a substantial yield of edited product observed (Figures 16A-16B). While the preferred sequence context for APOBEC1 substrates has been reported to be CC or TC, 51 It was anticipated that the increased effective molar concentration of the deaminase and its single-stranded DNA substrate, mediated by dCas9 binding to the target locus, might relax this limitation. To unravel the sequence context generality of NBE1, we assayed its ability to edit a 60-mer double-stranded DNA oligonucleotide containing a single repaired C at position 7 within the protospacer, as well as all 36 single-mutated variants in which protospacer bases 1–6 and 8–13 were individually changed to each of the other three bases. Each of these 37 sequences was treated for 2 h with 1.9 μM NBE1, 1.9 μM of the corresponding sgRNA, and 125 nM DNA, similar to standard conditions for in vitro Cas9 assays. 52High-throughput DNA sequencing (HTS) revealed 50 to 80% C-to-U conversions of the target strand (25 to 40% of the total sequence reads originating from both DNA strands; one of these is not a substrate for NBE1) (Figure 12A). Nucleotides surrounding the target C had a minor effect on editing efficiency. This was independent of sequence context, unless the base immediately 5′ to the target C was G, in which case editing efficiency was substantially lower (Figures 12A to 12B). In vitro NBE1 activity was assessed for all four NC motifs at positions 1 to 8 within the protospacer (Figures 12A to 12B). In general, NBE1 activity on the substrates was observed to follow the order TC ≥ CC ≥ AC > GC, with maximum editing efficiency achieved when the target C was at or near position 7. In addition, it was observed that nucleobase editors are highly processive and will efficiently convert the majority of all Cs to Us on the same DNA strand within a five-base activity window (Figure 17).
[0308] While BE1 efficiently processes substrates in vitro, in cells, a tree of possible DNA repair outcomes determines the fate of the initial U:G product of base editing (Figure 29A). To test the efficacy of nucleobase editing in human cells, we optimized NBE1 codon usage for mammalian expression and appended a C-terminal nuclear localization sequence (NLS). 53 , its ability to convert C to T in human cells was assayed with 14 Cs at six well-studied target sites in the human genome (Figure 37A). 54The editable C within each protospacer was confirmed in vitro by incubating NBE1 with synthetic 80-mers corresponding to six different genomic sites, followed by HTS (Figures 13A to 13C, Figure 29B, and Figure 25). Next, HEK293T cells were transfected with plasmids encoding NBE1 and one of the six target sgRNAs, allowed for 3 days for nucleobase editing to occur, genomic DNA was extracted from the cells, and the loci were analyzed by HTS. Cellular C to T editing at the target locus was observed in all six cases, but the nucleobase editing efficiency was 1.1% to 6.3% or 0.8% to 7.7% of the total DNA sequence (corresponding to 2.2% to 12.6% of the targeted strand), a 6.3- to 37-fold or 5- to 36-fold decrease in efficiency compared to in vitro nucleobase editing (Figures 13A to 13C, Figure 29B, and Figure 25). When substrate C is preceded by T, we observed that some base editing occurs outside the typical window of positions 4 to 8. We attribute this to the unusually high activity of APOBEC1 toward TC substrates. 48 .
[0309] We asked whether the cellular DNA repair response to the presence of U:G heteroduplex DNA was responsible for the large decrease in nucleobase editing efficiency in cells (Figure 29A). Uracil DNA glycosylase (UDG) catalyzes the removal of U from DNA in cells, initiating base excision repair (BER), with the most common outcome being reversion of U:G pairs to C:G pairs (Figure 29A). 55 Uracil DNA glycosylase inhibitor (UGI), an 83-residue protein from B. subtilis bacteriophage PBS1, potently blocks human UDG activity (IC 50 =12pM) 56UGI was fused to the C-terminus of NBE1 to create the second-generation nucleobase editor, BE2, and editing assays were repeated for all six genomic loci. Editing efficiency in human cells was on average 3-fold higher with BE2 than with NBE1, resulting in gene conversion efficiencies of up to 22.8% of the total sequenced DNA (up to 45.6% of the target strand) (Figures 13A to 13C and Figure 29B). To test base editing in human cells, BE1 codon usage was optimized for mammalian expression and a C-terminal nuclear localization sequence (NLS) was added. 53 .
[0310] Similar editing efficiencies were observed when a separate plasmid overexpressing UGI was cotransfected with BE1 (Figures 18A to 18H). However, while direct fusion of UGI to NBE1 did not result in a significant increase in C to T mutations at monitored non-targeted locations in the genome, overexpression of unfused UGI detectably increased the frequency of C to T mutations elsewhere in the genome (Figures 18A to 18H). The generality of BE2-mediated nucleobase editing was confirmed by assessing the editing efficiency of the same six genomic targets in U2OS cells, and similar results were observed as in HEK293T cells (Figure 19). Importantly, NBE2 typically did not result in any detectable indels (Figures 13C and 29C), consistent with the known mechanism of HEJ dependence on double-stranded DNA breaks. 57,78 Together, these results indicate that conjugating UGI to NBE1 can greatly increase the efficiency of nucleobase editing in human cells.
[0311] The performance of nucleobase editing in human cells was confirmed by monitoring editing efficiency over multiple cell divisions of HEK293T cells at two of the tested genomic loci. Genomic DNA was harvested at two time points: three days after transfection with a plasmid expressing NBE2 and the appropriate sgRNA, and after passage and growing the cells for an additional four days (approximately five subsequent cell divisions). No significant changes in editing efficiency were observed between unpassaged cells (editing was observed in 4.6% to 6.6% of targeted strands for three different target Cs) and passaged cells (editing was observed in 4.6% to 6.4% of targeted strands for the same three target Cs), confirming that nucleobase edits become permanent during cell division (Figure 20). In rare cases, indels may arise from processing of U:G lesions by cellular repair processes. This involves single-strand break intermediates known to lead to indels. 84 Considering that hundreds of endogenous U:G lesions are generated by spontaneous cytidine deaminases per human cell daily, 85 It was anticipated that the total indel frequency from U:G lesion repair would be unlikely to increase from BE1 or BE2 activity at a single target locus.
[0312] To further increase the efficiency of nucleobase editing in cells, it was anticipated that nicking the unedited strand would result in a smaller fraction of edited Us being removed by the cell, because the eukaryotic mismatch repair machinery uses strand discontinuities to direct DNA repair to either broken strand of a mismatched duplex (Figure 29A). 58,79,80 A catalytic His residue was restored at position 840 of the Cas9 HNH domain. 47,59This resulted in the third-generation nucleobase editor, BE3, which nicks the non-edited strand containing a G opposite the targeted C but does not cleave the target strand containing a C. Because BE3 still contains the Cas9 AsplOAla mutation, it does not induce double-stranded DNA breaks. This strategy of nicking the non-edited strand enhanced nucleobase editing efficiency in human cells by an additional 1.4 to 4.8-fold relative to NBE2, resulting in up to 36.3% of total DNA sequences containing targeted C to T conversions at the same six human genomic targets in HEK293T cells (Figures 13A to 13C and Figure 29B). Importantly, only a small frequency of indels (ranging from 0.2% to 1.6% for six different loci), averaging 0.8%, was observed with NBE3 treatment (Figures 13C, 29C, and 34). In contrast, when cells were treated with wild-type Cas9, sgRNA, and a single-stranded DNA donor template to mediate HDR at three of these loci, we observed an average C to T conversion efficiency of only 0.7%, with a much higher relative indel formation averaging 3.9% (Figures 13A-13C and Figure 29C). The ratio of allele conversion to NHEJ outcomes averaged >1,000 for BE2, 23 for BE3, and 0.17 for wild-type Cas9 (Figure 3c). We confirmed the performance of base editing in human cells by monitoring the editing efficiency over multiple cell divisions of HEK293T cells at the HEK293 site 3 and 4 genomic loci (Figure 38). Together, these results confirm that nucleobase editing can produce much more efficient targeted single-base edits in human cells than Cas9-mediated HDR, with significantly less (NBE3) or no (NBE2) indel formation.
[0313] Next, we evaluated the off-target activities of NBE1, NBE2, and NBE3 in human cells. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied (Figures 23-24 and 31-33). 54,60~62Consistent with the sequence context independence observed in Figures 12A-12B, the sequence preference of rAPOBEC1 has been shown to be independent of DNA bases more than one base away from the target C. 63 Potential off-target activity of nucleobase editors was suspected to arise from off-target Cas9 binding. Because only a fraction of Cas9 off-target sites will have Cs within the nucleobase editing activity window, off-target nucleobase editing sites should be a subset of the off-target sites of classical Cas9 variants. For each of the six sites studied, we sequenced the top 10 known Cas9 off-target loci in human cells previously determined using the GUIDE-seq method (Figures 23-27 and 31-33). 54,61 Detectable off-target nucleobase editing was observed at only a subset of known dCas9 off-target loci (16 / 34, 47% for NBE1 and NBE2, and 17 / 34, 50% for BE3). In all cases, the off-target base-edited substrate contained a C within the 5-base target window. In general, off-target C-to-T conversions followed the off-target Cas9 nuclease-mediated genome modification frequency (Figures 23-27). Approximately 1.8 x 10 6We also monitored C to T conversions at 2,500 distinct cytosines surrounding the six on-target and 34 off-target loci tested, representing a total of 14,700,000 sequence reads from cells, and observed no detectable increase in C to T conversions at any of these other sites with NBE1, NBE2, or NBE3 treatment compared to that of untreated cells (Figure 28). Together, these findings suggest that off-target substrates of nucleobase editors encompass a subset of Cas9 off-target substrates, and that in human cells, nucleobase editors do not induce non-target C to T conversions in the genome at levels that can be detected by the methods used here. No substantial change in editing efficiency was observed between unpassaged HEK293T cells (edits were observed in 1.8% to 2.6% of strands sequenced for the three target Cs in BE2 and in 6.2% to 14.3% in BE3) and cells that had undergone approximately five cell divisions after base editing (edits were observed in 1.9% to 2.3% of strands sequenced for the same target Cs in BE2 and in 6.4% to 14.5% in BE3), confirming that the base edits in these cells were durable (Extended Data Fig. 6).
[0314] Finally, we tested the potential of nucleobase editing to correct three disease-associated mutations in mammalian cells. The apolipoprotein E gene variant APOE4, which encodes two Arg residues at amino acid positions 112 and 158, is the largest and most common genetic risk factor for late-onset Alzheimer's disease. 64 ApoE variants with Cys residues at positions 112 or 158, including APOE2 (Cys112 / Cys158), APOE3 (Cys112 / Arg158), and APOE3' (Arg112 / Cys158), have been shown to confer a substantially lower risk of Alzheimer's disease than APOE4. 65 , or is presumed to be 81Encouraged by the ability of NBE1 to convert APOE4 to APOE3' in vitro (Figures 16A-16B), we tested this conversion in immortalized mouse astrocytes (Taconic) in which the endogenous mouse APOE gene was replaced with human APOE4. DNA encoding NBE3 and an appropriate sgRNA was delivered into these astrocytes by nucleofection (25% nucleofection efficiency). After 2 days, genomic DNA was extracted from all treated cells and editing efficiency was measured by HTS. Conversion of Arg158 to Cys158 was observed in 58-75% of total DNA sequencing reads (44% of nucleofected astrocytes) (Figures 14A-14C and 30A). As expected, 36-50% editing of the total DNA at the third position of codon 158 and 38-55% editing of the total DNA at the first position of Leu159 were also observed because all three of these Cs are within the active nucleobase editing window. However, neither of the other two C to T conversions results in a change in the amino acid sequence of the ApoE3' protein because both TGC and TGT encode Cys, and both CTG and TTG encode Leu. 1 × 10 6 From >1,500,000 sequencing reads derived from cells, we observed evidence of 1.7% indels at the target locus after NBE3 treatment (Figure 35). In contrast, identical treatment of astrocytes with wt Cas9 and donor ssDNA resulted in 0.1-0.3% APOE4 correction and 26-40% indels at the target locus, efficiencies consistent with previous reports of single-base correction using Cas9 and HDR. 45,75(Figures 30A and 40A). Astrocytes treated identically but with sgRNA targeting the VEGFA locus displayed no evidence of APOE4 base editing (Figures 34 and 40A). These results demonstrate how nucleobase editors can generate precise single amino acid changes in protein coding sequences as the primary editing product, even when their processivity results in more than one nucleotide change in genomic DNA. The off-target activities of Cas9, dCas9, and Cas9 nickase have been extensively studied. 54,60~62 In general, off-target C to T conversions by BE1, BE2, and BE3 mimicked the frequency of off-target Cas9 nuclease-mediated genome modifications.
[0315] Dominant-negative p53 mutations Tyr163Cys and Asn239Asp are strongly associated with several types of cancer 66,67Both of these mutations can be corrected by C->T conversion on the template strand (Figures 16A-16B). A human breast cancer cell line (HCC1954 cells) homozygous for the p53 Tyr163Cys mutation was nucleofected with DNA encoding NBE3 and an sgRNA programmed to correct Tyr163Cys. Because the nucleofection efficiency of HCC1954 cells was <10%, a plasmid expressing IRFP was co-nucleofected into these cells to allow isolation of nucleofected cells by fluorescence-activated cell sorting two days after treatment. HTS of genomic DNA revealed correction of the Tyr163Cys mutation in 7.6% of nucleofected HCC1954 cells (Figure 30B and Figures 40A-40B). A human lymphoma cell line (ST486 cells) heterozygous for p53 Asn239Asp was also nucleofected with DNA encoding NBE2 and an sgRNA programmed to correct Asn239Asp, resulting in a 92% nucleofection efficiency. Correction of the Asn239Asp mutation was observed in 11% of treated ST486 cells (12% of nucleofected ST486 cells). Consistent with the findings in HEK cells, no indels were observed from treatment of ST486 cells with NBE2, and 0.6% indel formation was observed from treatment of HCC1954 cells with NBE3. Other DNA changes within at least 50 base pairs on either side of the protospacer were observed in 2 × 10 5 Among >2,000,000 sequencing reads from cells, none were detected at frequencies above those of untreated controls (Figures 14A-14C, Figure 30B, and Table 1). Together, these results demonstrate the conversion of three disease-associated alleles to their wild-type forms in genomic DNA with an efficiency and in the absence of other genome modification events that, to our knowledge, is not currently achievable using other methods.
[0316] NCBI's ClinVar database to uncover the potential relevance of nucleobase editors to address human genetic diseases 68We searched for known genetic diseases that could, in principle, be corrected by this approach. First, we filtered ClinVar by examining only single nucleotide polymorphisms (SNPs) and then removing any non-pathogenic variants. Of the 24,670 pathogenic SNPs, 3,956 are caused by either T-to-C or A-to-G substitutions. This list was further filtered to include only variants with a nearby NGG PAM that would place the SNP within the deamination activity window, resulting in 1,089 clinically relevant pathogenic genetic variants that could, in principle, be corrected by the nucleobase editors described here (Figure 21 and Table 1). To uncover the potential relevance of base editors for addressing human genetic diseases, we used NCBI's ClinVar database. 68 We searched for known genetic diseases that could, in principle, be corrected by this approach. First, ClinVar was filtered by examining only single nucleotide polymorphisms (SNPs) and then removing any non-pathogenic variants. Of the 24,670 pathogenic SNPs, 3,956 are caused by either T-to-C or A-to-G substitutions. This list was further filtered to include only variants with a nearby NGG PAM that would place the SNP within the deamination activity window, resulting in 911 clinically relevant pathogenic genetic variants that could, in principle, be corrected by the base editors described here. Of these, 284 contain only a single C within the base editing activity window. A detailed list of these pathogenic mutations can be found in Table 1.
[0317] Table 1. List of 911 base-editable genetic variants associated with human diseases with NGG PAM (SEQ ID NOs: 747 to 1868 are listed below from top to bottom, respectively). "Y" in the protospacer and PAM sequences indicates the base to be edited, e.g., C (SEQ ID NOs: 747 to 1868 are listed below from top to bottom, respectively). [Table 1] TIFF2024164012000112.tif236163TIFF2024164012000113.tif223163TIFF2024164012000114.tif224163TIFF2024164012000115.tif228163TIFF2024164012000116.tif232163TIFF2024164012000117.tif228163TIFF2024164012000118.tif232163TIFF2024164012000119.tif224163TIFF2024164012000120.tif225163TIFF2024164012000121.tif223163TIFF2024164012000122.tif233163TIFF2024164012000123.tif229163TIFF2024164012000124.tif230163TIFF2024164012000125.tif228163TIFF2024164012000126.tif226163TIFF2024164012000127.tif225163TIFF2024164012000128.tif231163TIFF2024164012000129.tif227163TIFF2024164012000130.tif234163TIFF2024164012000131.tif230163TIFF2024164012000132.tif217163TIFF2024164012000133.tif228163TIFF2024164012000134.tif225163TIFF2024164012000135.tif230163TIFF2024164012000136.tif226163TIFF2024164012000137.tif73163
[0318] In some embodiments, any of the base editors provided herein can be used to treat a disease or disorder. For example, any of the base editors provided herein can be used to correct one or more mutations associated with any of the diseases or disorders provided herein. Exemplary diseases or disorders that can be treated include, but are not limited to, 3-methylglutaconic aciduria type 2, 46,XY gonadal dysplasia, 4-alpha-hydroxyphenylpyruvate hydroxylase deficiency, 6-pyruvoyltetrahydropterin synthase deficiency, color blindness, acid-labile subunit deficiency, acrodysostosis, palmar keratoderma, ACTH-refractory syndrome, ACTH-independent macronodular adrenal hyperplasia, activated PI3K delta syndrome, Acute intermittent porphyria, acute myeloid leukemia, Adams-Oliver syndrome 1 / 5 / 6, adenylosuccinate lyase deficiency, adrenoleukodystrophy, adult neuronal ceroid lipofuscinosis, adult-onset ataxia with oculomotor apraxia, advanced sleep phase syndrome, age-related macular degeneration, Alagille syndrome, Alexander disease, Allan Herndon-Dudley syndrome, X-linked recessive Alport syndrome, alternating hemiplegia of childhood, alveolar capillary dysplasia with pulmonary venous malalignment, enamelled retinal edema Plasma formation imperfecta, amyloidogenic transthyretin amyloidosis, amyotrophic lateral sclerosis, anemia (non-spherocytic hemolytic due to G6PD deficiency), anemia (sideroblastic, pyridoxine-refractory, autosomal recessive), onychosis, antithrombin III deficiency, aortic aneurysm, aplastic anemia, apolipoprotein C2 deficiency, apparent mineralocorticoid excess, aromatase deficiency, arrhythmogenic right ventricular cardiomyopathy, familial hypertrophic cardiomyopathy, hypertrophic cardiomyopathy, arthrogryposis multiplex congenita, amyloidosis Aspartylglycosaminuria, asphyxiating thoracic dystrophy, ataxia with vitamin E deficiency, ataxia (spastic), atrial fibrillation, atrial septal defect, atypical hemolytic uremic syndrome, autosomal dominant CD11C+ / CD1C+ dendritic cell deficiency, autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletion, Baraitser-Winter syndrome, Bartter syndrome, basal ganglia calcification, Beckwith-Wiedemann syndrome,Benign familial neonatal convulsions, benign scapuloperoneal muscular dystrophy, Bernard-Soulier syndrome, beta-thalassemia intermedia, beta-D-mannosidosis, Bietti-crystalline corneal retinal dystrophy, bile acid malabsorption, biotinidase deficiency, Beresson-Forssmann-Lehmann syndrome, Boucher-Neuhauser syndrome, Bowen-Conradi syndrome, brachydactyly, Brown-Vialet-Van Laar syndrome, Brugada syndrome, cardiac arrhythmias, cardio-facio-cutaneous syndrome, cardiomyopathy, Carnevale syndrome, carnitine palmitoyltransferase II deficiency, Carpenter syndrome, cataracts, catecholamine-induced polymorphic ventricular tachycardia, central core disease, centromeric instability and immunodeficiency of chromosomes 1, 9, and 16, autosomal dominant cerebral arteriopathy, cerebro-ocular-facial-skeletal syndrome, Ceroid lipofuscinosis, Charcot-Marie-Tooth disease, cholestanol storage disease, chondrocalcinosis, chondrodysplasia, chronic progressive multiple sclerosis, coenzyme Q10 deficiency, Cohen syndrome, combined factor V and factor VIII deficiency, combined immunodeficiency, combined oxidative phosphorylation deficiency, combined partial 17-alpha-hydroxylase / 17-20-lyase deficiency, complement factor d deficiency, combined complete 17-alpha-hydroxylase / 17,20-lyase deficiency, rod Cone dystrophy, congenital contracture arachnodactyly, congenital abnormalities of glycosylation, congenital lipomatous overgrowth, ovarian neoplasms, PIK3CA-related overgrowth spectrum, congenital long QT syndrome, congenital muscular dystrophies, congenital myometrial hypertrophy-encephalopathy, congenital myasthenic syndromes, congenital myopathy with fiber type disproportion, Eichsfeldt congenital muscular dystrophy, congenital stationary night blindness, corneal dystrophy, Cornelia-de-Lange syndrome, craniometaphyseal dysplasia, Crigler-Nagy syndrome Jahr syndrome, Crouzon syndrome, cutis laxa with osteodystrophy, cyanosis, cystic fibrosis, cystinosis, cytochrome c oxidase deficiency, mitochondrial complex I deficiency, D-2-hydroxyglutaric aciduria, Danon disease, labyrinth dysplasia, microtia, and deafness with microdontia (LAMM), hearing loss, acetyl-CoA acetyltransferase deficiency, ferroxidase deficiency, UDP-glucose-hexose-1-phosphate uridylyltransferase deficiency,Dejerine-Sottas disease, Debuquois syndrome, DFNA, diabetes mellitus type 2, diabetes mellitus deafness syndrome, Diamond-Blackfan anemia, flexural dysplasia, dihydropteridine reductase deficiency, dihydropyrimidinase deficiency, dilated cardiomyopathy, disseminated atypical mycobacterial infection, distal arthrogryposis, distal hereditary motor neuropathy, Donnai-Barrow Barrow syndrome, Duchenne muscular dystrophy, Becker muscular dystrophy, hereditary generalized pigmentary disorders, dyskeratosis congenita, dystonia, early infantile epileptic encephalopathy, Ehlers-Danlos syndrome, Eichsfeldt congenital muscular dystrophy, Emery-Dreifuss muscular dystrophy, amelo-renal syndrome, reversed dystrophic epidermolysis bullosa, epidermolysis bullosa herpetiformis, epilepsy, epilepsy ataxia, fluctuating erythrokeratoderma, erythropoietic protoporphyria, luck exercise intolerance, exudative vitreoretinopathy, Fabry disease, factor V deficiency, factor VII deficiency, factor XIII deficiency, familial adenomatous polyposis, breast cancer, ovarian cancer, cold urticaria, chronic infantile neurological cutaneous and articular syndrome, hemiplegic migraine, hypercholesterolemia, hypertrophic cardiomyopathy, hypoalphalipoproteinemia, hypokalemia and hypomagnesemia, juvenile gout, hyperlipoproteinemia, localized amyloidosis, vitamin D-refractory hypophosphatemic rickets, FG syndrome, extraocular muscle fibrosis, Finnish type Congenital nephrotic syndrome, focal epilepsy, focal segmental glomerulosclerosis, frontonasal dysplasia, frontotemporal dementia, fructose-biphosphatase deficiency, Gamstorp-Wohlfart syndrome, ganglioside sialidase deficiency, GATA1-related thrombocytopenia, Gaucher disease, giant axonal neuropathy, Glanzmann thrombasthenia, glomerular cystic kidney disease, glomerulopathy, glucocytes Corticoid insensitivity, glucose-6-phosphate transport disorders, glutaric aciduria, glycogen storage diseases, Gorlin syndrome, holoprosencephaly, GRACILE syndrome, hemorrhagic telangiectasia, hemochromatosis, hemoglobin H disease, hemolytic anemia, hemophagocytic syndrome, carcinoma of the colon, Myhre syndrome, leukoencephalopathy, hereditary factor IX deficiency, hereditary factor VIII deficiency, hereditary factor XI deficiency, hereditary fructosuria, hereditary nonpolyposis colon neoplasms, hereditary pancreatitis,Hereditary thermodysplastic erythrocyte disease, elliptocytosis, heterotaxy, heterotopic gray matter, histiocytic myeloreticulosis, histiocytosis-lymphadenopathy plus syndrome, HNSHA due to aldolase A deficiency, holocarboxylase synthetase deficiency, homocysteinemia, Howell-Evans syndrome, hydatidiform mole, hypercalciuric hypercalcemia, hyperimmunoglobulin D, mevalonic aciduria, hyperinsulinemic hypoglycemia, hyperkalemic periodic paralysis, von Eulenburg's congenital paramyotonia, hyperlipoproteinemia, hypermanganeseemia, hypermethionineemia, hyperphosphatemia, hypertension, hypomagnesemia calcemia, hypobetalipoproteinemia, hypocalcemia, hypogonadotropic hypogonadism, hypogonadotropic hypogonadism, hypohidrotic ectodermal dysplasia, hyper-IgM immunodeficiency, hypohidrotic X-linked ectodermal dysplasia, hypomagnesemia, hypoparathyroidism, idiopathic pulmonary fibrosis, immunodeficiency, immunoglobulin A deficiency, infantile hypophosphatasia, infantile dystonia-parkinsonism, insulin-dependent diabetes mellitus, intermediate maple syrup urine disease, ischiopatellar dysplasia, islet cell hyperplasia, isolated growth hormone deficiency, isolated lutropin deficiency, isovaleric acidemia, Joubert's disease syndrome, juvenile polyposis syndrome, juvenile retinoschisis, Kallmann syndrome, Kartagener syndrome, Kugelberg-Welander disease, lattice corneal dystrophy, Leber congenital amaurosis, Leber hereditary optic atrophy, left ventricular noncompaction, Leigh syndrome, mitochondrial complex I deficiency, leprosy, arthrogryposis, anterior horn cell disease, leukocyte adhesion deficiency, leukodystrophy, leukoencephalopathy, ovarian leukodystrophy, L-ferritin deficiency, Li-Fraumeni syndrome, limb-girdle muscular dystrophy-dystroglycanopathy, Lois-Deutsch syndrome Feats syndrome, long QT syndrome, macrocephaly / autism syndrome, macular corneal dystrophy, macular dystrophy, malignant hyperthermia predisposition, prostate cancer, maple syrup urine disease, Marden-Walker-like syndrome, Marfan syndrome, Marie-Unna hereditary hypotrichosis, mastocytosis, meconium-associated ileus, medium-chain acyl-coenzyme A dehydrogenase deficiency, Melnick-Fraser syndrome, mental retardation, merosin-deficient congenital muscular dystrophy, mesothelioma, metachromatic leukodystrophy, metaphyseal chondrodysplasia, methemoglobinemia, methylmalonic aciduria, homocystinuria, microcephaly,Chorioretinopathy, lymphedema, microphthalmia, mild non-PKU hyperphenylalaninemia, Mitchell-Riley syndrome, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency, mitochondrial complex I deficiency, mitochondrial complex III deficiency, mitochondrial myopathy, mucolipidosis III, mucopolysaccharidosis, multiple sulfatase deficiency, myasthenic syndrome, Mycobacterium tuberculosis, myeloperoxidase deficiency, Myhre syndrome, myoclonic epilepsy, myofibrillar myopathy, myoglobinuria, myopathy, myopia, Myotonia congenita, Navajo neurohepatopathy, nemaline myopathy, gastric neoplasms, nephrogenic diabetes insipidus, nephronophthisis, nephrotic syndrome, neurofibromatosis, triglyceride storage disease, Niemann-Pick disease, nonketotic hyperglycinemia, Noonan syndrome, Noonan-like syndrome, Norum disease, macular degeneration, N-terminal acetyltransferase deficiency, oculocutaneous albinism, oculodentodigital dysplasia, Odo syndrome, optic nerve agenesis, ornithine carbamoyltransferase deficiency, orofacial-digital syndrome, osteogenesis imperfecta, osteopetrosis, ovarian hypoplasia, onychomycosis, non-epidermolytic palmoplantar keratosis , Papillon-Lefèvre syndrome, Heim-Munk syndrome, periodontitis, peeling skin syndrome, Pendred syndrome, peroxisomal fatty acyl-CoA reductase 1 deficiency, peroxisome biogenesis disorder, Pfeiffer syndrome, phenylketonuria, non-PKU hyperphenylalaninemia, pituitary hormone deficiency, pityriasis rubra pilaris, polyarteritis nodosa, polycystic kidney disease, polycystic lipomembranous dysplasia, polymicrogyria, pontocerebellar hypoplasia, porokeratosis, posterior column ataxia, primary erythromelalgia, hyperoxaluria, progressive familial intrahepatic leukemia Cholestasis, progressive pseudorheumatic dysplasia, propionic acidemia, pseudohermaphroditism, pseudohypoaldosteronism, pseudoxanthoma elasticum, purine nucleoside phosphorylase deficiency, pyridoxal-5-phosphate-dependent epilepsy, renal dysplasia, retinitis pigmentosa, cerebellar ataxia, skeletal dysplasia, reticular dysplasia, retinitis pigmentosa, Usher syndrome, retinoblastoma, retinopathy, RRM2B-related mitochondrial disease, Rubinstein-Taybi syndrome, Schneider-Kristalin corneal dystrophy, sebaceous gland tumor, severe congenital neutropenia, severe myoclonic epilepsy of infancy,Severe X-linked myotubular myopathy, fingernail hypoplasia, facial dysmorphism, hypotrichosis, short-rib thoracic dysplasia, sialic acid storage disease, sialidosis, sideroblastic anemia, small fiber neuropathy, Smith-Magenis syndrome, Sorsby fundus dystrophy, spastic ataxia, spastic paraplegia, spermatogenesis imperfecta, spherocytosis, sphingomyelin / cholesterol lipidosis, spinocerebellar ataxia, cleft hand and foot, spondyloepiphyseal dysplasia, lethal squamovertebral dysplasia, squamous cell carcinoma of the head and neck, Stargardt disease, sucrase-isomaltase deficiency, infancy, Sudden infant death syndrome, supravalvar aortic stenosis, surfactant metabolic disorders, Tangier disease, Tutton-Brown-Lahman syndrome, thoracic aortic aneurysm and aortic dissection, thrombophilia, thyroid hormone insensitivity, TNF receptor-associated periodic fever syndrome (TRAPS), hypodontia, torsades de pointes, transposition of the great arteries, Treacher Collins syndrome, tuberous sclerosis syndrome, tyrosinase-negative oculocutaneous albinism, tyrosinase-positive oculocutaneous albinism, tyrosinemia, UDP-glucose-4-epimerase deficiency, Ullrich congenital muscular dystrophy, Bethlem myopathies These include Qi, Usher syndrome, UV-hypersensitivity syndrome, van der Woude syndrome, popliteal pterygium syndrome, very long-chain acyl-CoA dehydrogenase deficiency, vesicoureteral reflux, vitreoretinal choroidopathy, von Hippel-Lindau disease, von Willebrand disease, Waardenburg syndrome, Warsaw chromosome instability (breakage) syndrome, WFS1-related disorders, Wilson's disease, xeroderma pigmentosum, X-linked agammaglobulinemia, X-linked hereditary motor and sensory neuropathy, X-linked severe combined immunodeficiency, and Zellweger syndrome.
[0319] The development of nucleobase editing advances both the scope and efficacy of genome editing. The nucleobase editors described here offer researchers the option of editing with virtually no indel formation (NBE2) or more efficient editing with a low frequency of indel formation (here, typically ≦1%) (NBE3). The fact that the product of base editing is no longer the substrate by definition likely contributes to editing efficiency by preventing subsequent product conversion, which can hinder traditional Cas9 applications. By removing the reliance on double-stranded DNA breaks and stochastic DNA repair processes, which vary greatly depending on cellular conditions and cell type, nucleobase editing has the potential to expand the types of genome modifications that can be cleanly implemented, the efficiency of those modifications, and the cell types to which editing can be applied. Recent engineered Cas9 variants with improved DNA specificity 69,70,82 or delivery method 71 , and Cas9 variants with altered PAM specificity 72 It is likely that dCas9 can be integrated with this strategy to provide additional nucleobase editors with improved DNA specificity or capable of targeting a broader range of disease-associated mutations. These findings also suggest that engineering additional fusions of dCas9 with enzymes that catalyze additional nucleobase transversions will increase the fraction of possible DNA base changes that can be made by nucleobase editing. These results also suggest the construction of fusions of other DNA-modifying enzymes, including methylases and demethylases, that may enable additional types of programmable genome and epigenome base editing.
[0320] Materials and Methods Cloning. The DNA sequences of all constructs and primers used in this manuscript are listed in the Supplementary Sequences. Plasmids containing the genes encoding NBE1, NBE2, and NBE3 are available from Addgene. PCR was performed using VeraSeq ULtra DNA polymerase (Enzymatics) or Q5 Hot Start High-Fidelity DNA polymerase (New England Biolabs). NBE plasmids were constructed using USER cloning (New England Biolabs). The deaminase gene was synthesized using gBlocks gene fragments (Integrated DNA Technologies), and the Cas9 gene was cloned from a previously reported plasmid. 18 The deaminase and fusion genes were cloned into pCMV (mammalian codon-optimized) or pET28b (E. coli codon-optimized) backbones. sgRNA expression plasmids were constructed using site-directed mutagenesis. Briefly, the primers listed in the supplemental sequences were 5'-phosphorylated using T4 polynucleotide kinase (New England Biolabs) according to the manufacturer's instructions. PCR was then performed using Q5 Hot Start High-Fidelity polymerase (New England Biolabs) with the phosphorylated primers and plasmid pFYF1320 (EGFP sgRNA expression plasmid) as a template according to the manufacturer's instructions. The PCR product was incubated with DpnI (20 U, New England Biolabs) at 37°C for 1 h, purified using a QIAprep spin column (Qiagen), and ligated using Quick Ligase (New England Biolabs) according to the manufacturer's instructions. DNA vector amplification was performed using Mach1 competent cells (Thermo Fisher Scientific).
[0321] In vitro deaminase assay with ssDNA. The sequences of all ssDNA substrates are listed in the Supplementary Sequences. All Cy3-labeled substrates were obtained from Integrated DNA Technologies (IDT). Deaminases were expressed in vitro using 1 μg of plasmid with the TNT T7 Quick Coupled Transcription / Translation Kit (Promega) according to the manufacturer's instructions. After protein expression, 5 μL of lysate was combined with 35 μL of ssDNA (1.8 μM) and USER enzyme (1 unit) in CutSmart buffer (New England Biolabs) (50 mM potassium acetate, 29 mM Tris-acetate, 10 mM magnesium acetate, 100 μg / mL BSA, pH 7.9) and incubated at 37°C for 2 h. Cleaved U-containing substrates were separated from full-length unmodified substrates on a 10% TBE-urea gel (Bio-Rad).
[0322] Expression and purification of His6-rAPOBEC1-linker-dCas9 fusions. E. coli BL21 STAR (DE3) competent cells (Thermo Fisher Scientific) were transformed with a plasmid encoding pET28b-His6-rAPOBEC-linker-dCas9 with a GGS, (GGS)3 (SEQ ID NO: 596), XTEN, or (GGS)7 (SEQ ID NO: 597) linker. The resulting expression strain was grown overnight at 37°C in Luria-Bertani (LB) broth containing 100 μg / mL of kanamycin. Cells were diluted 1:100 in the same growth medium and purified at 37°C to an OD 600The culture was grown to a pH of 0.6. The culture was cooled to 4°C over a 2-h period, and isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added at 0.5 mM to induce protein expression. After ~16 h, cells were collected by centrifugation at 4,000 g and resuspended in lysis buffer (50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 7.0, 1 M NaCl, 20% glycerol, 10 mM tris(2-carboxyethyl)phosphine (TCEP, Soltec Ventures)). Cells were lysed by sonication (6 W power, 20 s pulse on, 20 s pulse off, total 8 min), and the lysate supernatant was isolated after centrifugation at 25,000 g for 15 min. The lysate was incubated with His-Pur nickel-nitriloacetic acid (nickel-NTA) resin (Thermo Fisher Scientific) for 1 h at 4°C to capture His-tagged fusion proteins. The resin was transferred to a column and washed with 40 mL of lysis buffer. The His-tagged fusion proteins were eluted with lysis buffer supplemented with 285 mM imidazole and concentrated to a total volume of 1 mL by ultrafiltration (Amicon-Millipore, 100 kDa molecular weight cutoff). The protein was diluted to 20 mL with low-salt purification buffer containing 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 7.0, 0.1 M NaCl, 20% glycerol, and 10 mM TCEP and loaded onto SP Sepharose Fast Flow resin (GE Life Sciences). The resin was washed with 40 mL of this low-salt buffer, and the protein was eluted with 5 mL of activity buffer containing 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl, pH 7.0, 0.5 M NaCl, 20% glycerol, and 10 mM TECEP. The eluted protein was quantified on an SDS-PAGE gel.
[0323] In vitro transcription of sgRNA. A linear DNA fragment containing the T7 promoter followed by the 20-bp sgRNA target sequence was in vitro transcribed using the TranscriptAid T7 High-Yield Transcription Kit (ThermoFisher Scientific) according to the manufacturer's instructions, using the primers listed in the Supplementary Sequence Table. The sgRNA product was purified using the MEGAclear kit (ThermoFisher Scientific) according to the manufacturer's instructions and quantified by UV absorbance.
[0324] Preparation of Cy3-conjugated dsDNA substrates. The sequences of the 80-nt unlabeled strands are listed in the Supplementary Sequence Table and were ordered from IDT as PAGE-purified oligonucleotides. The 25-nt Cy3-labeled primers listed in the Supplementary Sequence Table are complementary to the 3' end of each 80-nt substrate. These primers were ordered from IDT as HPLC-purified oligonucleotides. To create the Cy3-labeled dsDNA substrates, the 80-nt strands (5 μL of a 100 μM solution) were combined with the Cy3-labeled primers (5 μL of a 100 μM solution) in NEBuffer 2 (38.25 μL of a 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9, New England Biolabs) with dNTPs (0.75 μL of a 100 mM solution), heated to 95°C for 5 min, and then slowly cooled to 45°C at a rate of 0.1°C / s. After this annealing period, Klenow exo - (5U, New England Biolabs) was added and the reaction was incubated for 1 h at 37° C. The solution was diluted with Buffer PB (250 μL, Qiagen) and isopropanol (50 μL), purified on a QIAprep spin column (Qiagen), and eluted with 50 μL of Tris buffer.
[0325] Deaminase assay with dsDNA. Purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with 1 equivalent of the appropriate sgRNA and incubated at room temperature for 5 min. Cy3-labeled dsDNA substrate was added to a final concentration of 125 nM, and the resulting solution was incubated at 37°C for 2 h. dsDNA was separated from the fusion by the addition of Buffer PB (100 μL, Qiagen) and isopropanol (25 μL), purified on an EconoSpin microspin column (Epoch Life Science), and eluted with 20 μL of CutSmart buffer (New England Biolabs). USER enzyme (1 U, New England Biolabs) was added to the purified edited dsDNA and incubated at 37°C for 1 h. The Cy3-labeled strand was fully denatured from its complement by combining 5 μL of the reaction solution with 15 μL of DMSO-based loading buffer (5 mM Tris, 0.5 mM EDTA, 12.5% glycerol, 0.02% bromophenol blue, 0.02% xylene cyan, 80% DMSO). Full-length C-containing substrates were separated from edited substrates containing any truncated U on a 10% TBE-urea gel (Bio-Rad) and imaged with a GE Amersham Typhoon imager.
[0326] Preparation of in vitro edited dsDNA for high-throughput sequencing (HTS). Oligonucleotides listed in the supplemental sequences were obtained from IDT. Complementary sequences were combined in Tris buffer (5 μL of a 100 μM solution) and annealed by heating to 95°C for 5 min, followed by slow cooling to 45°C at a rate of 0.1°C / s to create a 60-bp dsDNA substrate. Purified fusion protein (20 μL of 1.9 μM in activity buffer) was combined with one equivalent of the appropriate sgRNA and incubated at room temperature for 5 min. The 60-mer dsDNA substrate was added to a final concentration of 125 nM, and the resulting solution was incubated at 37°C for 2 h. The dsDNA was separated from the fusion by adding Buffer PB (100 pL, Qiagen) and isopropanol (25 pL), purified using an EconoSpin microspin column (Epoch Life Science), and eluted with 20 μL of Tris buffer. The resulting edited DNA (1 μL used as template) was amplified by PCR using the HTS primer pair specified in the supplemental sequences and a VeraSeq Ultra (Enzymatics) system according to the manufacturer's instructions for 13 cycles of amplification. The PCR reaction products were purified using RapidTips (Diffinity Genomics), and the purified DNA was amplified by PCR with primers containing sequencing adapters, purified, and sequenced using a MiSeq high-throughput DNA sequencer (Illumina) as previously described. 73 .
[0327] Cell Culture. HEK293T (ATCC CRL-3216), U2OS (ATCC-HTB-96), and ST486 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium Plus GlutaMax (Thermo Fisher Scientific) supplemented with 10% (v / v) fetal bovine serum (FBS) and penicillin / streptomycin (1x, Amresco) at 37°C in 5% CO. HCC1954 cells (ATCC CRL-2338) were maintained in RPMI-1640 medium (Thermo Fisher Scientific) supplemented as described above. Immortalized rat astrocytes (Taconic Biosciences) containing the ApoE4 isoform of the APOE gene were cultured in Dulbecco's Modified Eagle's Medium Plus GlutaMax (Thermo Fisher Scientific) supplemented with 10% (v / v) fetal bovine serum (FBS) and 200 μg / mL Geneticin (Thermo Fisher Scientific).
[0328] Transfection. HEK293T cells were seeded in 48-well collagen-coated BioCoat plates (Corning) and transfected at approximately 85% confluence. Briefly, 750 ng of NBE expression plasmid and 250 ng of sgRNA expression plasmid were transfected per well using 1.5 μL of Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol. Astrocytes, U2OS, HCC1954, HEK293T, and ST486 cells were transfected using the appropriate AMAXA NUCLEOFECTOR™ II program according to the manufacturer's instructions. Infrared RFP (Addgene Plasmid 45457) 74Nucleofection efficiency in these cell lines was assessed by adding 40 ng of NADH to the nucleofection solution. Nucleofection efficiencies were 25%, 74%, and 92% in astrocytes, U2OS, and ST486 cells, respectively. Nucleofection efficiency was <10% in HCC1954 cells. Therefore, after trypsinization, HCC1954 cells were filtered through a 40-micron filter (Fisher Scientific), and nucleofected HCC1954 cells were collected using a Beckman Coulter MoFlo XDP cell sorter using iRFP signal (abs 643 nm, em 670 nm). Other cell lines were used without enrichment of nucleofected cells.
[0329] High-throughput DNA sequencing of genomic DNA samples. Transfected cells were harvested after 3 days, and genomic DNA was isolated using the Agencourt DNAdvance Genomic DNA Isolation Kit (Beckman Coulter) according to the manufacturer's instructions. On-target and off-target genomic regions of interest were amplified by PCR with the flanking HTS primer pairs listed in the Supplementary Sequence Table. PCR amplification was performed using 5 ng of genomic DNA as template with Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific) according to the manufacturer's instructions. The number of cycles was determined separately for each primer pair to ensure that the reaction was within the linear range of amplification (30, 28, 28, 28, 32, and 32 cycles for EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 primers, respectively). PCR products were purified using RapidTips (Diffinity Genomics). The purified DNA was amplified by PCR with primers containing sequencing adapters. The products were gel-purified and quantified using the QUANT-IT™ PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific) and the KAPA Library Quantification Kit-Illumina (KAPA Biosystems). Samples were sequenced by Illumina MiSeq as previously described. 73 .
[0330] Data Analysis. Sequencing reads were automatically de-duplicated using MiSeq Reporter (Illumina), and individual FASTQ files were analyzed using custom Matlab® scripts provided in the Supplementary Notes. Each read was pairwise aligned to the appropriate reference sequence using the Smith-Waterman algorithm. Base calls with a Q score below 31 were replaced by N and therefore excluded when calculating nucleotide frequencies. This procedure yields an expected MiSeq base calling error rate of approximately 1 in 1,000. Aligned sequences where the read and reference sequences contained no gaps were stored in an alignment table, from which base frequencies could be tabulated for each locus.
[0331] Indel frequencies were quantified by a custom Matlab script shown in the Supplementary Notes, using previously described criteria. 71 Sequencing reads were scanned for exact matches to two 10-bp sequences flanking a window of potential indels. If no exact match was found, the read was excluded from analysis. If the length of this indel window exactly matched the reference sequence, the read was classified as not containing an indel. If the indel window was more than two bases longer or shorter than the reference sequence, the sequencing read was classified as an insertion or deletion, respectively.
[0332] All publications, patents, patent applications, publications, and database entries (e.g., sequence database entries) mentioned herein, for example, in the Background, Summary, Detailed Description, Examples, and / or References sections, are hereby incorporated by reference in their entirety, as if each individual publication, patent, patent application, publication, and database entry were specifically and individually incorporated herein by reference. In case of conflict, the present application will control, including any definitions herein.
[0333] Supplementary Sequences Primers used to generate sgRNA transfection plasmids. rev_sgRNA_plasmid was used in all cases. The pFYF1320 plasmid was used as a template as seen in the Materials and Methods section. SEQ ID NOs: 329-338 are listed below from top to bottom, respectively.
number
[0334] The sequences of all ssDNA substrates used in the in vitro deaminase assay are listed below, from top to bottom, with SEQ ID NOs: 339-341.
number
[0335] Primers used to generate PCR products to serve as substrates for T7 transcription of sgRNA for gel-based deaminase assays. rev_gRNA_T7 was used in all cases. The pFYF1320 plasmid was used as a template, as seen in the Materials and Methods section. SEQ ID NOs: 342-365 are listed below from top to bottom, respectively.
number
[0336] Sequences of the 80-nucleotide unlabeled strand and Cy3-labeled universal primer used in the gel-based dsDNA deaminase assay. SEQ ID NOs: 366-390 are listed below from top to bottom, respectively.
number
[0337] Primer .rev_gRNA_T7 (top) was used in all cases to generate PCR products to serve as substrates for T7 transcription of sgRNA for high-throughput sequencing. The pFYF1320 plasmid was used as a template, as seen in the Materials and Methods section. SEQ ID NOs: 391-442 are listed below from top to bottom, respectively.
number
number
[0338] Sequences of in vitro edited dsDNA for high-throughput sequencing (HTS). The sequence of the edited strand is shown. Reverse complements of all sequences shown were also obtained. dsDNA substrates were obtained by annealing complementary strands as described in Materials and Methods. Oligonucleotides corresponding to the EMX1, FANCF, HEK293 site 2, HEK293 site 3, HEK293 site 4, and RNF2 loci were originally designed for use in gel-based deaminase assays and therefore contain the same 25-nt sequence at their 5' ends (matching that of the Cy3 primer). SEQ ID NOs: 443-494 are listed below from top to bottom, respectively.
number
number
[0339] Primers for HTS of in vitro edited dsDNA. SEQ ID NOs: 495 to 503 are listed below from top to bottom, respectively.
number
[0340] Primers for HTS of on-target and off-target sites from all mammalian cell culture experiments. SEQ ID NOs: 504-579 and 1869-1900 are listed below from top to bottom, respectively.
number
number
number
number
[0341] Sequence of the single-stranded oligonucleotide donor template (ssODN) used in HDR studies.
number
number
[0342] Deaminase gene gBlocks gene fragment
number
number
[0343] Amino acid sequences of NBE1, NBE2, and NBE3. NBE1 (His6-rAPOBEC1-XTEN-dCas9) (SEQ ID NO: 591) for E. coli expression
number
number
number
number
number
number
number
number
number
number
number
number
[0344] Basecall MATLAB script
number
number
number
[0345] INDEL detection Matlab script
number
number
number
[0346] Example 5: Cas9 variant sequences The present disclosure provides Cas9 variants, e.g., Cas9 proteins from one or more organisms, which may contain one or more mutations (e.g., to create dCas9 or Cas9 nickase). In some embodiments, one or more of the amino acid residues of a Cas9 protein identified below with an asterisk may be mutated. In some embodiments, the D10 and / or H840 residues of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, are mutated. In some embodiments, the D10 residue of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, is mutated to any amino acid residue other than D. In some embodiments, the D10 residue of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, is mutated to A. In some embodiments, the H840 residue of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding residue in any of the amino acid sequences provided by SEQ ID NOs: 11-260, is H. In some embodiments, residue H840 of the amino acid sequence provided by SEQ ID NO: 10, or the corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, is mutated to any amino acid residue other than H. In some embodiments, residue H840 of the amino acid sequence provide...
Claims
1. A fusion protein comprising: (i) a Cas9 domain; (ii) a cytidine deaminase domain; and (iii) a uracil glycosylase inhibitor (UGI) domain.
2. The fusion protein of claim 1, wherein the Cas9 domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence provided by SEQ ID NO:
674.
3. The fusion protein of claim 1, wherein the Cas9 domain is a Cas9 nickase domain that cleaves a nucleotide target strand of a nucleotide duplex, and the nucleotide target strand is the strand that binds to the gRNA of the Cas9 nickase domain.
4. 2. The fusion protein of claim 1, wherein the Cas9 domain is a nCas9 domain comprising a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
5. 2. The fusion protein of claim 1, wherein the Cas9 domain is a nCas9 domain comprising one or more of N496A, R660A, Q694A, and Q926A of the amino acid sequence provided by SEQ ID NO: 10, or one or more corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
6. The fusion protein of claim 1 , wherein the cytidine deaminase domain is a deaminase from the apolipoprotein B mRNA editing complex (APOBEC) family of deaminases.
7. The fusion protein of claim 6, wherein the APOBEC family deaminase is selected from the group consisting of APOBEC1 deaminase, APOBEC2 deaminase, APOBEC3A deaminase, APOBEC3B deaminase, APOBEC3C deaminase, APOBEC3D deaminase, APOBEC3F deaminase, APOBEC3G deaminase, and APOBEC3H deaminase.
8. 2. The fusion protein of claim 1, wherein the cytidine deaminase domain comprises an amino acid sequence that is at least 85% identical to an amino acid sequence of SEQ ID NOs: 266-284, 607-610, 5724-5736, or 5738-5741.
9. The fusion protein of claim 1, wherein the cytidine deaminase domain comprises an amino acid sequence of SEQ ID NO:266-284, 607-610, 5724-5736, or 5738-5741.
10. The fusion protein of claim 1, wherein the cytidine deaminase domain is a rat APOBEC1 (rAPOBEC1) deaminase comprising one or more mutations selected from the group consisting of W90Y, R126E, and R132E of SEQ ID NO: 284, or one or more corresponding mutations in another APOBEC deaminase.
11. The fusion protein of claim 1, wherein the cytidine deaminase domain is human APOBEC1 (hAPOBEC1) deaminase comprising one or more mutations selected from the group consisting of W90Y, Q126E, and R132E of SEQ ID NO: 5724, or one or more corresponding mutations in another APOBEC deaminase.
12. The fusion protein of claim 1, wherein the cytidine deaminase domain is a human APOBEC3G (hAPOBEC3G) deaminase comprising one or more mutations selected from the group consisting of W285Y, R320E, and R326E of SEQ ID NO: 275, or one or more corresponding mutations in another APOBEC deaminase.
13. The fusion protein of claim 1 , wherein the cytidine deaminase domain is activation-induced deaminase (AID).
14. The fusion protein of claim 1, wherein the cytidine deaminase domain is cytidine deaminase 1 (pmCDA1) from Petromyzon marinus.
15. The fusion protein of claim 1 , wherein the UGI domain comprises a domain capable of inhibiting UDG activity.
16. The fusion protein of claim 1, wherein the UGI domain comprises an amino acid sequence that is at least 85% identical to SEQ ID NO:
600.
17. The fusion protein of claim 1, wherein the UGI domain comprises the amino acid sequence set forth in SEQ ID NO:
600.
18. Fusion protein has structure: NH 2 The fusion protein of claim 1, comprising -[cytidine deaminase domain]-[Cas9 domain]-[UGI domain]-COOH, each of the "-"s comprising an optional linker.
19. The cytidine deaminase domain of (ii) and the nCas9 domain of (i) have the amino acid sequence (GGGS): n (SEQ ID NO:265), (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , (SGGS) n (SEQ ID NO: 4288), SGSETPGTSESATPES (SEQ ID NO: 7), or (XP) n 2. The fusion protein of claim 1, wherein n is independently an integer between 1 and 30, inclusive, and X is any amino acid.
20. The fusion protein of claim 1, wherein the cytidine deaminase domain of (ii) and the nCas9 domain of (i) are linked by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7).
21. The fusion protein of claim 1, further comprising a nuclear localization sequence (NLS).
22. The fusion protein of claim 21 , wherein the NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 741) or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 742).
23. Fusion protein has structure: NH 2 The fusion protein of claim 21, comprising -[cytidine deaminase domain]-[nCas9 domain]-[UGI domain]-[NLS]-COOH, each of the "-"s comprising an optional linker.
24. The fusion protein of claim 21 , wherein the UGI domain and the NLS are linked by a linker comprising the amino acid sequence: SGGS (SEQ ID NO: 4288), or the nCas9 domain and the UGI domain are linked by a linker comprising the amino acid sequence: SGGS (SEQ ID NO: 4288).
25. The fusion protein of claim 1, wherein the fusion protein comprises the amino acid sequence set forth in SEQ ID NO:
594.
26. A complex comprising the fusion protein of claim 1 and a guide RNA bound to the nCas9 domain of the fusion protein.
27. contacting a nucleic acid molecule with the fusion protein of claim 1 and a guide RNA, The guide RNA comprises a sequence of at least 10 consecutive nucleotides that is complementary to a target sequence in the genome of the organism and includes a target base pair; method.
28. 28. The method of claim 27, wherein the target base pair comprises a T→C point mutation associated with a disease or disorder, and deamination of the mutant C base results in a sequence that is not associated with the disease or disorder.
29. 28. The method of Claim 27, wherein the contacting results in less than 20% indel formation by base editing.
30. 28. The method of Claim 27, wherein the contacting results in at least a 2:1 ratio of intended products to unintended products through base editing.
31. (i) a nuclease-inactive Cas9 (dCas9) domain; and (ii) an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain; The deaminase domain is fused to the N-terminus of the dCas9 domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7); fusion protein.
32. 32. The fusion protein of claim 31 , wherein the nuclease-inactivated Cas9 (dCas9) domain of (i) comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO:
263.
33. The fusion protein of claim 31 , wherein the nuclease-inactivated Cas9 (dCas9) domain of (i) comprises the amino acid sequence set forth in SEQ ID NO:
263.
34. The fusion protein of any one of claims 31 to 33, wherein the deaminase is a rat APOBEC1 deaminase that is at least 85% identical to the amino acid sequence shown in (SEQ ID NO: 284).
35. The fusion protein of any one of claims 31 to 34, wherein the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence shown in (SEQ ID NO: 284).
36. The fusion protein of any one of claims 31 to 33, wherein the deaminase is a human APOBEC1 deaminase that is at least 85% identical to the amino acid sequence shown in (SEQ ID NO: 282).
37. The fusion protein according to any one of claims 31 to 33, wherein the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence shown in (SEQ ID NO: 282).
38. The fusion protein of any one of claims 31 to 37, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO:
600.
39. The fusion protein of any one of claims 31 to 38, wherein the UGI domain comprises the amino acid sequence set forth in SEQ ID NO:
600.
40. The fusion protein of any one of claims 31 to 37, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 322 to 324.
41. A fusion protein according to any one of claims 31 to 37, wherein the UGI domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 322 to 324.
42. The fusion protein of any one of claims 31 to 41, wherein the fusion protein comprises amino acid residues 11 to 1629 of the amino acid sequence set forth in SEQ ID NO:
591.
43. The fusion protein of any one of claims 31 to 41, wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 591-593, 611, 612, 615, 657, 658, and 5737.
44. A fusion protein comprising: (i) a nuclease-inactivated Cas9 (dCas9) domain; (ii) a nucleic acid editing domain; and (iii) a uracil glycosylase inhibitor (UGI) domain.
45. 45. The fusion protein of claim 44, wherein the amino acid sequence of the dCas9 domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, where X is any amino acid other than D.
46. The fusion protein of claim 44 or 45, wherein the amino acid sequence of the dCas9 domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
47. 47. The fusion protein of any one of claims 44-46, wherein the amino acid sequence of the dCas9 domain comprises an H840X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, wherein X is any amino acid other than H.
48. 48. The fusion protein of any one of claims 44-47, wherein the amino acid sequence of the dCas9 domain comprises an H840A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
49. The fusion protein of any one of claims 44 to 48, wherein the dCas9 domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO:
263.
50. The fusion protein of any one of claims 44 to 49, wherein the dCas9 domain comprises the amino acid sequence set forth in SEQ ID NO:
263.
51. 51. The fusion protein of any one of claims 44-50, wherein the dCas9 domain comprises one or more of the N497X, R661X, Q695X, and Q926X mutations of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, wherein X is any amino acid.
52. 52. The fusion protein of any one of claims 44-51, wherein the dCas9 domain comprises one or more of the N497A, R661A, Q695A, and Q926A mutations of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
53. 53. The fusion protein of any one of claims 44-52, wherein the dCas9 domain comprises the N497A, R661A, Q695A, and Q926A mutations of the amino acid sequence provided by SEQ ID NO: 10, or corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
54. The fusion protein of any one of claims 44 to 53, wherein the dCas9 domain comprises Staphylococcus aureus (SaCas9).
55. The fusion protein of claim 54, wherein SaCas9 comprises the amino acid sequence SEQ ID NO:4273.
56. The fusion protein of claim 54 or 55, wherein the SaCas9 domain comprises one or more of the E781K, N967K, or R1014H mutations of SEQ ID NO: 4273, or one or more corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
57. 54. The fusion protein of any one of claims 44-53, wherein the dCas9 domain comprises one or more of the D1134E, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
58. The fusion protein of any one of claims 44-53, wherein the dCas9 domain comprises one or more of the D1134V, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
59. 54. The fusion protein of any one of claims 44-53, wherein the dCas9 domain comprises one or more of the following mutations: D1134V, G1217R, R1334Q, and T1336R of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
60. The fusion protein of any one of claims 44 to 59, wherein the nucleic acid editing domain is fused to the N-terminus of the dCas9 domain.
61. The fusion protein of any one of claims 44 to 60, wherein the UGI domain is fused to the C-terminus of the dCas9 domain.
62. The fusion protein of any one of claims 44 to 61, wherein the dCas9 domain and the nucleic acid editing domain are fused by a linker.
63. The fusion protein of any one of claims 44 to 62, wherein the dCas9 domain and the UGI domain are fused by a linker.
64. The linker has the amino acid sequence (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , SGSETPGTSESATPES (SEQ ID NO: 7), SGGS (SEQ ID NO: 4288), (XP) n or any combination thereof, wherein n is independently an integer between 1 and 30, and X is any amino acid.
65. The fusion protein of claim 62 or 63, wherein the linker comprises a covalent bond.
66. Linker is amino acid sequence (GGS) n and n is 1, 3, or 7.
67. The fusion protein of claim 64, wherein the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7).
68. The fusion protein of claim 62, wherein the dCas9 domain and the nucleic acid editing domain are fused by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7).
69. The dCas9 domain and the nucleic acid editing domain are represented by the amino acid sequence (GGS) n and n is 1, 3, or 7. The fusion protein of claim 62, fused by a linker comprising:
70. The dCas9 domain and the UGI domain are n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , SGSETPGTSESATPES (SEQ ID NO: 7), SGGS (SEQ ID NO: 4288), (XP) n or any combination thereof, wherein n is independently an integer between 1 and 30, and X is any amino acid.
71. The fusion protein of claim 63, wherein the dCas9 domain and the UGI domain are fused by a linker comprising the amino acid sequence SGGS (SEQ ID NO: 4288).
72. The fusion protein of any one of claims 44 to 71, wherein the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker]-[dCas9 domain]-[optional linker]-[UGI].
73. The fusion protein has the structure: [nucleic acid editing domain]-[optional linker]-[UGI]-[optional linker]-[dCas9]; [UGI]-[any linker]-[nucleic acid editing domain]-[any linker]-[dCas9]; [UGI]-[any linker]-[dCas9]-[any linker]-[nucleic acid editing domain]; [dCas9]-[any linker]-[UGI]-[any linker]-[nucleic acid editing domain]; Or a fusion protein described in any one of claims 44 to 67 comprising [dCas9]-[any linker]-[nucleic acid editing domain]-[any linker]-[UGI].
74. The fusion protein of any one of claims 44 to 73, wherein the nucleic acid editing domain comprises a deaminase.
75. The fusion protein of claim 74, wherein the deaminase is a cytidine deaminase.
76. The fusion protein of claim 74 or 75, wherein the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase.
77. The fusion protein of any one of claims 74 to 76, wherein the deaminase is APOBEC1 deaminase.
78. The fusion protein of any one of claims 74 to 76, wherein the deaminase is an APOBEC2 deaminase.
79. The fusion protein of any one of claims 74 to 76, wherein the deaminase is APOBEC3A deaminase.
80. The fusion protein of any one of claims 74 to 76, wherein the deaminase is APOBEC3B deaminase.
81. The fusion protein of any one of claims 74 to 76, wherein the deaminase is an APOBEC3C deaminase.
82. The fusion protein of any one of claims 74 to 76, wherein the deaminase is an APOBEC3D deaminase.
83. The fusion protein of any one of claims 74 to 76, wherein the deaminase is APOBEC3F deaminase.
84. The fusion protein of any one of claims 74 to 76, wherein the deaminase is APOBEC3G deaminase.
85. The fusion protein of any one of claims 74 to 76, wherein the deaminase is an APOBEC3H deaminase.
86. The fusion protein of any one of claims 74 to 76, wherein the deaminase is an APOBEC4 deaminase.
87. The fusion protein of claim 74 or 75, wherein the deaminase is activation-induced deaminase (AID).
88. The fusion protein of claim 74 or 75, wherein the deaminase is an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBECl (sequence number 284), or one or more corresponding mutations in another APOBEC deaminase.
89. The fusion protein of claim 74 or 75, wherein the deaminase is an APOBEC deaminase comprising the W90Y, R126E, and R132E mutations of rAPOBECl (sequence number 284), or one or more corresponding mutations in another APOBEC deaminase.
90. 76. The fusion protein of claim 74 or 75, wherein the deaminase comprises one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G (SEQ ID NO: 275), or one or more corresponding mutations in another APOBEC deaminase.
91. 76. The fusion protein of claim 74 or 75, wherein the deaminase is an APOBEC deaminase comprising the W285Y, R320E, and R326E mutations of hAPOBEC3G (sequence number 275), or one or more corresponding mutations in another APOBEC deaminase.
92. The fusion protein of any one of claims 74 to 91, wherein the deaminase is from a human, a chimpanzee, a gorilla, a monkey, a cow, a dog, a rat, or a mouse.
93. The fusion protein of any one of claims 74 to 92, wherein the deaminase is from a human.
94. The fusion protein of any one of claims 74 to 92, wherein the deaminase is from rat.
95. 76. The fusion protein of claim 74 or 75, wherein the deaminase is cytidine deaminase 1 (pmCDA1) from Petromyzon marinus.
96. The fusion protein of any one of claims 74 to 76, wherein the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence shown in (SEQ ID NO: 284).
97. The fusion protein of any one of claims 74 to 76, wherein the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 282).
98. The fusion protein of claim 95, wherein pmCDA1 comprises the amino acid sequence shown in (sequence number 5738).
99. The fusion protein of claim 84, wherein the APOBEC3G is human APOBEC3G comprising the amino acid sequence shown in (SEQ ID NO: 275).
100. The fusion protein of claim 84, wherein the APOBEC3G is a human APOBEC3G variant comprising an amino acid sequence set forth in any one of (SEQ ID NOs: 5739-5741).
101. The fusion protein of claim 74 or 75, wherein the deaminase is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 266-284, 607-610, 5724-5736, and 5738-5741.
102. The fusion protein of claim 74 or 75, wherein the deaminase comprises an amino acid sequence set forth in any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, and 5738-5741.
103. The fusion protein of any one of claims 44 to 102, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO:
600.
104. The fusion protein of any one of claims 44 to 103, wherein the UGI domain comprises the amino acid sequence set forth in SEQ ID NO:
600.
105. The fusion protein of any one of claims 44 to 102, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 322 to 324.
106. The fusion protein according to any one of claims 44 to 102, wherein the UGI domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 322 to 324.
107. (i) a Cas9 nickase domain; and (ii) an apolipoprotein B mRNA editing complex 1 (APOBEC1) deaminase domain; The deaminase domain is fused to the N-terminus of the Cas9 nickase domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7); fusion protein.
108. The fusion protein of claim 107, wherein the deaminase is rat APOBEC1 (sequence number 284).
109. The fusion protein of claim 107 or 108, wherein the deaminase is human APOBEC1 (sequence number 282).
110. (i) a Cas9 nickase domain; and (ii) an apolipoprotein B mRNA editing complex 3G (APOBEC3G) deaminase domain; The deaminase domain is fused to the N-terminus of the Cas9 nickase domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7); fusion protein.
111. The fusion protein of claim 110, wherein the deaminase is a human APOBEC3G deaminase comprising an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in (SEQ ID NO: 275).
112. The fusion protein of claim 110 or 111, wherein the deaminase is human APOBEC3G (sequence number 275).
113. The fusion protein of claim 110, wherein the APOBEC3G is a human APOBEC3G variant comprising an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in any one of (SEQ ID NOs: 5739-5741).
114. The fusion protein of claim 110, wherein the APOBEC3G is a human APOBEC3G variant comprising an amino acid sequence set forth in any one of (SEQ ID NOs: 5739-5741).
115. (i) a Cas9 nickase domain; and (ii) a pmCDA1 domain; The deaminase domain is fused to the N-terminus of the Cas9 nickase domain by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7); fusion protein.
116. The fusion protein of claim 115, wherein pmCDA1 comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in (sequence number 5738).
117. A fusion protein described in claim 115 or 116, wherein pmCDA1 comprises the amino acid sequence shown in (sequence number 5738).
118. 118. The fusion protein of any one of claims 107 to 117, wherein the amino acid sequence of the Cas9 nickase domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11 to 260, wherein X is any amino acid other than D.
119. 119. The fusion protein of any one of claims 107 to 118, wherein the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11 to 260.
120. 120. The fusion protein of any one of claims 107-119, wherein the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided by SEQ ID NO: 10, or at the corresponding amino acid position in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
121. The fusion protein of any one of claims 107 to 120, wherein the amino acid sequence of the Cas9 nickase domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO:
674.
122. The fusion protein of any one of claims 107 to 121, wherein the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence set forth in SEQ ID NO:
674.
123. The fusion protein of any one of claims 107 to 122, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO:
600.
124. The fusion protein of any one of claims 107 to 123, wherein the UGI domain comprises the amino acid sequence set forth in SEQ ID NO:
600.
125. The fusion protein of any one of claims 107 to 122, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 322 to 324.
126. The fusion protein according to any one of claims 107 to 122, wherein the UGI domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 322 to 324.
127. The fusion protein of any one of claims 107 to 126, wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs: 594, 5743, 5745, and 5746.
128. A fusion protein comprising: (i) a Cas9 nickase (nCas9) domain; (ii) a nucleic acid editing domain; and (iii) a uracil glycosylase inhibitor (UGI) domain.
129. 129. The fusion protein of claim 128, wherein the amino acid sequence of the Cas9 nickase domain comprises a D10X mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, wherein X is any amino acid other than D.
130. 130. The fusion protein of claim 128 or 129, wherein the amino acid sequence of the Cas9 nickase domain comprises a D10A mutation in the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
131. 131. The fusion protein of any one of claims 128-130, wherein the amino acid sequence of the Cas9 nickase domain comprises a histidine at amino acid position 840 of the amino acid sequence provided by SEQ ID NO: 10, or at the corresponding amino acid position in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
132. The fusion protein of any one of claims 128 to 131, wherein the amino acid sequence of the Cas9 nickase domain comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO:
674.
133. The fusion protein of any one of claims 128 to 131, wherein the amino acid sequence of the Cas9 nickase domain comprises the amino acid sequence set forth in SEQ ID NO:
674.
134. 134. The fusion protein of any one of claims 128-133, wherein the Cas9 nickase domain comprises one or more of the N497X, R661X, Q695X, and Q926X mutations of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260, wherein X is any amino acid.
135. 135. The fusion protein of any one of claims 128-134, wherein the Cas9 nickase domain comprises one or more of the N497A, R661A, Q695A, and Q926A mutations of the amino acid sequence provided by SEQ ID NO: 10, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
136. 136. The fusion protein of any one of claims 128-135, wherein the Cas9 nickase domain comprises the N497A, R661A, Q695A, and Q926A mutations of the amino acid sequence provided by SEQ ID NO: 10, or corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
137. The fusion protein of any one of claims 128 to 136, wherein the Cas9 nickase domain comprises Staphylococcus aureus (SaCas9).
138. The fusion protein of claim 137, wherein SaCas9 comprises the amino acid sequence SEQ ID NO:4273.
139. The fusion protein of claim 137 or 138, wherein SaCas9 comprises one or more of the E781K, N967K, or R1014H mutations of SEQ ID NO: 4273, or one or more corresponding mutations in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
140. The fusion protein of any one of claims 128-136, wherein the dCas9 domain comprises one or more of the D1134E, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
141. The fusion protein of any one of claims 128-136, wherein the dCas9 domain comprises one or more of the D1134V, R1334Q, and T1336R mutations of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
142. The fusion protein of any one of claims 128-136, wherein the dCas9 domain comprises one or more of the following mutations: D1134V, G1217R, R1334Q, and T1336R of SEQ ID NO: 4276, or a corresponding mutation in any of the amino acid sequences provided by SEQ ID NOs: 11-260.
143. The fusion protein of any one of claims 128 to 142, wherein the nucleic acid editing domain is fused to the N-terminus of the Cas9 nickase domain.
144. The fusion protein of any one of claims 128 to 143, wherein the UGI domain is fused to the C-terminus of the Cas9 nickase domain.
145. The fusion protein of any one of claims 128 to 144, wherein the Cas9 nickase domain and the nucleic acid editing domain are fused via a linker.
146. The fusion protein of any one of claims 128 to 145, wherein the Cas9 nickase domain and the UGI domain are fused by a linker.
147. The linker has the amino acid sequence (GGGGS) n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n, SGSETPGTSESATPES (SEQ ID NO: 7), SGGS (SEQ ID NO: 4288), (XP) n or any combination thereof, wherein n is independently an integer between 1 and 30, and X is any amino acid.
148. The fusion protein of claim 145 or 146, wherein the linker comprises a covalent bond.
149. Linker is amino acid sequence (GGS) n and n is 1, 3, or 7.
150. The fusion protein of claim 147, wherein the linker comprises the amino acid sequence SGSETPGTSESATPES (sequence number 7).
151. The fusion protein of claim 145, wherein the nCas9 domain and the nucleic acid editing domain are fused by a linker comprising the amino acid sequence SGSETPGTSESATPES (SEQ ID NO:7).
152. The nCas9 domain and the nucleic acid editing domain are represented by the amino acid sequence (GGS). n and n is 1, 3, or 7. The fusion protein of claim 145, wherein n is 1, 3, or 7.
153. The nCas9 domain and the UGI domain are n (SEQ ID NO: 5), (G) n , (EAAAK) n (SEQ ID NO: 6), (GGS) n , SGSETPGTSESATPES (SEQ ID NO: 7), SGGS (SEQ ID NO: 4288), (XP) n or any combination thereof, wherein n is independently an integer between 1 and 30, and X is any amino acid.
154. The fusion protein of claim 146, wherein the nCas9 domain and the UGI domain are fused by a linker comprising the amino acid sequence SGGS (SEQ ID NO: 4288).
155. The fusion protein of any one of claims 128 to 154, wherein the fusion protein comprises the structure [nucleic acid editing domain]-[optional linker]-[Cas9 nickase]-[optional linker]-[UGI domain].
156. 155. The fusion protein of any one of claims 128 to 154, wherein the fusion protein comprises the structure: [nucleic acid editing domain]-[optional linker]-[UGI domain]-[optional linker]-[Cas9 nickase]; [UGI domain]-[optional linker]-[nucleic acid editing domain]-[optional linker]-[Cas9 nickase]; [UGI domain]-[optional linker]-[Cas9 nickase]-[optional linker]-[nucleic acid editing domain]; [Cas9 nickase]-[optional linker]-[UGI domain]-[optional linker]-[nucleic acid editing domain]; or [Cas9 nickase]-[optional linker]-[nucleic acid editing domain]-[optional linker]-[UGI domain].
157. The fusion protein of any one of claims 128 to 156, wherein the nucleic acid editing domain comprises a deaminase.
158. The fusion protein of claim 157, wherein the deaminase is a cytidine deaminase.
159. The fusion protein of claim 157 or 158, wherein the deaminase is an apolipoprotein B mRNA editing complex (APOBEC) family deaminase.
160. The fusion protein of any one of claims 157 to 159, wherein the deaminase is APOBEC1 deaminase.
161. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC2 deaminase.
162. The fusion protein of any one of claims 157 to 159, wherein the deaminase is APOBEC3A deaminase.
163. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC3B deaminase.
164. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC3C deaminase.
165. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC3D deaminase.
166. The fusion protein of any one of claims 157 to 159, wherein the deaminase is APOBEC3F deaminase.
167. The fusion protein of any one of claims 157 to 159, wherein the deaminase is APOBEC3G deaminase.
168. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC3H deaminase.
169. The fusion protein of any one of claims 157 to 159, wherein the deaminase is an APOBEC4 deaminase.
170. The fusion protein of claim 157 or 158, wherein the deaminase is activation-induced deaminase (AID).
171. The fusion protein of claim 157 or 158, wherein the deaminase is an APOBEC deaminase comprising one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBECl (sequence number 284), or one or more corresponding mutations in another APOBEC deaminase.
172. The fusion protein of claim 157 or 158, wherein the deaminase is an APOBEC deaminase comprising the W90Y, R126E, and R132E mutations of rAPOBECl (sequence number 284), or one or more corresponding mutations in another APOBEC deaminase.
173. The fusion protein of claim 157 or 158, wherein the deaminase comprises one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G (sequence number 275), or one or more corresponding mutations in another APOBEC deaminase.
174. The fusion protein of claim 157 or 158, wherein the deaminase is an APOBEC deaminase comprising the W285Y, R320E, and R326E mutations of hAPOBEC3G (sequence number 275), or one or more corresponding mutations in another APOBEC deaminase.
175. 175. The fusion protein of any one of claims 157-174, wherein the deaminase is from a human, a chimpanzee, a gorilla, a monkey, a cow, a dog, a rat, or a mouse.
176. The fusion protein of any one of claims 157 to 175, wherein the deaminase is from a human.
177. The fusion protein of any one of claims 157 to 175, wherein the deaminase is from rat.
178. A fusion protein described in claim 157 or 158, wherein the deaminase is cytidine deaminase 1 (pmCDA1) from Petromyzon marinus.
179. The fusion protein of any one of claims 157 to 159, wherein the deaminase is a rat APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 284).
180. The fusion protein of any one of claims 157 to 159, wherein the deaminase is a human APOBEC1 deaminase comprising the amino acid sequence set forth in (SEQ ID NO: 282).
181. The fusion protein of claim 178, wherein pmCDA1 comprises the amino acid sequence shown in (sequence number 5738).
182. The fusion protein of claim 167, wherein the APOBEC3G is human APOBEC3G comprising the amino acid sequence shown in (SEQ ID NO: 275).
183. The fusion protein of claim 167, wherein the APOBEC3G is a human APOBEC3G variant comprising an amino acid sequence set forth in any one of (SEQ ID NOs: 5739-5741).
184. The fusion protein of claim 157 or 158, wherein the deaminase is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in SEQ ID NOs: 266-284, 607-610, 5724-5736, and 5738-5741.
185. The fusion protein of claim 157 or 158, wherein the deaminase comprises an amino acid sequence set forth in any one of SEQ ID NOs: 266-284, 607-610, 5724-5736, and 5738-5741.
186. The fusion protein of any one of claims 128 to 185, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to SEQ ID NO:
600.
187. The fusion protein of any one of claims 128 to 186, wherein the UGI domain comprises the amino acid sequence set forth in SEQ ID NO:
600.
188. The fusion protein of any one of claims 128 to 185, wherein the UGI domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of SEQ ID NOs: 322 to 324.
189. The fusion protein of any one of claims 128 to 185, wherein the UGI domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 322 to 324.
190. A complex comprising the fusion protein of any one of claims 1 to 30 and a guide RNA (gRNA) bound to the Cas9 domain of the fusion protein.
191. A complex comprising the fusion protein of any one of claims 31 to 106 and a guide RNA (gRNA) bound to the dCas9 domain of the fusion protein.
192. 190. A complex comprising the fusion protein of any one of claims 107 to 189 and a guide RNA (gRNA) bound to the Cas9 nickase (nCas9) domain of the fusion protein.
193. 193. The complex of any one of claims 190 to 192, wherein the guide RNA is 15 to 100 nucleotides in length and comprises a sequence of at least 10 contiguous nucleotides that is complementary to the target sequence.
194. 200, 201, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length.
195. 195. The complex of any one of claims 190-194, wherein the guide RNA comprises a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 consecutive nucleotides that are complementary to the target sequence.
196. The complex of any one of claims 190 to 195, wherein the target sequence is a DNA sequence.
197. The complex of claim 196, wherein the target sequence is in the genome of an organism.
198. The complex of claim 197, wherein the organism is a prokaryote.
199. The complex of claim 198, wherein the prokaryote is a bacterium.
200. The complex of claim 197, wherein the organism is a eukaryote.
201. The complex of claim 200, wherein the organism is a plant.
202. The complex of claim 200, wherein the organism is a vertebrate.
203. The complex of claim 202, wherein the vertebrate is a mammal.
204. The conjugate of claim 203, wherein the mammal is a mouse or a rat.
205. The conjugate of claim 203, wherein the mammal is a human.
206. contacting a nucleic acid molecule with a fusion protein according to any one of claims 1 to 189 and a guide RNA, The guide RNA is 15-100 nucleotides in length and comprises a sequence of at least 10 consecutive nucleotides that is complementary to the target sequence; method.
207. A method comprising contacting a nucleic acid molecule with a complex according to any one of claims 190 to 205.
208. The method of claim 206 or 207, wherein the nucleic acid is DNA.
209. 209. The method of claim 208, wherein the nucleic acid is double-stranded DNA.
210. The method of any one of claims 206 to 209, wherein the target sequence comprises a sequence associated with a disease or disorder.
211. 211. The method of claim 210, wherein the target sequence comprises a point mutation associated with a disease or disorder.
212. The method of claim 211, wherein the activity of the fusion protein or complex results in correction of the point mutation.
213. 213. The method of any one of claims 206 to 212, wherein the target sequence comprises a T to C point mutation associated with a disease or disorder, and deamination of the mutant C base results in a sequence that is not associated with the disease or disorder.
214. 214. The method of claim 213, wherein the target sequence encodes a protein and the point mutation is in a codon, resulting in a change in the amino acid encoded by the mutant codon compared to the wild-type codon.
215. 215. The method of claim 214, wherein deamination of mutant C results in a change in the amino acid encoded by the mutant codon.
216. The method of claim 215, wherein deamination of mutant C results in a codon encoding a wild-type amino acid.
217. The method of any one of claims 206 to 216, wherein the contacting is performed in vivo in a subject.
218. The method of any one of claims 206 to 216, wherein the contacting is performed in vitro.
219. The method of claim 217, wherein the subject has been diagnosed with a disease or disorder.
220. 220. The method of any one of claims 210 to 219, wherein the disease or disorder is cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), Charcot-Marie-Tooth disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), congenital myotonia, hereditary renal amyloidosis, dilated cardiomyopathy (DCM), hereditary lymphedema, familial Alzheimer's disease, HIV, prion disease, chronic infantile neurological cutaneous and articular syndrome (CINCA), desmin-related myopathy (DRM), a neoplastic disease associated with mutant PI3KCA protein, mutant CTNNB1 protein, mutant HRAS protein, or mutant p53 protein.
221. 221. The method of any one of claims 211 to 220, wherein the disease or disorder is associated with a T>C or A>G mutation in a gene selected from the genes disclosed in Table 1.
222. 221. The method of any one of claims 211 to 220, wherein the disease or disorder is associated with a T>C or A>G mutation in a gene selected from the genes disclosed in Table 2 or Table 3.
223. The method of any one of claims 206-222, wherein the guide RNA comprises a nucleotide sequence of any one of the protospacer sequences of Table 2 or Table 3.
224. Here's how: a. contacting a target region of a double stranded DNA sequence with a complex comprising a nucleobase editor and a guide nucleic acid, wherein the target region comprises a target nucleobase pair; b. inducing strand separation of the target region; c. converting a first nucleobase of said target nucleobase pair on a single strand of a target region to a second nucleobase; d. cleaving only one strand of the target region; Including, a third nucleobase complementary to the first nucleobase is replaced by a fourth nucleobase complementary to the second nucleobase, and the method causes less than 20% indel formation in the double stranded DNA sequence. A method for editing nucleobase pairs in a double-stranded DNA sequence.
225. 225. The method of claim 224, wherein the method causes less than 20%, 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, or 1% indel formation.
226. 226. The method of claim 224 or 225, further comprising replacing the second nucleobase with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating the intended edited base pair.
227. The method of any one of claims 224-226, wherein the efficiency of producing the intended edited base pair is at least 5%.
228. 228. The method of claim 227, wherein the efficiency is at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.
229. 227. The method of claim 226, wherein the ratio of intended product to unintended product at the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:
1.
230. The method of claim 226, wherein the ratio of intended point mutations to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:
1.
231. The method of any one of claims 224 to 230, wherein the single strand to be cleaved is hybridized to a guide nucleic acid.
232. 232. The method of any one of claims 224 to 231, wherein the single strand that is cleaved is opposite the strand that includes the first nucleobase.
233. 233. The method of any one of claims 224 to 232, wherein the first base is a cytosine.
234. 234. The method of any one of claims 224-233, wherein the second nucleobase is not G, C, A, or T.
235. 235. The method of any one of claims 224 to 234, wherein the second base is uracil.
236. The method of any one of Claims 224-235, wherein the nucleobase editor comprises UGI activity.
237. The method of any one of Claims 224-236, wherein the nucleobase editor comprises a nickase activity.
238. The method of any one of claims 226-237, wherein the intended edited base pair is upstream of the PAM site.
239. The method of claim 238, wherein the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site.
240. The method of claim 239, wherein the intended edited base pair is downstream of the PAM site.
241. 241. The method of claim 240, wherein the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream of the PAM site.
242. 242. The method of any one of claims 224 to 241, wherein the method does not require a classical PAM site.
243. The method of claim 242, wherein the classical PAM site (sit) comprises NGG, wherein N is A, T, C, or G.
244. The method of any one of Claims 224-243, wherein the nucleobase editor comprises a linker.
245. 245. The method of claim 244, wherein the linker is 1 to 25 amino acids in length.
246. The method of claim 244 or 245, wherein the linker is 5 to 20 amino acids in length.
247. 247. The method of any one of claims 244-246, wherein the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length.
248. 248. The method of any one of claims 224 to 247, wherein the target region comprises a target window, and the target window comprises a target nucleic acid base pair.
249. 249. The method of claim 248, wherein the target window comprises 1 to 10 nucleotides.
250. 249. The method of claim 248, wherein the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length.
251. 249. The method of claim 248, wherein the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
252. The method of any one of claims 224-251, wherein the intended edited base pair is within a target window.
253. The method of any one of claims 224-252, wherein the target window comprises the intended edited base pair.
254. The method of any one of claims 224-253, wherein the nucleobase editor comprises any one of the fusion proteins of claims 1-189.
255. Here's how: a. contacting a target region of a double stranded DNA sequence with a complex comprising a nucleobase editor and a guide nucleic acid, wherein the target region comprises a target nucleobase pair; b. inducing strand separation of the target region; c. converting a first nucleobase of said target nucleobase pair on a single strand of a target region to a second nucleobase; d. cleaving only one strand of the target region; replacing a third nucleobase complementary to the first nucleobase with a fourth nucleobase complementary to the second nucleobase; e. replacing the second nucleobase with a fifth nucleobase that is complementary to the fourth nucleobase, thereby generating an intended edited base pair, and having an efficiency of generating the intended edited base pair of at least 5%; Including, A method for editing nucleobase pairs in a double-stranded DNA sequence.
256. 256. The method of claim 255, wherein the efficiency is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.
257. The method of claim 255 or 256, wherein the method causes less than 19%, 18%, 16%, 14%, 12%, 10%, 8%, 6%, 4%, 2%, or 1% indel formation.
258. 258. The method of any one of claims 255-257, wherein the ratio of intended product to unintended product at the target nucleotide is at least 2:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, or 200:
1.
259. 259. The method of any one of claims 255-258, wherein the ratio of intended point mutations to indel formation is greater than 1:1, 10:1, 50:1, 100:1, 500:1, or 1000:
1.
260. The method of any one of claims 255 to 259, wherein the single strand to be cleaved is hybridized to a guide nucleic acid.
261. 261. The method of any one of claims 255 to 260, wherein the single strand that is cleaved is opposite the strand that includes the first nucleobase.
262. 262. The method of any one of claims 255 to 261, wherein the first base is a cytosine.
263. 263. The method of any one of claims 255-262, wherein the second nucleobase is not G, C, A, or T.
264. 264. The method of any one of claims 255 to 263, wherein the second base is uracil.
265. The method of any one of Claims 255-264, wherein the nucleobase editor comprises UGI activity.
266. 266. The method of any one of Claims 255-265, wherein the nucleobase editor comprises nickase activity.
267. The method of any one of claims 255-266, wherein the intended edited base pair is upstream of the PAM site.
268. The method of claim 267, wherein the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site.
269. The method of any one of claims 255-266, wherein the intended edited base pair is downstream of the PAM site.
270. 270. The method of claim 269, wherein the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream of the PAM site.
271. 271. The method of any one of claims 255 to 270, wherein the method does not require a classical PAM site.
272. The method of claim 271, wherein the classical PAM site comprises NGG, wherein N is A, T, C, or G.
273. The method of any one of Claims 255-272, wherein the nucleobase editor comprises a linker.
274. 274. The method of claim 273, wherein the linker is 1 to 25 amino acids in length.
275. 276. The method of claim 274 or 275, wherein the linker is 5 to 20 amino acids in length.
276. 276. The method of any one of claims 274-275, wherein the linker is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length.
277. 277. The method of any one of claims 274 to 276, wherein the target region comprises a target window, and the target window comprises a target nucleic acid base pair.
278. 278. The method of claim 277, wherein the target window comprises 1 to 10 nucleotides.
279. 278. The method of claim 277, wherein the target window is 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 nucleotides in length.
280. 278. The method of claim 277, wherein the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
281. The method of any one of claims 277-280, wherein the intended edited base pair is within a target window.
282. 282. The method of any one of claims 277-281, wherein the target window comprises the intended edited base pair.
283. The method of any one of claims 255-282, wherein the nucleobase editor comprises any one of the fusion proteins of claims 1-189.
284. Nucleic acid-induced deaminases coupled to inhibitors of base excision repair.
285. The nucleic acid-induced deaminase of claim 284, comprising an initiator of mismatch repair.
286. 285. The nucleic acid-induced deaminase of claim 284, comprising a nickase.
287. Here's how: a. contacting a target region of a double stranded DNA sequence with a nucleic acid-induced deaminase, the target region comprising a target nucleic acid base pair; b. converting a first nucleobase of said target nucleobase pair of a target region to a second nucleobase; c. inhibiting base excision repair of a second nucleobase; and Including, A method for editing nucleobase pairs in a double-stranded DNA sequence.
288. The method of claim 287, further comprising nicking the unedited strand of the target double-stranded DNA sequence.
289. 288. The method of claim 287, further comprising initiating mismatch repair to convert a nucleobase complementary to a first nucleobase on the unedited strand to a nucleobase complementary to a second nucleobase.
290. 288. The method of claim 287, further comprising inducing strand separation in the target region.
291. Here's how: a. contacting a target region of a double stranded DNA sequence with a nucleic acid-induced deaminase, the target region comprising a target nucleic acid base pair; b. converting a first nucleobase of said target nucleobase pair in a target region to a second nucleobase; c. Initiating mismatch repair to convert a nucleobase complementary to a first nucleobase on the unedited strand to a nucleobase complementary to a second nucleobase; Including, A method for editing nucleobase pairs in a double-stranded DNA sequence.
292. 292. The method of claim 291, further comprising inhibiting base excision repair of the second nucleobase.
293. 300. The method of claim 291, further comprising inducing strand separation in the target region.
294. 292. The method of claim 287 or 291, wherein the nucleic acid-induced deaminase is a nucleic acid-induced cytidine deaminase.
295. (a) a nucleic acid sequence encoding a fusion protein according to any one of claims 1 to 189; (b) a heterologous promoter driving expression of the sequence of (a); and A kit comprising a nucleic acid construct comprising:
296. Further comprising an expression construct encoding a guide RNA backbone, The construct comprises a cloning site positioned to allow cloning of a nucleic acid sequence identical or complementary to the target sequence into the guide RNA backbone; The kit described in claim 256.
297. A polynucleotide encoding the fusion protein of any one of claims 1 to 189.
298. A vector comprising the polynucleotide of claim 258.
299. The vector of claim 259, wherein the vector comprises a heterologous promoter driving expression of the polynucleotide.
300. A cell comprising the fusion protein of any one of claims 1 to 189.
301. A cell comprising the complex of any one of claims 190 to 205.
302. A cell comprising a nucleic acid molecule encoding the fusion protein of any one of claims 1 to 189.
Citation Information
Patent Citations
Genomic sequence modification method for specifically converting nucleic acid bases of targeted DNA sequence, and molecular complex for use in same
WO2015133554A1
